{
  "meta": {
    "id": "test6",
    "title": "Medical Oncology",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which cancer site had the highest incidence rate among males in 2021?",
      "options": [
        {
          "label": "A",
          "text": "Lung",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prostate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Colorectal",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pancreas",
          "correct": false
        }
      ],
      "correct_answer": "B. Prostate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Prostate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lung: While lung cancer is the leading cause of cancer deaths, it does not have the highest number of new cases (incidence) among males (12%).</li><li>\u2022 Option A. Lung:</li><li>\u2022 Option C. Colorectal: Colorectal cancer is the third most common (8%) cancer in men, but its incidence rate is lower than that of prostate cancer.</li><li>\u2022 Option C. Colorectal:</li><li>\u2022 Option D. Pancreas: Pancreatic cancer is less common than prostate cancer, with a lower incidence rate.</li><li>\u2022 Option D. Pancreas:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Prostate cancer screening and early detection are crucial for men's health.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b8a19745",
      "audio": ""
    },
    {
      "text": "A 50-year-old man, with a history of silicosis presents with progressive dyspnea and pleural plaques on imaging. Which of the following malignancies is he most likely at risk for developing in future?",
      "options": [
        {
          "label": "A",
          "text": "Small cell lung cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mesothelioma",
          "correct": true
        },
        {
          "label": "C",
          "text": "Squamous cell carcinoma of the lung",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adenocarcinoma of the lung",
          "correct": false
        }
      ],
      "correct_answer": "B. Mesothelioma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Mesothelioma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Small cell lung cancer: While smoking is the primary risk factor, it's not directly associated with silicosis or pleural plaques.</li><li>\u2022 Option A. Small cell lung cancer:</li><li>\u2022 Option C. Squamous cell carcinoma of the lung: Also primarily linked to smoking, not specifically to silicosis or asbestos.</li><li>\u2022 Option C. Squamous cell carcinoma of the lung:</li><li>\u2022 Option D. Adenocarcinoma of the lung: The most common type of lung cancer but not directly associated with silicosis or asbestos.</li><li>\u2022 Option D. Adenocarcinoma of the lung:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The combination of silicosis and pleural plaques is a strong indicator of asbestos exposure and significantly increases the risk of developing mesothelioma. Early detection and monitoring are crucial for individuals with this history.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0632c529",
      "audio": ""
    },
    {
      "text": "A farmer from a developing country presents with jaundice, abdominal distention, and elevated alpha-fetoprotein (AFP) levels. Which of the following dietary contaminants is MOST likely associated with his suspected malignancy?",
      "options": [
        {
          "label": "A",
          "text": "Asbestos",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aflatoxin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Arsenic",
          "correct": false
        },
        {
          "label": "D",
          "text": "Benzene",
          "correct": false
        }
      ],
      "correct_answer": "B. Aflatoxin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Aflatoxin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Asbestos: While asbestos is a known carcinogen, it primarily affects the lungs and pleura, causing mesothelioma and lung cancer. It is not typically associated with hepatocellular carcinoma (HCC) or the symptoms presented by the farmer.</li><li>\u2022 Option A. Asbestos:</li><li>\u2022 Option C. Arsenic: Arsenic exposure is linked to various cancers, including skin, bladder, and lung cancer. However, it is not the primary risk factor for HCC in the scenario described.</li><li>\u2022 Option C. Arsenic:</li><li>\u2022 Option D. Benzene: Benzene is an industrial solvent and a known carcinogen, primarily associated with leukemia and other blood cancers. It is not a major risk factor for HCC in the context of this patient.</li><li>\u2022 Option D. Benzene:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Aflatoxin contamination of food is a major global health concern and a significant risk factor for HCC.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "542412c4",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of smoking presents with cough, hemoptysis, and a lung mass on chest X-ray. Which of the following tumor markers is MOST likely to be elevated?",
      "options": [
        {
          "label": "A",
          "text": "CEA",
          "correct": false
        },
        {
          "label": "B",
          "text": "AFP",
          "correct": false
        },
        {
          "label": "C",
          "text": "NSE",
          "correct": true
        },
        {
          "label": "D",
          "text": "CA 19-9",
          "correct": false
        }
      ],
      "correct_answer": "C. NSE",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. CEA (Carcinoembryonic Antigen): While CEA can be elevated in some lung cancers, it's more commonly associated with colorectal, breast, and other gastrointestinal cancers.</li><li>\u2022 Option A. CEA (Carcinoembryonic Antigen):</li><li>\u2022 Option B. AFP (Alpha-fetoprotein): AFP is primarily used as a marker for liver cancer (hepatocellular carcinoma) and certain germ cell tumors. It's not typically elevated in lung cancers.</li><li>\u2022 Option B. AFP (Alpha-fetoprotein):</li><li>\u2022 Option D. CA 19-9 (Carbohydrate Antigen 19-9): CA 19-9 is most commonly used as a marker for pancreatic cancer and some other gastrointestinal malignancies. It's not a primary marker for lung cancers.</li><li>\u2022 Option D. CA 19-9 (Carbohydrate Antigen 19-9):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 NSE is a useful marker for the diagnosis and monitoring of neuroendocrine tumors, particularly SCLC.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb9dbcb8",
      "audio": ""
    },
    {
      "text": "A 50-year-old man with chronic pancreatitis presents with jaundice and weight loss. Which tumor marker would be the MOST helpful in evaluating for a possible malignancy?",
      "options": [
        {
          "label": "A",
          "text": "CA 19-9",
          "correct": true
        },
        {
          "label": "B",
          "text": "CA-125",
          "correct": false
        },
        {
          "label": "C",
          "text": "PSA",
          "correct": false
        },
        {
          "label": "D",
          "text": "CD30",
          "correct": false
        }
      ],
      "correct_answer": "A. CA 19-9",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CA 19-9</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. CA-125: This marker is primarily used for ovarian cancer and is not typically elevated in pancreatic cancer.</li><li>\u2022 Option B. CA-125:</li><li>\u2022 Option C. PSA: This marker is specific for prostate cancer and would not be helpful in evaluating for a pancreatic malignancy.</li><li>\u2022 Option C. PSA:</li><li>\u2022 Option D. CD30: This marker is used in lymphoma diagnosis and is not relevant for pancreatic cancer.</li><li>\u2022 Option D. CD30:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 CA 19-9 can be a useful marker in evaluating for pancreatic cancer, especially in patients with risk factors like chronic pancreatitis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "76020e45",
      "audio": ""
    },
    {
      "text": "Which of the following is the leading cause of cancer-related deaths in males worldwide?",
      "options": [
        {
          "label": "A",
          "text": "Lung cancer",
          "correct": true
        },
        {
          "label": "B",
          "text": "Prostate cancer",
          "correct": false
        },
        {
          "label": "C",
          "text": "Colorectal cancer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Liver cancer",
          "correct": false
        }
      ],
      "correct_answer": "A. Lung cancer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . Prostate cancer is a common cancer in males, but it generally has a better prognosis than lung cancer, and thus it is not the leading cause of cancer-related deaths.</li><li>\u2022 Option</li><li>\u2022 B</li><li>\u2022 Option C. Colorectal cancer is also a common cancer in males, but it is not the leading cause of cancer-related deaths.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D . Liver cancer is a significant cause of cancer-related deaths, but it is not the leading cause globally in males.</li><li>\u2022 Option D</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lung cancer is the leading cause of cancer-related deaths in males worldwide, due to its high incidence and poor prognosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed412464",
      "audio": ""
    },
    {
      "text": "Which of the following statements about e-cigarettes (vaping) is MOST accurate?",
      "options": [
        {
          "label": "A",
          "text": "They are a safe alternative to smoking.",
          "correct": false
        },
        {
          "label": "B",
          "text": "They are proven to cause lung cancer.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Long-term cancer risks are unknown.",
          "correct": true
        },
        {
          "label": "D",
          "text": "They only cause oral cancers.",
          "correct": false
        }
      ],
      "correct_answer": "C. Long-term cancer risks are unknown.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. They are a safe alternative to smoking. E-cigarettes are not harmless. While they may expose users to fewer toxins than traditional cigarettes, they still contain potentially harmful chemicals like nicotine and heavy metals.</li><li>\u2022 Option A. They are a safe alternative to smoking.</li><li>\u2022 Option B. They are proven to cause lung cancer. While some studies have shown e-cigarettes contain carcinogenic substances, definitive long-term studies directly linking them to lung cancer are lacking. More research is needed.</li><li>\u2022 Option B. They are proven to cause lung cancer.</li><li>\u2022 Option D. They only cause oral cancers. While e-cigarettes expose the oral cavity to potentially harmful substances, their impact is not limited to this area. There are concerns about potential damage to the lungs and cardiovascular system as well.</li><li>\u2022 Option D. They only cause oral cancers.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 E-cigarettes are not harmless, and more research is needed to determine their long-term cancer risks.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1e726b69",
      "audio": ""
    },
    {
      "text": "Smoking is a major risk factor for various types of cancer. What percentage of cancer-related deaths are attributed to smoking?",
      "options": [
        {
          "label": "A",
          "text": "50%",
          "correct": false
        },
        {
          "label": "B",
          "text": "80%",
          "correct": false
        },
        {
          "label": "C",
          "text": "30%",
          "correct": true
        },
        {
          "label": "D",
          "text": "10%",
          "correct": false
        }
      ],
      "correct_answer": "C. 30%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "751ea663",
      "audio": ""
    },
    {
      "text": "A 35-year-old man with HIV presents with multiple violet-colored skin lesions and lymphadenopathy. The lesion is shown below. Which of the following is the most common etiological agent for his skin condition?",
      "options": [
        {
          "label": "A",
          "text": "Human herpesvirus 8 (HHV-8)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Epstein-Barr virus (EBV)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Human papillomavirus (HPV)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Human T-lymphotropic virus 1 (HTLV-1)",
          "correct": false
        }
      ],
      "correct_answer": "A. Human herpesvirus 8 (HHV-8)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-162222.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Epstein-Barr virus (EBV): While EBV is associated with several malignancies (lymphoma, nasopharyngeal carcinoma), it doesn't typically cause the characteristic skin lesions seen in Kaposi sarcoma.</li><li>\u2022 Option B. Epstein-Barr virus (EBV):</li><li>\u2022 Option C. Human papillomavirus (HPV): HPV is primarily associated with cervical cancer and other anogenital cancers. It doesn't cause the type of lesions seen in this patient.</li><li>\u2022 Option C. Human papillomavirus (HPV):</li><li>\u2022 Option D. Human T-lymphotropic virus 1 (HTLV-1): HTLV-1 is associated with adult T-cell leukemia/lymphoma, a type of blood cancer. It doesn't usually cause the distinctive skin lesions of Kaposi sarcoma.</li><li>\u2022 Option D. Human T-lymphotropic virus 1 (HTLV-1):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 HHV-8 is the causative agent of Kaposi sarcoma, a malignancy often seen in HIV-infected individuals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb40e807",
      "audio": ""
    },
    {
      "text": "Which of the following types of UV radiation is MOST strongly linked to the development of skin cancer?",
      "options": [
        {
          "label": "A",
          "text": "gamma rays",
          "correct": false
        },
        {
          "label": "B",
          "text": "UVB",
          "correct": true
        },
        {
          "label": "C",
          "text": "x-rays",
          "correct": false
        },
        {
          "label": "D",
          "text": "alpha - rays",
          "correct": false
        }
      ],
      "correct_answer": "B. UVB",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) UVB</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. gamma rays: Gamma rays are a type of ionizing radiation with very short wavelengths and high energy. While they are carcinogenic, they are not the primary type of radiation associated with skin cancer.</li><li>\u2022 Option A. gamma rays:</li><li>\u2022 Option C. x-rays: X-rays are also a type of ionizing radiation with shorter wavelengths than UV radiation. They are used in medical imaging and can also be carcinogenic, but their primary association is not with skin cancer.</li><li>\u2022 Option C. x-rays:</li><li>\u2022 Option D. alpha-rays: Alpha rays are a type of particle radiation consisting of two protons and two neutrons. They have low penetrating power and are not associated with skin cancer.</li><li>\u2022 Option D. alpha-rays:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 UVB radiation is the most significant contributor to skin cancer development.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fcb999f5",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with a palpable breast mass and nipple discharge. Which tumor marker would be MOST appropriate to order in this scenario?",
      "options": [
        {
          "label": "A",
          "text": "CA 19-9",
          "correct": false
        },
        {
          "label": "B",
          "text": "CA 15-3",
          "correct": true
        },
        {
          "label": "C",
          "text": "CA-125",
          "correct": false
        },
        {
          "label": "D",
          "text": "CEA",
          "correct": false
        }
      ],
      "correct_answer": "B. CA 15-3",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) CA 15-3</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. CA 19-9: This marker is primarily associated with pancreatic cancer and some gastrointestinal malignancies. It's not routinely used in the initial evaluation of breast masses.</li><li>\u2022 Option A. CA 19-9:</li><li>\u2022 Option C. CA-125: This marker is primarily associated with ovarian cancer and is not routinely used in the evaluation of breast masses.</li><li>\u2022 Option C. CA-125:</li><li>\u2022 Option D. CEA: This marker can be elevated in various cancers, including breast cancer. However, it is not specific for breast cancer and is typically used to monitor response to treatment or detect recurrence rather than in the initial diagnosis of a breast mass.</li><li>\u2022 Option D. CEA:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 CA 15-3 is a useful marker for monitoring breast cancer progression and treatment response.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2121d8f6",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a strong family history of breast and ovarian cancer undergoes genetic testing and is found to have a BRCA1 mutation. Which of the following statements is MOST accurate regarding her risk of developing breast cancer?",
      "options": [
        {
          "label": "A",
          "text": "She has a 10-20% lifetime risk of developing breast cancer.",
          "correct": false
        },
        {
          "label": "B",
          "text": "She has a 30-40% lifetime risk of developing breast cancer.",
          "correct": false
        },
        {
          "label": "C",
          "text": "She has a 60-80% lifetime risk of developing breast cancer.",
          "correct": true
        },
        {
          "label": "D",
          "text": "She has a 90-100% lifetime risk of developing breast cancer.",
          "correct": false
        }
      ],
      "correct_answer": "C. She has a 60-80% lifetime risk of developing breast cancer.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) She has a 60-80% lifetime risk of developing breast cancer.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a25e4532",
      "audio": ""
    },
    {
      "text": "A 38-year-old woman with a BRCA1 mutation wants to know the best breast cancer screening approach for her. Which of the following is MOST appropriate?",
      "options": [
        {
          "label": "A",
          "text": "Annual mammogram",
          "correct": false
        },
        {
          "label": "B",
          "text": "Annual MRI",
          "correct": true
        },
        {
          "label": "C",
          "text": "Biennial mammogram",
          "correct": false
        },
        {
          "label": "D",
          "text": "Clinical breast exam only",
          "correct": false
        }
      ],
      "correct_answer": "B. Annual MRI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Annual MRI</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Annual mammogram: While mammograms are an important part of breast cancer screening, they are less sensitive than MRI in detecting cancer in women with BRCA mutations, especially those with dense breast tissue.</li><li>\u2022 Option A. Annual mammogram:</li><li>\u2022 Option C. Biennial mammogram: The frequency is not sufficient for women with BRCA mutations, who are at higher risk and require more frequent screening.</li><li>\u2022 Option C. Biennial mammogram:</li><li>\u2022 Option D. Clinical breast exam only: Clinical breast exams are important, but they are not enough for screening high-risk women. Imaging modalities like MRI are more effective for early detection.</li><li>\u2022 Option D. Clinical breast exam only:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Annual MRI (superior to MMG in high risk young female) is recommended for women with BRCA mutations due to their increased breast cancer risk.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7204f65c",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman with a strong family history of breast cancer wants to know the recommended age to start breast cancer screening. According to the American Cancer Society (ACS), what is the MOST appropriate recommendation?",
      "options": [
        {
          "label": "A",
          "text": "Begin annual mammograms at age 40",
          "correct": false
        },
        {
          "label": "B",
          "text": "Begin biennial mammograms at age 40",
          "correct": false
        },
        {
          "label": "C",
          "text": "Begin annual mammograms at age 45",
          "correct": true
        },
        {
          "label": "D",
          "text": "Begin biennial mammograms at age 50",
          "correct": false
        }
      ],
      "correct_answer": "C. Begin annual mammograms at age 45",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Begin annual mammograms at age 45</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Begin annual mammograms at age 40: While some organizations recommend starting at age 40, the ACS specifically suggests starting annual screening at 45 for average-risk women.</li><li>\u2022 Option A. Begin annual mammograms at age 40:</li><li>\u2022 Option B. Begin biennial mammograms at age 40: This option is less frequent than the ACS recommendation for average-risk women, and biennial screening might miss some early-stage cancers.</li><li>\u2022 Option B. Begin biennial mammograms at age 40:</li><li>\u2022 Option D. Begin biennial mammograms at age 50: This is the recommended starting age for biennial mammograms according to the U.S. Preventive Services Task Force (USPSTF), but the ACS recommends starting earlier for average-risk women and even earlier for women with increased risk due to family history.</li><li>\u2022 Option D. Begin biennial mammograms at age 50:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The ACS recommends starting annual mammograms at age 45 for average-risk women.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9892989e",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman with a known BRCA1 mutation desires the most effective risk reduction strategy for breast cancer. Which of the following options would you recommend?",
      "options": [
        {
          "label": "A",
          "text": "Bilateral salpingo-oophorectomy (rrBSO)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Risk-reducing bilateral mastectomy (rrBLM)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Annual mammogram starting at age 40",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tamoxifen chemoprevention",
          "correct": false
        }
      ],
      "correct_answer": "B. Risk-reducing bilateral mastectomy (rrBLM)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Risk-reducing bilateral mastectomy (rrBLM)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bilateral salpingo-oophorectomy (rrBSO): While rrBSO is a risk-reducing surgery, it primarily targets ovarian cancer risk. Although it can somewhat decrease breast cancer risk in premenopausal women, it is not as effective as rrBLM in directly addressing breast cancer.</li><li>\u2022 Option A. Bilateral salpingo-oophorectomy (rrBSO):</li><li>\u2022 Option C. Annual mammogram starting at age 40: Mammography is a screening tool for early detection, not a preventive measure. In women with BRCA1 mutations, who often develop breast cancer at a younger age, mammography alone may not be sufficient for early detection.</li><li>\u2022 Option C. Annual mammogram starting at age 40:</li><li>\u2022 Option D. Tamoxifen chemoprevention: While tamoxifen can reduce the risk of breast cancer in women with BRCA2 mutations, its effectiveness is not as high as rrBLM in BRCA1 carriers. Additionally, it comes with potential side effects and is not suitable for all women.</li><li>\u2022 Option D. Tamoxifen chemoprevention:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 rrBLM is the most effective risk reduction strategy for breast cancer in BRCA1/2 mutation carriers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f0b6d57d",
      "audio": ""
    },
    {
      "text": "Which of the following HPV types are covered by BOTH Gardasil and Cervarix vaccines?",
      "options": [
        {
          "label": "A",
          "text": "6 and 11",
          "correct": false
        },
        {
          "label": "B",
          "text": "16 and 18",
          "correct": true
        },
        {
          "label": "C",
          "text": "6, 11, and 16",
          "correct": false
        },
        {
          "label": "D",
          "text": "11, 16, and 18",
          "correct": false
        }
      ],
      "correct_answer": "B. 16 and 18",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 16 and 18</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "55b4b912",
      "audio": ""
    },
    {
      "text": "A 67-year-old woman has a history of negative Pap smears for the past 10 years and underwent a total hysterectomy for benign reasons. Does she require further cervical cancer screening?",
      "options": [
        {
          "label": "A",
          "text": "Yes, she should continue with annual Pap smears.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Yes, she should have a Pap smear every 3 years.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years.",
          "correct": false
        },
        {
          "label": "D",
          "text": "No, she does not require further screening.",
          "correct": true
        }
      ],
      "correct_answer": "D. No, she does not require further screening.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) No, she does not require further screening.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Yes, she should continue with annual Pap smears: This is incorrect because the patient has a history of negative Pap smears for 10 years and had a total hysterectomy for benign reasons, which means her cervix was removed. There is no remaining cervical tissue to test.</li><li>\u2022 Option A. Yes, she should continue with annual Pap smears:</li><li>\u2022 Option B. Yes, she should have a Pap smear every 3 years: This is also incorrect for the same reasons as option A. There's no need for Pap smears if there's no cervix.</li><li>\u2022 Option B. Yes, she should have a Pap smear every 3 years:</li><li>\u2022 Option C. Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years: This is incorrect because co-testing is typically recommended for women aged 30-65. Since the patient is 67 and has a history of negative results, further testing is not necessary.</li><li>\u2022 Option C. Yes, she should have co-testing (Pap smear and HPV DNA test) every 5 years:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Women with a history of adequate negative screening and no cervix do not require further cervical cancer screening.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "743a615c",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman has a father who was diagnosed with colorectal cancer at age 55. When should she initiate screening for colorectal cancer, according to the image?",
      "options": [
        {
          "label": "A",
          "text": "Immediately",
          "correct": false
        },
        {
          "label": "B",
          "text": "At age 45",
          "correct": false
        },
        {
          "label": "C",
          "text": "At age 50",
          "correct": false
        },
        {
          "label": "D",
          "text": "10 years before her father's age of diagnosis (i.e., at age 45)",
          "correct": true
        }
      ],
      "correct_answer": "D. 10 years before her father's age of diagnosis (i.e., at age 45)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) 10 years before her father's age of diagnosis (i.e., at age 45)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Immediately: While having a family history of colorectal cancer (CRC) does increase risk, immediate screening is not recommended unless there are other concerning symptoms or risk factors.</li><li>\u2022 Option A. Immediately:</li><li>\u2022 Option B. At age 45: This is the general recommended age to begin screening for those with average risk, but with a family history of CRC, earlier screening is appropriate.</li><li>\u2022 Option B. At age 45:</li><li>\u2022 Option C. At age 50: This is too late for someone with a first-degree relative diagnosed with CRC at age 55. Earlier screening is necessary to detect potential problems early.</li><li>\u2022 Option C. At age 50:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Individuals with a family history of colorectal cancer should start screening 10 years younger than the age at which their first-degree relative was diagnosed. This allows for early detection and intervention of precancerous polyps or early-stage cancer, ultimately improving outcomes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a688df12",
      "audio": ""
    },
    {
      "text": "A 65-year-old patient with metastatic lung cancer reports fatigue but is still able to perform most of their daily activities, including light housework and grocery shopping. Which ECOG performance status is MOST appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "0",
          "correct": false
        },
        {
          "label": "B",
          "text": "1",
          "correct": true
        },
        {
          "label": "C",
          "text": "2",
          "correct": false
        },
        {
          "label": "D",
          "text": "3",
          "correct": false
        }
      ],
      "correct_answer": "B. 1",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/06/screenshot-2024-08-06-172340.jpg"
      ],
      "explanation": "<p><strong>Ans. B) 1</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "94b9d9a8",
      "audio": ""
    },
    {
      "text": "A 15-year-old boy presents to the emergency department with severe pain in his lower back and legs. He reports that he has experienced similar pain episodes in the past, usually during times of stress or dehydration. He also mentions that he had a recent upper respiratory infection. On examination, he appears to be in distress due to pain, his temperature is 37.8\u00b0C (100\u00b0F), and his sclerae are icteric. Laboratory tests reveal a hemoglobin level of 8 g/dL, reticulocyte count of 12%, and elevated bilirubin. Peripheral blood smear shows sickle-shaped red blood cells. Which of the following is the most likely mutation responsible for the condition?",
      "options": [
        {
          "label": "A",
          "text": "Non-sense mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Conservative missense mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-conservative missense mutation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Frameshift mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. Non-conservative missense mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Non-sense mutation : This type of mutation introduces a premature stop codon, leading to truncated proteins. It is not the cause of sickle cell disease.</li><li>\u2022 Option A. Non-sense mutation</li><li>\u2022 Option B. Conservative missense mutation : This type of mutation changes an amino acid to another with similar properties, which usually does not significantly affect protein function. Sickle cell disease is caused by a non-conservative missense mutation.</li><li>\u2022 Option B. Conservative missense mutation</li><li>\u2022 Option D. Frameshift mutation : This type of mutation is caused by insertions or deletions that shift the reading frame of the genetic code, resulting in a completely different amino acid sequence downstream. It is not the cause of sickle cell disease.</li><li>\u2022 Option D. Frameshift mutation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Sickle cell disease is caused by a non-conservative missense mutation in the HBB gene, leading to the substitution of glutamic acid with valine at the sixth position of the beta-globin chain. This mutation alters the properties of hemoglobin, causing red blood cells to assume a sickle shape under low oxygen conditions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e43aabe7",
      "audio": ""
    },
    {
      "text": "A 35-year-old male presents with fatigue, weight loss, and splenomegaly. Blood tests reveal an elevated white blood cell count with a predominance of immature myeloid cells. Cytogenetic analysis of the patient's bone marrow cells is most likely to reveal which of the following abnormalities?",
      "options": [
        {
          "label": "A",
          "text": "HER2/ERBB2 amplification",
          "correct": false
        },
        {
          "label": "B",
          "text": "BCR-ABL1 fusion gene",
          "correct": true
        },
        {
          "label": "C",
          "text": "CBFB-MYH11 fusion gene",
          "correct": false
        },
        {
          "label": "D",
          "text": "Polyploidy",
          "correct": false
        }
      ],
      "correct_answer": "B. BCR-ABL1 fusion gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. HER2/ERBB2 amplification is associated with breast and other solid tumors.</li><li>\u2022 Option A. HER2/ERBB2 amplification</li><li>\u2022 Option C. CBFB-MYH11 and FIP1L1-PDGFRA are fusion genes associated with other hematological malignancies.</li><li>\u2022 Option C. CBFB-MYH11 and FIP1L1-PDGFRA</li><li>\u2022 Option D. Polyploidy refers to an increased number of chromosome sets and is not typically seen in CML.</li><li>\u2022 Option D. Polyploidy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The BCR-ABL1 fusion gene is a specific genetic abnormality that is highly diagnostic for CML and serves as a target for tyrosine kinase inhibitor therapy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c0dfdc31",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with a family history of breast and ovarian cancer. Genetic testing reveals a germline mutation in a gene that normally functions to inhibit cell cycle progression and repair DNA damage. Which of the following best describes the role of the affected gene in this patient's cancer predisposition?",
      "options": [
        {
          "label": "A",
          "text": "It promotes cell growth and division",
          "correct": false
        },
        {
          "label": "B",
          "text": "It controls proto-oncogene activity",
          "correct": true
        },
        {
          "label": "C",
          "text": "It induces angiogenesis",
          "correct": false
        },
        {
          "label": "D",
          "text": "It evades apoptosis",
          "correct": false
        }
      ],
      "correct_answer": "B. It controls proto-oncogene activity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Promote cell growth and division: This is the opposite of what tumor suppressor genes do. They actually inhibit cell growth and division, acting as a brake on the cell cycle.</li><li>\u2022 Option A. Promote cell growth and division:</li><li>\u2022 Option C. Induce angiogenesis: Angiogenesis (the formation of new blood vessels) is often promoted by cancer cells, not suppressed. Tumor suppressor genes may indirectly inhibit angiogenesis by preventing uncontrolled cell growth.</li><li>\u2022 Option C. Induce angiogenesis:</li><li>\u2022 Option D. Evade apoptosis: Apoptosis (programmed cell death) is a crucial process for eliminating damaged or abnormal cells. Tumor suppressor genes often promote apoptosis, not evade it.</li><li>\u2022 Option D. Evade apoptosis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The primary function of tumor suppressor genes is to control proto-oncogene activity, thereby preventing uncontrolled cell growth and maintaining genomic stability. Inherited mutations in tumor suppressor genes can significantly increase an individual's risk of developing certain types of cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a12a4c7",
      "audio": ""
    },
    {
      "text": "A 56-year-old man presents to his primary care physician with a 3-month history of worsening fatigue and unintentional weight loss. His past medical history is significant for hypertension and type 2 diabetes, both well-controlled with medications. He has a 30-pack-year smoking history but quit 10 years ago. Physical examination reveals pallor and generalized lymphadenopathy. Laboratory studies show anemia and thrombocytopenia. A peripheral blood smear demonstrates blast cells. A bone marrow biopsy is performed, and the pathology report indicates acute myeloid leukemia (AML) with a specific chromosomal translocation. Further molecular studies reveal a mutation leading to increased activity of histone deacetylases (HDACs), which is known to be associated with a poor prognosis in this type of leukemia. The oncologist discusses treatment options with the patient, focusing on the potential use of HDAC inhibitors as part of his chemotherapy regimen. Which of the following is not a HDAC inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Ivosidenib",
          "correct": true
        },
        {
          "label": "B",
          "text": "Romidepsin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Panobinostat",
          "correct": false
        },
        {
          "label": "D",
          "text": "Belinostat",
          "correct": false
        }
      ],
      "correct_answer": "A. Ivosidenib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B) Romidepsin, C)  panobinostat, and D) belinostat are all examples of HDAC inhibitors. These drugs work by inhibiting histone deacetylases, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these enzymes, HDAC inhibitors can induce cell cycle arrest, differentiation, and apoptosis of cancer cells, making them useful in the treatment of certain hematologic malignancies and solid tumors.</li><li>\u2022 Option B) Romidepsin, C)  panobinostat, and D) belinostat</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 HDAC inhibitors, such as romidepsin, panobinostat, and belinostat, are used in cancer therapy to inhibit histone deacetylases, leading to epigenetic modulation of gene expression and inducing apoptosis in cancer cells. Ivosidenib, on the other hand, is an IDH1 inhibitor used in the treatment of cancers with IDH1 mutations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a87f8093",
      "audio": ""
    },
    {
      "text": "A 40-year-old patient presents with a darkly pigmented skin lesion that has been growing rapidly. A biopsy is performed and the pathology report reveals a malignant melanoma. Further molecular analysis identifies a BRAFV600E Mutation. This specific alteration is best classified as:",
      "options": [
        {
          "label": "A",
          "text": "Substitution",
          "correct": true
        },
        {
          "label": "B",
          "text": "Deletion",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insertion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Translocation",
          "correct": false
        }
      ],
      "correct_answer": "A. Substitution",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Deletions involve the removal of one or more nucleotides from the DNA sequence.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Option C. Insertions involve the addition of one or more nucleotides to the DNA sequence.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. Translocations involve the rearrangement of genetic material between non-homologous chromosomes.</li><li>\u2022 Option D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The BRAFV600E mutation is a common driver mutation in melanoma and is a target for targeted therapy with BRAF inhibitors. Recognizing this type of mutation has important implications for treatment decisions and prognosis in patients with melanoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8001ee5f",
      "audio": ""
    },
    {
      "text": "In the context of cancer development, which of the following statements best differentiates proto-oncogenes from tumor suppressor genes?",
      "options": [
        {
          "label": "A",
          "text": "Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Proto-oncogenes are typically inactivated in cancer, while tumor suppressor genes are overactivated.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Proto-oncogenes are exclusively found in malignant tumors, while tumor suppressor genes are found in benign tumors.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Proto-oncogenes encode for growth factors, while tumor suppressor genes encode for growth factor receptors.",
          "correct": false
        }
      ],
      "correct_answer": "A. Proto-oncogenes causes cancer by gain of function mutations, while tumor suppressor genes cause cancer due to loss of function mutations.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B . Proto-oncogenes are not typically inactivated in cancer; they are activated or overexpressed. Tumor suppressor genes are often inactivated or under expressed in cancer.</li><li>\u2022 Option B</li><li>\u2022 Option C. Both proto-oncogenes and tumor suppressor genes can be involved in both malignant and benign tumors.</li><li>\u2022 Option C.</li><li>\u2022 Option D. Proto-oncogenes and tumor suppressor genes can encode a variety of proteins, not limited to growth factors and growth factor receptors.</li><li>\u2022 Option D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Proto-oncogenes and tumor suppressor genes are two key classes of genes involved in cancer development. Proto-oncogenes promote cell growth and proliferation and can lead to cancer when mutated to gain function. Tumor suppressor genes normally inhibit cell growth, and their inactivation or loss of function can contribute to cancer development.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b564424a",
      "audio": ""
    },
    {
      "text": "Which of the following mutations is MOST likely to be associated with a myeloproliferative neoplasm?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F",
          "correct": true
        },
        {
          "label": "B",
          "text": "EGFR exon 20 insertion",
          "correct": false
        },
        {
          "label": "C",
          "text": "BRAF V600E",
          "correct": false
        },
        {
          "label": "D",
          "text": "5q deletion",
          "correct": false
        }
      ],
      "correct_answer": "A. JAK2 V617F",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. EGFR exon 20 insertion: This mutation is commonly found in non-small cell lung cancer (NSCLC) and is associated with resistance to certain targeted therapies.</li><li>\u2022 Option B. EGFR exon 20 insertion:</li><li>\u2022 Option C. BRAF V600E: This mutation is commonly found in melanoma and some other solid tumors. It is not typically associated with myeloproliferative neoplasms.</li><li>\u2022 Option C. BRAF V600E:</li><li>\u2022 Option D. 5q deletion: This is a chromosomal deletion frequently found in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), but not as commonly in myeloproliferative neoplasms.</li><li>\u2022 Option D. 5q deletion:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 JAK2 V617F is a key driver mutation in several myeloproliferative neoplasms and a target for therapies like ruxolitinib.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d36fac1",
      "audio": ""
    },
    {
      "text": "A 15-year-old African American boy presents with acute onset of severe bone pain in his lower extremities. His history includes similar episodes, often precipitated by dehydration or stress. Lab results reveal anemia, elevated reticulocyte count, and indirect hyperbilirubinemia. A peripheral blood smear demonstrates sickled erythrocytes. Which genetic alteration is MOST likely responsible for this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Trinucleotide repeat expansion in the HTT gene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Deletion of phenylalanine at position 508 of the CFTR gene",
          "correct": false
        },
        {
          "label": "C",
          "text": "Point mutation resulting in a glutamate to valine substitution in the \u03b2-globin gene",
          "correct": true
        },
        {
          "label": "D",
          "text": "Translocation between chromosomes 9 and 22 (t(9;22))",
          "correct": false
        }
      ],
      "correct_answer": "C. Point mutation resulting in a glutamate to valine substitution in the \u03b2-globin gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Trinucleotide repeat expansion in the HTT gene: This mutation is associated with Huntington's disease, a neurodegenerative disorder.</li><li>\u2022 Option A. Trinucleotide repeat expansion in the HTT gene:</li><li>\u2022 Option B. Deletion of phenylalanine at position 508 of the CFTR gene: This is the most common mutation in cystic fibrosis, causing defective chloride ion transport.</li><li>\u2022 Option B. Deletion of phenylalanine at position 508 of the CFTR gene:</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22 (t(9;22)): This is the Philadelphia chromosome, a hallmark of chronic myeloid leukemia (CML).</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22 (t(9;22)):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Sickle cell disease is a monogenic disorder caused by a specific point mutation in the \u03b2-globin gene. Understanding the molecular basis of SCD is crucial for diagnosis, management, and potential future gene therapies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e0560885",
      "audio": ""
    },
    {
      "text": "Which of the following is an example of an epigenetic change that can contribute to cancer development?",
      "options": [
        {
          "label": "A",
          "text": "Point mutation in the p53 gene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Deletion of the RB1 gene",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypermethylation of the promoter region of a tumor suppressor gene",
          "correct": true
        },
        {
          "label": "D",
          "text": "Translocation between chromosomes 9 and 22",
          "correct": false
        }
      ],
      "correct_answer": "C. Hypermethylation of the promoter region of a tumor suppressor gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Point mutation in the p53 gene: This is a genetic alteration where a single nucleotide in the DNA sequence of the p53 gene is changed. This can lead to the production of a dysfunctional p53 protein, which is a tumor suppressor.</li><li>\u2022 Option A. Point mutation in the p53 gene:</li><li>\u2022 Option B. Deletion of the RB1 gene: This is also a genetic alteration where a portion of the RB1 gene, another tumor suppressor, is removed. The absence of the RB1 protein can contribute to uncontrolled cell growth.</li><li>\u2022 Option B. Deletion of the RB1 gene:</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22: This is a chromosomal rearrangement where a piece of chromosome 9 is transferred to chromosome 22, and vice versa. This translocation creates a new fusion gene, often the BCR-ABL gene, which drives the development of chronic myeloid leukemia (CML).</li><li>\u2022 Option D. Translocation between chromosomes 9 and 22:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Epigenetic modifications, like DNA methylation, play a significant role in carcinogenesis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f683fbf2",
      "audio": ""
    },
    {
      "text": "Which of the following HPV genes is MOST directly implicated in the development of cervical cancer?",
      "options": [
        {
          "label": "A",
          "text": "E2",
          "correct": false
        },
        {
          "label": "B",
          "text": "E4",
          "correct": false
        },
        {
          "label": "C",
          "text": "E6",
          "correct": true
        },
        {
          "label": "D",
          "text": "E8",
          "correct": false
        }
      ],
      "correct_answer": "C. E6",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. E2: E2 is involved in viral replication and gene expression regulation. While important for the HPV lifecycle, it's not directly implicated in cellular transformation and cancer development.</li><li>\u2022 Option A. E2:</li><li>\u2022 Option B. E4: E4 plays a role in viral release and assembly. It's not considered a major oncogenic protein in the context of cervical cancer.</li><li>\u2022 Option B. E4:</li><li>\u2022 Option D. E8: There is no E8 gene in the HPV genome.</li><li>\u2022 Option D. E8:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The E6 and E7 proteins are the primary oncoproteins of HPV that drive the development of cervical cancer by interfering with critical cellular pathways that regulate cell growth and survival.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bca5a36b",
      "audio": ""
    },
    {
      "text": "A 58-year-old man with a history of refractory acute myeloid leukemia (AML) presents to the oncology clinic for a follow-up visit. He was recently started on enasidenib after genetic testing revealed a specific mutation in his leukemia cells. The patient has noticed a decrease in fatigue and an improvement in his overall well-being since starting the treatment. The oncologist explains the mechanism of action of the medication, which targets the leukemia cells. Which of the following best describes the mechanism of action of enasidenib?",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of BCR-ABL tyrosine kinase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Inhibition of mutant IDH2 enzyme",
          "correct": true
        },
        {
          "label": "C",
          "text": "Stimulation of the immune system to attack leukemia cells",
          "correct": false
        },
        {
          "label": "D",
          "text": "Induction of differentiation of leukemia cells",
          "correct": false
        }
      ],
      "correct_answer": "B. Inhibition of mutant IDH2 enzyme",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Inhibition of mutant IDH2 enzyme</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Inhibition of BCR-ABL tyrosine kinase : This is the mechanism of action of drugs like imatinib, which are used to treat chronic myeloid leukemia (CML), not AML.</li><li>\u2022 Option A. Inhibition of BCR-ABL tyrosine kinase</li><li>\u2022 Option C. Stimulation of the immune system to attack leukemia cells : This describes the mechanism of action of immunotherapies, such as CAR T-cell therapy, rather than enasidenib.</li><li>\u2022 Option C. Stimulation of the immune system to attack leukemia cells</li><li>\u2022 Option D. Induction of differentiation of leukemia cells : While enasidenib does lead to differentiation of leukemia cells, it is more specific to say that it inhibits the mutant IDH2 enzyme, which is the direct target of the drug.</li><li>\u2022 Option D. Induction of differentiation of leukemia cells</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Enasidenib is a targeted therapy used to treat patients with acute myeloid leukemia (AML) who have a specific mutation in the IDH2 enzyme. It works by inhibiting the mutant enzyme, leading to a reduction in the oncometabolite 2-HG and promoting the differentiation of myeloid cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1838691d",
      "audio": ""
    },
    {
      "text": "A patient presents with mantle cell lymphoma (MCL). Which of the following genetic alterations is MOST likely associated with this malignancy?",
      "options": [
        {
          "label": "A",
          "text": "CDKN2A (p16INK4A) mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "CDKN1B (p27) mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "CCND1 amplification",
          "correct": true
        },
        {
          "label": "D",
          "text": "TP53 mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. CCND1 amplification",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CDKN2A (p16INK4A) mutation: While CDKN2A mutations can be seen in various cancers, they are more commonly associated with melanoma and other solid tumors. In mantle cell lymphoma, CDKN2A deletions are associated with poor prognosis but are not the primary driver of the disease.</li><li>\u2022 Option A. CDKN2A (p16INK4A) mutation:</li><li>\u2022 Option B. CDKN1B (p27) mutation: Mutations in CDKN1B are associated with MEN4 syndrome (multiple endocrine neoplasia type 4) and can be seen in other cancers, but not typically in mantle cell lymphoma.</li><li>\u2022 Option B. CDKN1B (p27) mutation:</li><li>\u2022 Option D. TP53 mutation: TP53 is a tumor suppressor gene, and mutations are found in various cancers. While TP53 mutations can occur in MCL and are associated with a worse prognosis, they are not the primary genetic alteration driving the disease.</li><li>\u2022 Option D. TP53 mutation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 CCND1 amplification is a hallmark of mantle cell lymphoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "133f64d1",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman is diagnosed with breast cancer and is referred to an oncologist for treatment. The tumor is found to be estrogen receptor-positive and HER2-negative. The oncologist discusses the use of a targeted therapy that specifically interferes with the cell cycle of cancer cells, thereby inhibiting their proliferation. The medication targets a specific phase of the cell cycle, leading to cell cycle arrest and eventual apoptosis of the cancer cells. Which of the following best describes the mechanism of action of the medication likely prescribed to this patient?",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition",
          "correct": true
        },
        {
          "label": "B",
          "text": "Activation of topoisomerase II in the S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibition of microtubule formation in the M phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Activation of DNA repair enzymes in the G2 phase",
          "correct": false
        }
      ],
      "correct_answer": "A. Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Activation of topoisomerase II in the S phase : Topoisomerase II inhibitors, such as etoposide, work by interfering with the action of topoisomerase II, an enzyme involved in DNA replication and cell division during the S phase. This mechanism is not specific to CDK inhibitors used in breast cancer treatment.</li><li>\u2022 Option B. Activation of topoisomerase II in the S phase</li><li>\u2022 Option C. Inhibition of microtubule formation in the M phase : Microtubule inhibitors, such as taxanes (e.g., paclitaxel), target the M phase of the cell cycle by preventing the formation of microtubules, which are essential for chromosome separation during cell division. This mechanism is different from that of CDK inhibitors.</li><li>\u2022 Option C. Inhibition of microtubule formation in the M phase</li><li>\u2022 Option D. Activation of DNA repair enzymes in the G2 phase : This option is not a common mechanism for targeted therapy in breast cancer. Drugs that target DNA repair pathways typically work by inhibiting, not activating, DNA repair enzymes to prevent cancer cells from repairing DNA damage.</li><li>\u2022 Option D. Activation of DNA repair enzymes in the G2 phase</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in the treatment of estrogen receptor-positive, HER2-negative breast cancer. They work by inhibiting CDK4/6, leading to cell cycle arrest at the G1/S transition and preventing cancer cell proliferation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4065a86c",
      "audio": ""
    },
    {
      "text": "Which of the following is a negative regulator that prevents the progression of cells from the G1 phase to the S phase in the cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "Cyclin A",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cyclin-dependent kinase 2 (CDK2)",
          "correct": false
        },
        {
          "label": "C",
          "text": "p21",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cyclin E",
          "correct": false
        }
      ],
      "correct_answer": "C. p21",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cyclin A: Is a positive regulator of the cell cycle that activates CDK2, promoting progression through the S phase.</li><li>\u2022 Option A. Cyclin A:</li><li>\u2022 Option B. Cyclin-dependent kinase 2 (CDK2): Is a positive regulator that, when activated by cyclins such as cyclin E and cyclin A, helps drive the cell cycle from the G1 phase to the S phase.</li><li>\u2022 Option B. Cyclin-dependent kinase 2 (CDK2):</li><li>\u2022 Option D. Cyclin E: Is a positive regulator of the cell cycle that activates CDK2, promoting the transition from the G1 phase to the S phase.</li><li>\u2022 Option D. Cyclin E:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 p21 is a negative regulator of the cell cycle that inhibits the activity of cyclin-CDK complexes, preventing the progression of cells from the G1 phase to the S phase.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ad6abb42",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman presents with a family history of early-onset colon cancer and multiple family members affected by various types of cancer. Which of the following genetic mutations is MOST likely responsible for her increased cancer risk?",
      "options": [
        {
          "label": "A",
          "text": "BRCA1 mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "MUTYH mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "MSH2 mutation",
          "correct": true
        },
        {
          "label": "D",
          "text": "ATM mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. MSH2 mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. BRCA1 mutation: BRCA1 mutations are primarily associated with increased risks of breast and ovarian cancers. While they can increase the risk of other cancers, the patient's family history of colon cancer makes this less likely.</li><li>\u2022 Option A. BRCA1 mutation:</li><li>\u2022 Option B. MUTYH mutation: MUTYH mutations are associated with MUTYH-associated polyposis (MAP), a hereditary condition that increases the risk of colorectal cancer. However, MAP usually presents with multiple polyps, and the patient's family history doesn't necessarily fit this pattern.</li><li>\u2022 Option B. MUTYH mutation:</li><li>\u2022 Option D. ATM mutation: ATM mutations are associated with ataxia-telangiectasia, a rare neurodegenerative disorder characterized by ataxia, telangiectasias (small dilated blood vessels), and immune deficiencies. While individuals with ataxia-telangiectasia have an increased risk of certain cancers, the presentation in this question doesn't match the typical features of this condition.</li><li>\u2022 Option D. ATM mutation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 MSH2 mutations are associated with Lynch syndrome, a hereditary cancer syndrome that significantly increases the risk of various cancers, including colorectal, endometrial, and ovarian cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ff976101",
      "audio": ""
    },
    {
      "text": "A 38-year-old woman presents to your clinic with a newly discovered breast mass. Her family history is significant for multiple cases of breast and ovarian cancer, including her mother and sister. Genetic testing reveals a germline BRCA1 mutation. Which of the following DNA repair pathways is MOST likely deficient in this patient, contributing to her increased cancer risk?",
      "options": [
        {
          "label": "A",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Base excision repair (BER)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Homologous recombination (HR)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Single-strand break repair",
          "correct": false
        }
      ],
      "correct_answer": "C. Homologous recombination (HR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Non-homologous end joining (NHEJ): While important for DNA repair, NHEJ is not the primary pathway affected by BRCA1 mutations.</li><li>\u2022 Option A. Non-homologous end joining (NHEJ):</li><li>\u2022 Option B. Base excision repair (BER): BER is primarily responsible for repairing single-base DNA damage and is not directly affected by BRCA1 mutations.</li><li>\u2022 Option B. Base excision repair (BER):</li><li>\u2022 Option D. Single-strand break repair: This is a broader term encompassing several pathways, including BER and PARP. While PARP inhibitors are used in BRCA-mutant cancers, the primary defect lies in HR.</li><li>\u2022 Option D. Single-strand break repair:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 BRCA1 mutations lead to a deficiency in homologous recombination (HR), a critical DNA repair mechanism. This defect contributes to genomic instability and significantly increases the risk of breast and ovarian cancers in affected individuals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5556e8d8",
      "audio": ""
    },
    {
      "text": "A 5-year-old child is brought to your clinic by their parents, who are concerned about their child's extreme sensitivity to sunlight. The child easily sunburns and has developed multiple freckles and skin lesions after minimal sun exposure. On examination, you notice dry skin and patches of hypopigmentation. You suspect an underlying genetic disorder affecting DNA repair mechanisms. Which of the following DNA repair pathways is MOST likely deficient in this child?",
      "options": [
        {
          "label": "A",
          "text": "Base excision repair (BER)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nucleotide excision repair (NER)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Homologous recombination (HR)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        }
      ],
      "correct_answer": "B. Nucleotide excision repair (NER)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Base excision repair (BER): BER primarily repairs damage to single bases in DNA, often caused by oxidation or alkylation. While important, it's not the primary pathway for repairing the type of damage caused by UV radiation.</li><li>\u2022 Option A. Base excision repair (BER):</li><li>\u2022 Option C. Homologous recombination (HR): HR is a complex process used to repair double-stranded DNA breaks. While critical for genome stability, it's not the main mechanism for repairing UV-induced DNA damage.</li><li>\u2022 Option C. Homologous recombination (HR):</li><li>\u2022 Option D. Non-homologous end joining (NHEJ): Similar to HR, NHEJ repairs double-stranded breaks but does not play a major role in repairing UV-induced damage.</li><li>\u2022 Option D. Non-homologous end joining (NHEJ):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The inability to repair UV-induced DNA damage in XP leads to a significantly increased risk of skin cancer at a young age, as well as other complications like ocular problems and neurological abnormalities. Early diagnosis and strict sun protection measures are crucial for managing XP.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6cb3aef0",
      "audio": ""
    },
    {
      "text": "A researcher is investigating a new drug that inhibits the formation of the inflammasome complex. Which of the following types of cell death would be MOST directly affected by this drug?",
      "options": [
        {
          "label": "A",
          "text": "Apoptosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Necroptosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pyroptosis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Necrosis",
          "correct": false
        }
      ],
      "correct_answer": "C. Pyroptosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Apoptosis: Apoptosis is a programmed cell death pathway, but it is not directly dependent on the inflammasome. It involves a different set of caspases (caspase-3, -6, -7) and is not typically associated with the same inflammatory response as pyroptosis.</li><li>\u2022 Option A. Apoptosis:</li><li>\u2022 Option B. Necroptosis: Necroptosis is another form of programmed cell death, but it is regulated by the RIPK1-RIPK3-MLKL pathway, not the inflammasome.</li><li>\u2022 Option B. Necroptosis:</li><li>\u2022 Option D. Necrosis: Necrosis is an unregulated form of cell death that is typically caused by injury or trauma. It is not a programmed process and is not mediated by the inflammasome.</li><li>\u2022 Option D. Necrosis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The inflammasome is a multiprotein complex that plays a central role in pyroptosis. It senses danger signals and activates caspase-1, leading to the production of pro-inflammatory cytokines and ultimately cell death with membrane rupture. By inhibiting the inflammasome, the drug would directly block the pyroptotic pathway.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2c0ab4c1",
      "audio": ""
    },
    {
      "text": "A biopsy of a patient's liver reveals hepatocytes with extensive swelling, loss of plasma membrane integrity, and leakage of cellular contents into the surrounding tissue. Which of the following types of cell death is MOST likely occurring in these cells?",
      "options": [
        {
          "label": "A",
          "text": "Apoptosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Necroptosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pyroptosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Necrosis",
          "correct": true
        }
      ],
      "correct_answer": "D. Necrosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Apoptosis: Apoptosis is a programmed cell death that involves cell shrinkage, nuclear condensation, and fragmentation into apoptotic bodies, without leakage of cellular contents.</li><li>\u2022 Option A. Apoptosis:</li><li>\u2022 Option B. Necroptosis: Necroptosis is a regulated form of cell death that shares some features with necrosis, such as cell swelling and membrane rupture. However, it is initiated by specific signaling pathways and does not typically occur in the liver in response to injury.</li><li>\u2022 Option B. Necroptosis:</li><li>\u2022 Option C. Pyroptosis: Pyroptosis is an inflammatory form of programmed cell death that involves the formation of pores in the cell membrane, but it is primarily associated with immune responses to infection.</li><li>\u2022 Option C. Pyroptosis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Necrosis is an unregulated cell death process characterized by cell swelling, membrane rupture, and leakage of cellular contents.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "967211c8",
      "audio": ""
    },
    {
      "text": "A patient with follicular lymphoma (FL) is found to have a t(14;18) translocation. Which of the following is the MOST likely consequence of this translocation?",
      "options": [
        {
          "label": "A",
          "text": "Overexpression of BCL-2",
          "correct": true
        },
        {
          "label": "B",
          "text": "Loss of p53 function",
          "correct": false
        },
        {
          "label": "C",
          "text": "Activation of RAS",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amplification of MYC",
          "correct": false
        }
      ],
      "correct_answer": "A. Overexpression of BCL-2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Loss of p53 function: While TP53 mutations (leading to loss of p53 function) are common in many cancers, they are not the primary driver of follicular lymphoma.</li><li>\u2022 Option B. Loss of p53 function:</li><li>\u2022 Option C. Activation of RAS: RAS mutations are associated with various cancers, but they are not the hallmark of follicular lymphoma.</li><li>\u2022 Option C. Activation of RAS:</li><li>\u2022 Option D. Amplification of MYC: MYC amplification is more commonly associated with Burkitt lymphoma and other aggressive lymphomas.</li><li>\u2022 Option D. Amplification of MYC:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 The t(14;18) translocation is a hallmark of follicular lymphoma and contributes to its pathogenesis by inhibiting apoptosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06861856",
      "audio": ""
    },
    {
      "text": "A 35-year-old patient presents with painless hematuria and flank pain. Imaging reveals a renal mass with characteristic features of clear cell renal cell carcinoma (RCC). Which of the following genetic alterations is MOST likely involved in the pathogenesis of this tumor?",
      "options": [
        {
          "label": "A",
          "text": "Mutation in BRCA1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amplification of HER2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Loss of function mutation in VHL",
          "correct": true
        },
        {
          "label": "D",
          "text": "Activation of KRAS",
          "correct": false
        }
      ],
      "correct_answer": "C. Loss of function mutation in VHL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mutation in BRCA1: BRCA1 is a tumor suppressor gene primarily associated with breast and ovarian cancers. While it can be involved in other cancers, it's not the primary driver of clear cell renal cell carcinoma (RCC).</li><li>\u2022 Option A. Mutation in BRCA1:</li><li>\u2022 Option B. Amplification of HER2: HER2 amplification is a key feature of certain breast cancers and some other malignancies, but not clear cell RCC.</li><li>\u2022 Option B. Amplification of HER2:</li><li>\u2022 Option D. Activation of KRAS: KRAS is an oncogene involved in various cancers, including some types of lung and colon cancer. It is not the hallmark of clear cell RCC.</li><li>\u2022 Option D. Activation of KRAS:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The VHL gene plays a crucial role in oxygen sensing and regulation of blood vessel growth. When VHL is inactivated, it leads to the stabilization and activation of hypoxia-inducible factor (HIF), which promotes angiogenesis (new blood vessel formation) and tumor growth. This is why VHL loss-of-function mutations are so strongly linked to clear cell RCC.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "675174be",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is a monoclonal antibody targeting VEGF and is used in the treatment of various cancers, including renal cell carcinoma?",
      "options": [
        {
          "label": "A",
          "text": "Bevacizumab",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cetuximab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trastuzumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rituximab",
          "correct": false
        }
      ],
      "correct_answer": "A. Bevacizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Cetuximab: This monoclonal antibody targets the epidermal growth factor receptor (EGFR), which is involved in cell growth and proliferation. It is not typically used to treat renal cell carcinoma.</li><li>\u2022 Option B. Cetuximab:</li><li>\u2022 Option C. Trastuzumab: This monoclonal antibody targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast and stomach cancers. It is not indicated for renal cell carcinoma.</li><li>\u2022 Option C. Trastuzumab:</li><li>\u2022 Option D. Rituximab: This monoclonal antibody targets CD20, a protein found on the surface of B cells. It is used to treat certain types of lymphomas and leukemias but not renal cell carcinoma.</li><li>\u2022 Option D. Rituximab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bevacizumab stands out as the correct answer because it specifically targets VEGF, a key player in angiogenesis, which is a crucial process for tumor growth and survival. The other options are monoclonal antibodies targeting different receptors or proteins involved in other cancer types.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "333eebd7",
      "audio": ""
    },
    {
      "text": "A 52-year-old man with metastatic melanoma has progressed on previous therapy. You are considering starting him on an immune checkpoint inhibitor along with nivolumab after which you are planning to keep him on nibolumab. Which of the following immune checkpoint molecules is the DIRECT target for the drug which you have planned to give for this patient along with nivolumab?",
      "options": [
        {
          "label": "A",
          "text": "PD-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "PD-L1",
          "correct": false
        },
        {
          "label": "C",
          "text": "CTLA-4",
          "correct": true
        },
        {
          "label": "D",
          "text": "CD80/86",
          "correct": false
        }
      ],
      "correct_answer": "C. CTLA-4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. PD-1: PD-1 is another inhibitory checkpoint on T cells, but it's targeted by different drugs like nivolumab and pembrolizumab.</li><li>\u2022 Option A. PD-1:</li><li>\u2022 Option B. PD-L1: PD-L1 is the ligand for PD-1, and it's also targeted by different drugs like atezolizumab and durvalumab.</li><li>\u2022 Option B. PD-L1:</li><li>\u2022 Option D. CD80/86: These are the ligands for CTLA-4, but ipilimumab doesn't directly bind to them; it binds to CTLA-4 itself.</li><li>\u2022 Option D. CD80/86:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the specific targets of immune checkpoint inhibitors is crucial for selecting the right therapy for different types of cancer and managing potential immune-related side effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bce25a5b",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman with metastatic Merkel cell carcinoma has progressed on chemotherapy and is now being considered for immunotherapy. You plan to start him on an a monoclonal antibody designed to enhance the anti-tumor immune response. Which of the following immune checkpoint molecules is the DIRECT target of that drug?",
      "options": [
        {
          "label": "A",
          "text": "CTLA-4",
          "correct": false
        },
        {
          "label": "B",
          "text": "PD-1",
          "correct": false
        },
        {
          "label": "C",
          "text": "PD-L1",
          "correct": true
        },
        {
          "label": "D",
          "text": "LAG-3",
          "correct": false
        }
      ],
      "correct_answer": "C. PD-L1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. CTLA-4: CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) is another immune checkpoint molecule, but it is targeted by different drugs like ipilimumab. Avelumab does not directly bind to or inhibit CTLA-4.</li><li>\u2022 Option A. CTLA-4:</li><li>\u2022 Option B. PD-1: PD-1 (Programmed Cell Death Protein 1) is the receptor on T cells that PD-L1 binds to. While avelumab indirectly affects PD-1 signaling by blocking its interaction with PD-L1, it doesn't directly bind to PD-1. Other drugs like nivolumab and pembrolizumab are designed to directly target PD-1.</li><li>\u2022 Option B. PD-1:</li><li>\u2022 Option D. LAG-3: LAG-3 (Lymphocyte Activation Gene-3) is another inhibitory receptor on T cells that is being investigated as a target for immunotherapy. However, avelumab does not target LAG-3.</li><li>\u2022 Option D. LAG-3:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Avelumab is a PD-L1 inhibitor used in the treatment of metastatic Merkel cell carcinoma and other cancers to unleash the body's immune system against tumors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fcb6dca1",
      "audio": ""
    },
    {
      "text": "A researcher is studying the metabolic profile of cancer cells and notices that they primarily produce energy through glycolysis, even in the presence of oxygen. This phenomenon is BEST described as:",
      "options": [
        {
          "label": "A",
          "text": "Oxidative phosphorylation",
          "correct": false
        },
        {
          "label": "B",
          "text": "The Cori cycle",
          "correct": false
        },
        {
          "label": "C",
          "text": "The Warburg effect",
          "correct": true
        },
        {
          "label": "D",
          "text": "Gluconeogenesis",
          "correct": false
        }
      ],
      "correct_answer": "C. The Warburg effect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Oxidative phosphorylation: This is the normal process of energy production in cells with sufficient oxygen. It occurs in the mitochondria and is much more efficient at generating ATP than glycolysis.</li><li>\u2022 Option A. Oxidative phosphorylation:</li><li>\u2022 Option B. The Cori cycle: This is a metabolic pathway that involves the interconversion of lactate and glucose between the liver and muscles. While lactate is a byproduct of glycolysis, the Cori cycle itself isn't the primary energy production method in cancer cells.</li><li>\u2022 Option B. The Cori cycle:</li><li>\u2022 Option D. Gluconeogenesis: This is the process of synthesizing glucose from non-carbohydrate sources (like amino acids or lactate). While cancer cells may engage in gluconeogenesis, it's not the main energy-producing pathway they rely on.</li><li>\u2022 Option D. Gluconeogenesis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The Warburg effect is a hallmark of cancer metabolism and has implications for both cancer diagnosis and potential therapeutic targets.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a654e717",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman with metastatic renal cell carcinoma has recently shown disease progression despite initial chemotherapy. Her oncologist is considering a treatment strategy to target the tumor's ability to create its own blood supply. Which of the following classes of drugs would be MOST appropriate for this purpose?",
      "options": [
        {
          "label": "A",
          "text": "Cyclin-dependent kinase inhibitors",
          "correct": false
        },
        {
          "label": "B",
          "text": "BH3 mimetics",
          "correct": false
        },
        {
          "label": "C",
          "text": "VEGF signaling inhibitors",
          "correct": true
        },
        {
          "label": "D",
          "text": "PARP inhibitors",
          "correct": false
        }
      ],
      "correct_answer": "C. VEGF signaling inhibitors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cyclin-dependent kinase inhibitors: These drugs target cell cycle progression and are not directly involved in angiogenesis.</li><li>\u2022 Option A. Cyclin-dependent kinase inhibitors:</li><li>\u2022 Option B. BH3 mimetics: These drugs target the apoptotic pathway to induce cell death and are not directly involved in angiogenesis.</li><li>\u2022 Option B. BH3 mimetics:</li><li>\u2022 Option D. PARP inhibitors: These drugs exploit DNA repair defects in cancer cells and are not directly involved in angiogenesis.</li><li>\u2022 Option D. PARP inhibitors:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 VEGF signaling inhibitors are a class of drugs that target angiogenesis, a crucial process for tumor growth and survival. They are used in the treatment of various cancers, including renal cell carcinoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aec4dc90",
      "audio": ""
    },
    {
      "text": "A 32-year-old male presents with progressive headaches, gait instability, and visual disturbances. MRI was taken and shown below. Patient also has, multiple retinal angiomas. His family history is notable for his father died of uncontrolled hypertension during his 50s and his paternal side uncle was diagnosed with a brain tumor and uncontrolled hypertension along with frequent anger outbursts seeking psychiatric counselling. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Neurofibromatosis type 2",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tuberous sclerosis complex",
          "correct": false
        },
        {
          "label": "C",
          "text": "Von Hippel-Lindau disease",
          "correct": true
        },
        {
          "label": "D",
          "text": "Li-Fraumeni syndrome",
          "correct": false
        }
      ],
      "correct_answer": "C. Von Hippel-Lindau disease",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-172814.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Neurofibromatosis type 2: This condition is associated with bilateral vestibular schwannomas (tumors of the nerve responsible for hearing and balance) and other nerve tumors, not the specific findings in this case.</li><li>\u2022 Option A. Neurofibromatosis type 2:</li><li>\u2022 Option B. Tuberous sclerosis complex: This syndrome is associated with benign tumors in various organs, including the brain, kidneys, heart, eyes, lungs, and skin. The characteristic brain tumors are cortical tubers and subependymal giant cell astrocytomas, not hemangioblastomas.</li><li>\u2022 Option B. Tuberous sclerosis complex:</li><li>\u2022 Option D. Li-Fraumeni syndrome: This syndrome predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. It is not typically associated with the specific combination of findings in this patient.</li><li>\u2022 Option D. Li-Fraumeni syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The presence of a cerebellar hemangioblastoma and retinal angiomas, especially in conjunction with a suggestive family history, should raise strong suspicion for Von Hippel-Lindau disease. Early diagnosis and surveillance are crucial for managing this condition and preventing complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "beeb4387",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman presents with a family history of early-onset colon and endometrial cancer. Which of the following hereditary cancer syndromes is MOST likely in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Li-Fraumeni syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Von Hippel-Lindau disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hereditary diffuse gastric cancer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lynch syndrome (HNPCC)",
          "correct": true
        }
      ],
      "correct_answer": "D. Lynch syndrome (HNPCC)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Li-Fraumeni syndrome: Li-Fraumeni syndrome is associated with a broader range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. While colon cancer can occur in Li-Fraumeni syndrome, the prominence of endometrial cancer in the family history makes Lynch syndrome more likely.</li><li>\u2022 Option A. Li-Fraumeni syndrome:</li><li>\u2022 Option B. Von Hippel-Lindau disease: This syndrome is primarily characterized by the development of hemangioblastomas, renal cell carcinomas, and pheochromocytomas. It's not typically associated with a strong family history of colon or endometrial cancer.</li><li>\u2022 Option B. Von Hippel-Lindau disease:</li><li>\u2022 Option C. Hereditary diffuse gastric cancer: This syndrome is mainly linked to an increased risk of diffuse gastric cancer and lobular breast cancer. While other cancers can occur, the family history in this case points more towards Lynch syndrome.</li><li>\u2022 Option C. Hereditary diffuse gastric cancer:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lynch syndrome is an inherited cancer syndrome characterized by an increased risk of colorectal, endometrial, and other cancers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4155ff9f",
      "audio": ""
    },
    {
      "text": "A 28-year-old man presents with multiple pigmented skin lesions and cardiac myxomas. He also reports a family history of sudden cardiac death. Which gene is MOST likely to be mutated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "PRKAR1A",
          "correct": true
        },
        {
          "label": "B",
          "text": "CDKN2A",
          "correct": false
        },
        {
          "label": "C",
          "text": "SDH",
          "correct": false
        },
        {
          "label": "D",
          "text": "MET",
          "correct": false
        }
      ],
      "correct_answer": "A. PRKAR1A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. CDKN2A : This gene is associated with melanoma and pancreatic cancer in the context of familial atypical multiple mole melanoma (FAMMM) syndrome. While pigmented skin lesions can be present in FAMMM, cardiac myxomas and a family history of sudden cardiac death are not characteristic features.</li><li>\u2022 Option B. CDKN2A</li><li>\u2022 Option C. SDH : Mutations in SDH genes are linked to hereditary paraganglioma-pheochromocytoma syndrome, which primarily manifests with tumors of the adrenal glands and nervous system. Cardiac myxomas and pigmented skin lesions are not associated with this syndrome.</li><li>\u2022 Option C. SDH</li><li>\u2022 Option D. MET : MET mutations are involved in hereditary papillary renal cell carcinoma. This condition is not typically associated with cardiac myxomas or pigmented skin lesions.</li><li>\u2022 Option D. MET</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The specific constellation of findings in this patient, including pigmented skin lesions, cardiac myxomas, and a family history of sudden cardiac death, is strongly suggestive of Carney complex, a rare autosomal dominant disorder caused by mutations in the PRKAR1A gene.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38300b32",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman presents with a history of recurrent kidney stones and hypercalcemia. Her family history is significant for her mother having a pituitary tumor and her brother having undergone surgery for a parathyroid adenoma. Given the patient's clinical presentation and family history, which of the following tumors is LEAST likely to be associated with her suspected diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Gastrinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prolactinoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Medullary thyroid carcinoma",
          "correct": true
        },
        {
          "label": "D",
          "text": "Insulinoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Medullary thyroid carcinoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Gastrinoma: Gastrinomas are tumors of the pancreas that secrete gastrin, leading to excessive stomach acid production and peptic ulcers. They are a common feature of MEN1.</li><li>\u2022 Option A. Gastrinoma:</li><li>\u2022 Option B. Prolactinoma: Prolactinomas are pituitary tumors that secrete prolactin, causing symptoms like irregular periods, infertility, and milk production in women. Pituitary tumors are a key component of MEN1.</li><li>\u2022 Option B. Prolactinoma:</li><li>\u2022 Option D. Insulinoma: Insulinomas are pancreatic tumors that secrete insulin, leading to hypoglycemia. They are another common manifestation of MEN1.</li><li>\u2022 Option D. Insulinoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The constellation of findings in this patient points strongly towards MEN1. While MEN1 can have a variety of manifestations, medullary thyroid carcinoma is a hallmark of MEN2 and is not typically associated with MEN1.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "86a0b38f",
      "audio": ""
    },
    {
      "text": "A 7-year-old boy is brought to the pediatrician due to concerns about his small stature and sun sensitivity. He has also had recurrent respiratory infections. On physical examination, he is noted to have a photosensitive rash on his face, microcephaly, and low body weight for his age. Which of the following DNA repair pathways is MOST likely deficient in this child?",
      "options": [
        {
          "label": "A",
          "text": "Homologous recombination (HR)",
          "correct": true
        },
        {
          "label": "B",
          "text": "DNA crosslink repair",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-homologous end joining (NHEJ)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mismatch repair (MMR)",
          "correct": false
        }
      ],
      "correct_answer": "A. Homologous recombination (HR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Homologous recombination (HR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. DNA crosslink repair: Defects in DNA crosslink repair are seen in Fanconi anemia, which presents with bone marrow failure, developmental abnormalities, and increased risk of leukemia, but not the other features seen in this patient.</li><li>\u2022 Option B. DNA crosslink repair:</li><li>\u2022 Option C. Non-homologous end joining (NHEJ): NHEJ is another DNA repair pathway that repairs double-strand breaks. While important for maintaining genomic stability, it's not the primary pathway affected in Bloom syndrome.</li><li>\u2022 Option C. Non-homologous end joining (NHEJ):</li><li>\u2022 Option D. Mismatch repair (MMR): MMR corrects errors that occur during DNA replication. Defects in MMR are seen in Lynch syndrome, which is associated with an increased risk of colorectal and other cancers, but not the characteristic features of Bloom syndrome.</li><li>\u2022 Option D. Mismatch repair (MMR):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Bloom syndrome is a rare genetic disorder characterized by growth retardation, sun sensitivity, immunodeficiency, and predisposition to various cancers. It is caused by mutations in the BLM gene, which leads to defective homologous recombination and genomic instability.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1e52eb1f",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with premature aging, bilateral cataracts, and diabetes mellitus. She also has a family history of early-onset cancer. On examination, you observe that she has a bird-like peculiar facial feature. Which of the following genetic disorders is MOST likely?",
      "options": [
        {
          "label": "A",
          "text": "Ataxia-telangiectasia (AT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bloom syndrome (BLMS)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fanconi anemia (FA)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Werner syndrome (WRN)",
          "correct": true
        }
      ],
      "correct_answer": "D. Werner syndrome (WRN)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ataxia-telangiectasia (AT): This condition presents in childhood with ataxia (uncoordinated movements), telangiectasias (dilated blood vessels), and immune deficiency. While it also predisposes to cancer, the premature aging features and cataracts are not characteristic.</li><li>\u2022 Option A. Ataxia-telangiectasia (AT):</li><li>\u2022 Option B. Bloom syndrome (BLMS): Bloom syndrome is also associated with an increased cancer risk and sun sensitivity, but the hallmark feature is short stature, not premature aging or cataracts.</li><li>\u2022 Option B. Bloom syndrome (BLMS):</li><li>\u2022 Option C. Fanconi anemia (FA): This condition is primarily characterized by bone marrow failure and an increased risk of leukemia and other cancers. Premature aging and cataracts are not typical features.</li><li>\u2022 Option C. Fanconi anemia (FA):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The combination of premature aging, cataracts, diabetes, a family history of early-onset cancer, and a \"bird-like\" facial appearance strongly supports the diagnosis of Werner syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "042af92d",
      "audio": ""
    },
    {
      "text": "A 58-year-old woman with metastatic pancreatic cancer is undergoing chemotherapy. Her oncologist is considering adding an antimetabolite that not only disrupts DNA synthesis but also has an inhibitory effect on RNA reductase to further hinder cancer cell growth. Which of the following medications would BEST fit this description?",
      "options": [
        {
          "label": "A",
          "text": "Fludarabine",
          "correct": false
        },
        {
          "label": "B",
          "text": "6-Mercaptopurine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gemcitabine",
          "correct": true
        },
        {
          "label": "D",
          "text": "5-Fluorouracil (5-FU)",
          "correct": false
        }
      ],
      "correct_answer": "C. Gemcitabine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Gemcitabine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Fludarabine : Fludarabine primarily acts by incorporating into DNA and inhibiting DNA polymerase and other enzymes involved in DNA synthesis and repair. It does not have a known mechanism of action involving RNA reductase inhibition.</li><li>\u2022 Option A. Fludarabine</li><li>\u2022 Option B. 6-Mercaptopurine : This purine analog inhibits purine synthesis, indirectly affecting both DNA and RNA synthesis. However, its primary target is not RNA reductase.</li><li>\u2022 Option B. 6-Mercaptopurine</li><li>\u2022 Option D. 5-Fluorouracil (5-FU) : 5-FU acts by inhibiting thymidylate synthase, an enzyme crucial for DNA synthesis. It does not directly inhibit RNA reductase.</li><li>\u2022 Option D. 5-Fluorouracil (5-FU)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Gemcitabine's dual mechanism of action, targeting both DNA and RNA synthesis, makes it a valuable chemotherapeutic option for various cancers, including pancreatic cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e1762e3a",
      "audio": ""
    },
    {
      "text": "A patient with breast cancer is being treated with a drug that stabilizes microtubules, preventing their depolymerization. Which of the following drugs is MOST likely being used?",
      "options": [
        {
          "label": "A",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paclitaxel",
          "correct": true
        },
        {
          "label": "C",
          "text": "Eribulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "5-Fluorouracil",
          "correct": false
        }
      ],
      "correct_answer": "B. Paclitaxel",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vincristine: Vincristine is a vinca alkaloid that destabilizes microtubules by binding to tubulin and preventing its polymerization. This leads to disruption of the mitotic spindle and cell death.</li><li>\u2022 Option A. Vincristine:</li><li>\u2022 Option C. Eribulin: Eribulin is also a microtubule-destabilizing agent, though its mechanism of action is slightly different from vinca alkaloids. It binds to the plus end of microtubules, preventing their growth and leading to mitotic arrest.</li><li>\u2022 Option C. Eribulin:</li><li>\u2022 Option D. 5-Fluorouracil (5-FU): 5-FU is an antimetabolite that interferes with DNA synthesis. It has no direct effect on microtubules.</li><li>\u2022 Option D. 5-Fluorouracil (5-FU):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The key difference lies in the mechanism of action. Paclitaxel stabilizes microtubules, preventing their normal breakdown, which is essential for cell division. In contrast, vinca alkaloids and eribulin destabilize microtubules, also disrupting cell division but through a different process.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd1fa20e",
      "audio": ""
    },
    {
      "text": "A 60-year-old male with Hodgkin's lymphoma is undergoing combination chemotherapy. During a follow-up visit, he reports a new onset of dry cough and shortness of breath. Chest X-ray reveals diffuse interstitial infiltrates. Which of the following drugs included in his chemotherapy regimen is MOST likely responsible for these findings?",
      "options": [
        {
          "label": "A",
          "text": "Mitoxantrone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dactinomycin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Mitomycin",
          "correct": false
        }
      ],
      "correct_answer": "C. Bleomycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mitoxantrone: While mitoxantrone can cause some pulmonary toxicity, it is less common and less severe than that associated with bleomycin.</li><li>\u2022 Option A. Mitoxantrone:</li><li>\u2022 Option B. Dactinomycin: Dactinomycin is not typically associated with significant pulmonary toxicity.</li><li>\u2022 Option B. Dactinomycin:</li><li>\u2022 Option D. Mitomycin: Mitomycin is more commonly associated with hemorrhagic cystitis (inflammation of the bladder with bleeding) and myelosuppression.</li><li>\u2022 Option D. Mitomycin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bleomycin is an important antitumor antibiotic with a significant risk of pulmonary toxicity, which can manifest as pneumonitis and fibrosis. Careful monitoring of lung function is essential during and after treatment with bleomycin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "81545ab6",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with a 40 pack-year smoking history presents with a persistent cough and hemoptysis. Imaging reveals a central lung mass, and biopsy confirms small cell lung cancer (SCLC). He is started on a chemotherapy regimen including etoposide. Etoposide exerts its anti-cancer effects by targeting a specific phase of the cell cycle. During which phase is etoposide MOST effective?",
      "options": [
        {
          "label": "A",
          "text": "G1 phase",
          "correct": false
        },
        {
          "label": "B",
          "text": "S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "G2 phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "M phase",
          "correct": true
        }
      ],
      "correct_answer": "D. M phase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. G1 phase: This is the phase where the cell grows and prepares for DNA replication. Etoposide's mechanism doesn't directly target processes in this phase.</li><li>\u2022 Option A. G1 phase:</li><li>\u2022 Option B. S phase: This is the phase of DNA replication. While DNA damage can occur here, etoposide's primary action is on the M phase.</li><li>\u2022 Option B. S phase:</li><li>\u2022 Option C. G2 phase: This phase involves further cell growth and preparation for mitosis. Again, etoposide's primary target is the M phase.</li><li>\u2022 Option C. G2 phase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Etoposide is a topoisomerase II inhibitor that is most effective during the M phase of the cell cycle, where it disrupts chromosome segregation and leads to cell death. Understanding the cell cycle specificity of chemotherapy drugs is crucial for optimizing treatment regimens.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f4051472",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with platinum-resistant ovarian cancer is started on topotecan. You counsel her that this medication works by:",
      "options": [
        {
          "label": "A",
          "text": "Directly blocking DNA synthesis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Preventing cell division by disrupting microtubules",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trapping an enzyme involved in DNA unwinding, leading to DNA breaks",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inserting itself into DNA, causing structural damage",
          "correct": false
        }
      ],
      "correct_answer": "C. Trapping an enzyme involved in DNA unwinding, leading to DNA breaks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Directly blocking DNA synthesis: While topotecan ultimately disrupts DNA replication, it doesn't directly block DNA synthesis in the same way that antimetabolites do. Antimetabolites, like 5-FU, are structurally similar to DNA building blocks and get incorporated into the DNA strand, thus halting its growth.</li><li>\u2022 Option A. Directly blocking DNA synthesis:</li><li>\u2022 Option B. Preventing cell division by disrupting microtubules: This is the mechanism of action of drugs like taxanes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). They interfere with the formation of the mitotic spindle, which is essential for cell division.</li><li>\u2022 Option B. Preventing cell division by disrupting microtubules:</li><li>\u2022 Option D. Inserting itself into DNA, causing structural damage: This describes the mechanism of action of anthracyclines (doxorubicin, daunorubicin). These drugs intercalate between DNA base pairs, leading to distortion of the DNA structure and interfering with replication and transcription.</li><li>\u2022 Option D. Inserting itself into DNA, causing structural damage:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Topotecan targets topoisomerase I, disrupting DNA replication and causing lethal DNA damage in cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c77cfb5f",
      "audio": ""
    },
    {
      "text": "A patient with chronic myeloid leukemia (CML) is started on a drug that alkylates DNA and forms cross-links. Which of the following drugs is MOST likely being used?",
      "options": [
        {
          "label": "A",
          "text": "Busulfan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cisplatin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Temozolomide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Procarbazine",
          "correct": false
        }
      ],
      "correct_answer": "A. Busulfan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Busulfan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Cisplatin: Cisplatin is a platinum compound, not an alkylsulfonate. While it also forms DNA cross-links, it does so through a different mechanism involving platinum adducts. It's not the primary choice for CML.</li><li>\u2022 Option B. Cisplatin:</li><li>\u2022 Option C. Temozolomide: Temozolomide is a triazene, a type of alkylating agent that primarily causes methylation of DNA. While effective in certain brain tumors and melanomas, it's not the first-line treatment for CML.</li><li>\u2022 Option C. Temozolomide:</li><li>\u2022 Option D. Procarbazine: Procarbazine is a miscellaneous alkylating agent with a complex mechanism of action involving free radical generation. It's less commonly used in CML and doesn't primarily cause DNA cross-linking.</li><li>\u2022 Option D. Procarbazine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alkylsulfonates are bifunctional alkylating agents that cause DNA cross-linking, which is particularly effective against rapidly dividing cells like those in CML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d6165c3c",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with non-Hodgkin lymphoma is undergoing chemotherapy. He presents to the emergency room with complaints of burning urination and blood in his urine. Which of the following classes of chemotherapeutic agents is MOST likely responsible for his symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Nitrogen mustards",
          "correct": true
        },
        {
          "label": "B",
          "text": "Nitrosoureas",
          "correct": false
        },
        {
          "label": "C",
          "text": "Platinum compounds",
          "correct": false
        },
        {
          "label": "D",
          "text": "Triazenes",
          "correct": false
        }
      ],
      "correct_answer": "A. Nitrogen mustards",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nitrogen mustards</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Nitrosoureas: While nitrosoureas can cause some bladder toxicity, they are more commonly associated with delayed myelosuppression and neurotoxicity.</li><li>\u2022 Option B. Nitrosoureas:</li><li>\u2022 Option C. Platinum compounds: Platinum-based drugs like cisplatin and carboplatin can cause renal toxicity, but hemorrhagic cystitis is not a typical side effect.</li><li>\u2022 Option C. Platinum compounds:</li><li>\u2022 Option D. Triazenes: Triazenes are alkylating agents, but they are not specifically known to cause hemorrhagic cystitis.</li><li>\u2022 Option D. Triazenes:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Hemorrhagic cystitis is a significant side effect of certain nitrogen mustards like cyclophosphamide. Preventive measures, including adequate hydration and the use of mesna (a drug that binds to acrolein), are crucial in managing this complication.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cea51f07",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman with breast cancer has completed her primary treatment, which included several cycles of doxorubicin-containing chemotherapy. She is now in remission and attending a follow-up visit with her oncologist. Which of the following long-term complications is the oncologist MOST concerned about?",
      "options": [
        {
          "label": "A",
          "text": "Nausea and vomiting",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alopecia (hair loss)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cardiotoxicity",
          "correct": true
        },
        {
          "label": "D",
          "text": "Myelosuppression (bone marrow suppression)",
          "correct": false
        }
      ],
      "correct_answer": "C. Cardiotoxicity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cardiotoxicity</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nausea and vomiting: While common during active chemotherapy treatment, nausea and vomiting are usually acute side effects and not a significant long-term concern.</li><li>\u2022 Option A. Nausea and vomiting:</li><li>\u2022 Option B. Alopecia (hair loss): Hair loss is another common acute side effect of chemotherapy, but hair usually regrows after treatment is completed.</li><li>\u2022 Option B. Alopecia (hair loss):</li><li>\u2022 Option D. Myelosuppression: Myelosuppression (suppression of bone marrow function, leading to decreased blood cell counts) is a significant side effect during active chemotherapy. However, it typically resolves once treatment is stopped and is not a major long-term concern in the same way as cardiotoxicity.</li><li>\u2022 Option D. Myelosuppression:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anthracyclines, like doxorubicin, can cause delayed cardiotoxicity. Patients who have received these drugs need long-term cardiac follow-up, even years after completing treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a38315cc",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with testicular cancer is scheduled to receive bleomycin- containing chemotherapy regimen. Bleomycin is MOST effective during which phase of the cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "G1 phase",
          "correct": false
        },
        {
          "label": "B",
          "text": "S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "G2 phase",
          "correct": true
        },
        {
          "label": "D",
          "text": "M phase",
          "correct": false
        }
      ],
      "correct_answer": "C. G2 phase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) G2 phase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. G1 phase: This is the phase where the cell grows and prepares for DNA replication. Bleomycin's DNA-damaging effects are not specifically targeted to this phase.</li><li>\u2022 Option A. G1 phase:</li><li>\u2022 Option B. S phase: This is the phase of DNA replication. While DNA damage can occur here, bleomycin's peak activity is in the G2 phase.</li><li>\u2022 Option B. S phase:</li><li>\u2022 Option D. M phase: This is the phase of actual cell division (mitosis). While bleomycin-induced DNA damage can also affect mitosis, it's most potent during the G2 phase when the cell is actively preparing for division.</li><li>\u2022 Option D. M phase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bleomycin is a cell cycle-specific antitumor antibiotic that primarily targets the G2 phase of the cell cycle.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e5dacedf",
      "audio": ""
    },
    {
      "text": "A patient with rapidly dividing tumor cells is being treated with a chemotherapy regimen that includes a drug that targets the M phase of the cell cycle. Which of the following drugs is MOST likely included in this regimen?",
      "options": [
        {
          "label": "A",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Doxorubicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paclitaxel",
          "correct": true
        },
        {
          "label": "D",
          "text": "5-Fluorouracil",
          "correct": false
        }
      ],
      "correct_answer": "C. Paclitaxel",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Paclitaxel</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Methotrexate: Methotrexate is an antimetabolite that targets the S phase.</li><li>\u2022 Option A. Methotrexate:</li><li>\u2022 Option B. Doxorubicin: Doxorubicin is an antitumor antibiotic that is cell cycle non-specific.</li><li>\u2022 Option B. Doxorubicin:</li><li>\u2022 Option D. 5-Fluorouracil: 5-Fluorouracil is an antimetabolite that also targets the S phase.</li><li>\u2022 Option D. 5-Fluorouracil:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Antimicrotubular agents like paclitaxel are effective in treating rapidly dividing tumors because they disrupt the M phase of the cell cycle, leading to cell death.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d4620b06",
      "audio": ""
    },
    {
      "text": "A patient with acute myeloid leukemia (AML) is being treated with a drug that interferes with DNA synthesis. This drug is most likely:",
      "options": [
        {
          "label": "A",
          "text": "Bleomycin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cytarabine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cisplatin",
          "correct": false
        }
      ],
      "correct_answer": "B. Cytarabine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bleomycin: Bleomycin is an antitumor antibiotic that acts on the G2 phase.</li><li>\u2022 Option A. Bleomycin:</li><li>\u2022 Option C. Vincristine: Vincristine is an antimicrotubular agent that acts on the M phase.</li><li>\u2022 Option C. Vincristine:</li><li>\u2022 Option D. Cisplatin: Cisplatin is an alkylating agent that is cell cycle non-specific.</li><li>\u2022 Option D. Cisplatin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Antimetabolites disrupt DNA synthesis, making them effective against rapidly dividing cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "12b4f273",
      "audio": ""
    },
    {
      "text": "A postmenopausal woman with breast cancer is found to have a tumor that overexpresses aromatase. Which of the following medications is MOST likely to be effective in treating this patient?",
      "options": [
        {
          "label": "A",
          "text": "Tamoxifen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anastrozole",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fulvestrant",
          "correct": false
        },
        {
          "label": "D",
          "text": "Leuprolide",
          "correct": false
        }
      ],
      "correct_answer": "B. Anastrozole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tamoxifen: Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that acts as an estrogen antagonist in breast tissue but an agonist in other tissues like the bone and uterus. While it can be effective in some cases of hormone-receptor-positive breast cancer, it doesn't directly address the issue of increased estrogen production in tumors that overexpress aromatase.</li><li>\u2022 Option A. Tamoxifen:</li><li>\u2022 Option C. Fulvestrant: Fulvestrant is a Selective Estrogen Receptor Downregulator (SERD) that binds to and degrades estrogen receptors. While effective in hormone-receptor-positive breast cancer, it also doesn't directly target the increased estrogen production in this case.</li><li>\u2022 Option C. Fulvestrant:</li><li>\u2022 Option D. Leuprolide: Leuprolide is a Gonadotropin-Releasing Hormone (GnRH) agonist that suppresses ovarian function, leading to decreased estrogen production. However, it's primarily used in premenopausal women. In postmenopausal women, the ovaries are already inactive, and most estrogen production occurs in peripheral tissues through aromatase.</li><li>\u2022 Option D. Leuprolide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aromatase inhibitors are effective in treating hormone-receptor-positive breast cancer in postmenopausal women by reducing estrogen production.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ddfa12e6",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with prostate cancer has been on androgen deprivation therapy (ADT) but recently shows signs of disease progression. His oncologist suspects that his tumor may be utilizing an alternative pathway to maintain androgen signalling. Which enzyme is MOST likely responsible for converting testosterone to a more potent androgen within the prostate, contributing to this resistance?",
      "options": [
        {
          "label": "A",
          "text": "5-alpha reductase (5-AR)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Aromatase",
          "correct": false
        },
        {
          "label": "C",
          "text": "17-alpha hydroxylase (17\u03b11)",
          "correct": false
        },
        {
          "label": "D",
          "text": "CYP17",
          "correct": false
        }
      ],
      "correct_answer": "A. 5-alpha reductase (5-AR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 5-alpha reductase (5-AR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Aromatase: Aromatase converts androgens to estrogens and is relevant in breast cancer, not prostate cancer.</li><li>\u2022 Option B. Aromatase:</li><li>\u2022 Option C. 17-alpha hydroxylase (17\u03b11): This enzyme is involved in the early steps of steroid hormone synthesis in the adrenal glands and gonads. It doesn't directly convert testosterone to DHT.</li><li>\u2022 Option C. 17-alpha hydroxylase (17\u03b11):</li><li>\u2022 Option D. CYP17: CYP17 is another enzyme involved in steroid hormone synthesis, but it doesn't directly convert testosterone to DHT.</li><li>\u2022 Option D. CYP17:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Understanding the role of 5-alpha reductase in androgen metabolism is important for comprehending mechanisms of resistance to hormone therapy in prostate cancer and for selecting appropriate treatment strategies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "53be09f5",
      "audio": ""
    },
    {
      "text": "A patient with chronic myeloid leukemia (CML) initially responds well to imatinib therapy but later develops resistance. Which of the following mechanisms is MOST likely responsible for this acquired resistance?",
      "options": [
        {
          "label": "A",
          "text": "Drug Efflux",
          "correct": false
        },
        {
          "label": "B",
          "text": "Drug Inactivation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drug Target Alteration",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cell Death Inhibition",
          "correct": false
        }
      ],
      "correct_answer": "C. Drug Target Alteration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Drug Efflux: While drug efflux pumps can contribute to resistance in some cancers, it's not the most common mechanism in CML specifically. Imatinib resistance is primarily driven by mutations in the BCR-ABL target itself.</li><li>\u2022 Option A. Drug Efflux:</li><li>\u2022 Option B. Drug Inactivation: This mechanism involves the cancer cells metabolizing or breaking down the drug, rendering it ineffective. While this can occur, it's less common in CML compared to target alteration.</li><li>\u2022 Option B. Drug Inactivation:</li><li>\u2022 Option D. Cell Death Inhibition: While cancer cells can develop mechanisms to evade apoptosis (programmed cell death), this is usually a contributing factor to resistance rather than the primary cause in CML after imatinib therapy.</li><li>\u2022 Option D. Cell Death Inhibition:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drug target alteration is a common mechanism of acquired resistance, particularly in targeted therapies like imatinib.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "666f315d",
      "audio": ""
    },
    {
      "text": "Which of the following mechanisms of drug resistance involves increased expression of proteins that pump drugs out of cancer cells?",
      "options": [
        {
          "label": "A",
          "text": "Drug Influx",
          "correct": false
        },
        {
          "label": "B",
          "text": "Drug Efflux",
          "correct": true
        },
        {
          "label": "C",
          "text": "DNA Damage Repair",
          "correct": false
        },
        {
          "label": "D",
          "text": "EMT",
          "correct": false
        }
      ],
      "correct_answer": "B. Drug Efflux",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Drug Influx: This is the opposite of the correct answer. Drug influx refers to the movement of drugs into the cell, which would increase their effectiveness, not contribute to resistance.</li><li>\u2022 Option A. Drug Influx:</li><li>\u2022 Option C. DNA Damage Repair: DNA damage repair mechanisms help cells fix damage caused by chemotherapy or radiation. While enhanced repair can contribute to resistance, it doesn't directly involve pumping drugs out of the cell.</li><li>\u2022 Option C. DNA Damage Repair:</li><li>\u2022 Option D. EMT (Epithelial-Mesenchymal Transition): EMT is a process where cells lose their epithelial characteristics and gain mesenchymal properties, allowing them to migrate and invade. While EMT can contribute to resistance, it does so through various mechanisms, not specifically increased drug efflux.</li><li>\u2022 Option D. EMT (Epithelial-Mesenchymal Transition):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drug efflux pumps can contribute to multidrug resistance in cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "91fd0f94",
      "audio": ""
    },
    {
      "text": "A patient is about to start a chemotherapy regimen containing high-dose cyclophosphamide (>1500mg/m\u00b2). Which antiemetic regimen is MOST appropriate for preventing CINV in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Dexamethasone alone",
          "correct": false
        },
        {
          "label": "B",
          "text": "5HT3 antagonist alone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dexamethasone + 5HT3 antagonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist",
          "correct": true
        }
      ],
      "correct_answer": "D. Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Dexamethasone + 5HT3 antagonist + NK1 receptor antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dexamethasone alone: While dexamethasone has antiemetic properties, it is not sufficient on its own to prevent CINV in high-risk regimens like those involving high-dose cyclophosphamide.</li><li>\u2022 Option A. Dexamethasone alone:</li><li>\u2022 Option B. 5HT3 antagonist alone: 5HT3 antagonists are effective antiemetics, but they are not potent enough to control CINV in high-risk settings when used alone.</li><li>\u2022 Option B. 5HT3 antagonist alone:</li><li>\u2022 Option C. Dexamethasone + 5HT3 antagonist: This combination provides better control than either drug alone, but it may still be inadequate for high-risk chemotherapy. The addition of an NK1 receptor antagonist further enhances antiemetic efficacy in these cases.</li><li>\u2022 Option C. Dexamethasone + 5HT3 antagonist:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 High-risk emetogenic chemotherapy requires a triple-drug antiemetic regimen to effectively prevent CINV.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f539ca2e",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman undergoing chemotherapy for ovarian cancer presents to your clinic with complaints of frequent, loose stools for the past 3 days. She reports having 5-6 bowel movements per day, with no blood or mucus. Her vital signs are stable, and she is otherwise feeling well. Which medication would be the MOST appropriate initial treatment for her chemotherapy-induced diarrhea?",
      "options": [
        {
          "label": "A",
          "text": "Loperamide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Octreotide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ondansetron",
          "correct": false
        },
        {
          "label": "D",
          "text": "Palifermin",
          "correct": false
        }
      ],
      "correct_answer": "A. Loperamide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Loperamide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Octreotide: Octreotide is a somatostatin analog that can be used for refractory cases of chemotherapy-induced diarrhea, particularly if there is a secretory component. It is not the initial drug of choice.</li><li>\u2022 Option B. Octreotide:</li><li>\u2022 Option C. Ondansetron: Ondansetron is a 5-HT3 receptor antagonist primarily used for nausea and vomiting. It is not effective for diarrhea.</li><li>\u2022 Option C. Ondansetron:</li><li>\u2022 Option D. Racicodotril: Racicodotril is an antisecretory anti-diarrheal agent that works by inhibiting enkephalinase, an enzyme that breaks down enkephalins. Enkephalins are naturally occurring substances that decrease intestinal secretion. While it can be effective in some cases of diarrhoea, it is not the first-line treatment for chemotherapy-induced diarrhoea.</li><li>\u2022 Option D. Racicodotril:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Loperamide is the first-line treatment for chemotherapy-induced diarrhoea. It acts by slowing down gut motility and reducing the frequency of bowel movements.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "500f8946",
      "audio": ""
    },
    {
      "text": "You are seeing a 60-year-old woman with newly diagnosed breast cancer scheduled to start chemotherapy with a regimen known to have a high risk of causing neutropenia. In which of the following scenarios is the use of G-CSF therapy MOST strongly indicated for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.",
          "correct": false
        },
        {
          "label": "B",
          "text": "She has a history of febrile neutropenia from prior chemotherapy.",
          "correct": true
        },
        {
          "label": "C",
          "text": "She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment.",
          "correct": false
        },
        {
          "label": "D",
          "text": "She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.",
          "correct": false
        }
      ],
      "correct_answer": "B. She has a history of febrile neutropenia from prior chemotherapy.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) She has a history of febrile neutropenia from prior chemotherapy.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia. While this is a moderate risk, it's not high enough to warrant primary prophylaxis with G-CSF in the absence of other risk factors.</li><li>\u2022 Option A. Her current chemotherapy regimen has a 15% risk of causing febrile neutropenia.</li><li>\u2022 Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment. This scenario indicates the patient has already developed febrile neutropenia. G-CSF would be used for secondary prophylaxis in this case, not primary prophylaxis.</li><li>\u2022 Option C. She develops a fever and her absolute neutrophil count (ANC) drops to 500/\u00b5L during her current treatment.</li><li>\u2022 Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy. Radiation therapy to the chest wall can sometimes cause a decrease in blood counts, but it's not a primary indication for G-CSF prophylaxis.</li><li>\u2022 Option D. She is also scheduled to receive radiation therapy to her chest wall after completing chemotherapy.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 A history of febrile neutropenia is a strong indication for G-CSF prophylaxis, even if the current chemotherapy regimen is not considered high-risk. This is because patients who have experienced febrile neutropenia in the past are at a significantly higher risk of developing it again with subsequent chemotherapy. Use if FN risk \u2265 20%, H/o Febrile Neutropenia, Neutropenia prior to starting chemo or active infection while starting chemo.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3d6e2e12",
      "audio": ""
    },
    {
      "text": "What is the primary purpose of the instrument shown in the image?",
      "options": [
        {
          "label": "A",
          "text": "To provide a site for repeated blood transfusions",
          "correct": false
        },
        {
          "label": "B",
          "text": "To deliver high-dose chemotherapy directly to the tumor",
          "correct": false
        },
        {
          "label": "C",
          "text": "To facilitate the continuous and safe administration of chemotherapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "To monitor the progression of cancer through imaging",
          "correct": false
        }
      ],
      "correct_answer": "C. To facilitate the continuous and safe administration of chemotherapy",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-093031.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) To facilitate the continuous and safe administration of chemotherapy.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. To provide a site for repeated blood transfusions: While a port can be used for blood transfusions, its primary function is for chemotherapy administration.</li><li>\u2022 Option A. To provide a site for repeated blood transfusions:</li><li>\u2022 Option B. To deliver high-dose chemotherapy directly to the tumor: Ports deliver chemotherapy systemically, not directly to the tumor.</li><li>\u2022 Option B. To deliver high-dose chemotherapy directly to the tumor:</li><li>\u2022 Option D. To monitor the progression of cancer through imaging: Ports are not used for imaging or monitoring cancer progression.</li><li>\u2022 Option D. To monitor the progression of cancer through imaging:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Chemotherapy ports are implanted devices that provide convenient and safe access to the bloodstream for patients undergoing long-term chemotherapy or other intravenous treatments.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "00bb725e",
      "audio": ""
    },
    {
      "text": "Which of the following is the MOST common adverse drug reaction (ADR) associated with immune checkpoint inhibitors, as indicated in the image?",
      "options": [
        {
          "label": "A",
          "text": "Rash",
          "correct": true
        },
        {
          "label": "B",
          "text": "pneumonitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Colitis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hepatitis",
          "correct": false
        }
      ],
      "correct_answer": "A. Rash",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Rash</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Pneumonitis: While pneumonitis (inflammation of the lungs) is a serious potential side effect of immune checkpoint inhibitors, it's not as frequent as rash .</li><li>\u2022 Option B. Pneumonitis:</li><li>\u2022 .</li><li>\u2022 Option C. Colitis: Colitis (inflammation of the colon) is another immune-related adverse event, but it's also less common than rash.</li><li>\u2022 Option C. Colitis:</li><li>\u2022 Option D. Hepatitis: Hepatitis (inflammation of the liver) can occur with immune checkpoint inhibitors, but it's less frequent compared to rash.</li><li>\u2022 Option D. Hepatitis:</li><li>\u2022 Key point: Rash is the most common adverse event associated with immune checkpoint inhibitors, although other serious immune-related adverse events can occur and require vigilant monitoring .</li><li>\u2022 Key point:</li><li>\u2022 .</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "643ffec3",
      "audio": ""
    },
    {
      "text": "A 68-year-old woman with breast cancer is scheduled to begin a chemotherapy regimen including doxorubicin. Which of the following pre-treatment evaluations is MOST essential for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary function tests",
          "correct": false
        },
        {
          "label": "B",
          "text": "Echocardiogram",
          "correct": true
        },
        {
          "label": "C",
          "text": "Renal ultrasound",
          "correct": false
        },
        {
          "label": "D",
          "text": "Liver function tests",
          "correct": false
        }
      ],
      "correct_answer": "B. Echocardiogram",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Echocardiogram</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pulmonary function tests (PFTs): PFTs assess lung function and are not directly relevant to the primary concern of cardiotoxicity associated with doxorubicin.</li><li>\u2022 Option A. Pulmonary function tests (PFTs):</li><li>\u2022 Option C. Renal ultrasound: While some chemotherapy drugs can affect kidney function, it's not the primary concern with doxorubicin.</li><li>\u2022 Option C. Renal ultrasound:</li><li>\u2022 Option D. Liver function tests: Liver function tests are important for evaluating the liver's ability to metabolize medications, but doxorubicin's primary toxicity is cardiac, not hepatic.</li><li>\u2022 Option D. Liver function tests:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Baseline cardiac evaluation with an echocardiogram is essential before starting anthracycline-based chemotherapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "75c8f57e",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of heavy smoking is diagnosed with squamous cell lung cancer. He is started on chemotherapy with carboplatin and paclitaxel, along with bevacizumab, a targeted therapy. During his treatment, which of the following adverse events is his oncologist MOST concerned about monitoring for, given his specific cancer type and treatment regimen?",
      "options": [
        {
          "label": "A",
          "text": "Hemorrhagic cystitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pulmonary hemorrhage",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cardiomyopathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Corneal opacity",
          "correct": false
        }
      ],
      "correct_answer": "B. Pulmonary hemorrhage",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Pulmonary hemorrhage</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hemorrhagic cystitis: This is a potential side effect of certain chemotherapy drugs, like cyclophosphamide, but not typically associated with bevacizumab.</li><li>\u2022 Option A. Hemorrhagic cystitis:</li><li>\u2022 Option C. Cardiomyopathy: While some chemotherapy drugs can cause cardiotoxicity, it's not a major concern with bevacizumab.</li><li>\u2022 Option C. Cardiomyopathy:</li><li>\u2022 Option D. Corneal opacity : Corneal opacity is not a recognized side effect of bevacizumab or the other drugs in this regimen.</li><li>\u2022 Option D. Corneal opacity</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Bevacizumab, while effective in treating various cancers, carries a risk of pulmonary hemorrhage, particularly in patients with squamous cell lung cancer. Close monitoring for any signs of respiratory distress or bleeding is essential in these patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "33b033ba",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy with cyclophosphamide. During her second cycle, she complains of burning sensation while urinating and notices blood in her urine. You suspect a complication due to chemotherapy. Which of the following medications is MOST likely to prevent this complication?",
      "options": [
        {
          "label": "A",
          "text": "Mesna",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dexamethasone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ondansetron",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allopurinol",
          "correct": false
        }
      ],
      "correct_answer": "A. Mesna",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Mesna</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Dexamethasone: A corticosteroid used to manage nausea and vomiting associated with chemotherapy; it has no role in preventing hemorrhagic cystitis.</li><li>\u2022 Option B. Dexamethasone:</li><li>\u2022 Option C. Ondansetron: A 5-HT3 receptor antagonist used to manage nausea and vomiting; it's not effective for preventing hemorrhagic cystitis</li><li>\u2022 Option C. Ondansetron:</li><li>\u2022 Option D. Allopurinol: A medication used to reduce uric acid levels, often in the context of tumor lysis syndrome; it has no role in preventing hemorrhagic cystitis.</li><li>\u2022 Option D. Allopurinol:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Mesna is the standard preventive agent for hemorrhagic cystitis associated with cyclophosphamide. It should be administered concurrently with cyclophosphamide to minimize bladder toxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4f3ae253",
      "audio": ""
    },
    {
      "text": "A patient receiving chemotherapy develops a \"glove and stocking\" pattern of numbness and tingling in their hands and feet. Which of the following drugs is MOST likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Cytarabine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ifosfamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cisplatin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Gemcitabine",
          "correct": false
        }
      ],
      "correct_answer": "C. Cisplatin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cisplatin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cytarabine: Cytarabine is primarily associated with cerebellar toxicity and myelosuppression. While it can rarely cause peripheral neuropathy, it is not typically characterized by a glove and stocking distribution.</li><li>\u2022 Option A. Cytarabine:</li><li>\u2022 Option B. Ifosfamide: Ifosfamide can cause hemorrhagic cystitis and neurotoxicity, but the characteristic glove and stocking neuropathy is less common.</li><li>\u2022 Option B. Ifosfamide:</li><li>\u2022 Option D. Gemcitabine: Gemcitabine is associated with myelosuppression, flu-like symptoms, and rash. Peripheral neuropathy is not a typical side effect of this drug.</li><li>\u2022 Option D. Gemcitabine:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Platinum-based chemotherapy agents carry the risk of peripheral neuropathy and ototoxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9b02635b",
      "audio": ""
    },
    {
      "text": "A patient receiving pembrolizumab develops new-onset cough and shortness of breath. Chest X-ray shows interstitial infiltrates. Which of the following adverse drug reactions (ADRs) is MOST likely?",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary hemorrhage",
          "correct": false
        },
        {
          "label": "B",
          "text": "Colitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pneumonitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hepatitis",
          "correct": false
        }
      ],
      "correct_answer": "C. Pneumonitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Pneumonitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pulmonary hemorrhage: While possible, pulmonary hemorrhage is less common than pneumonitis as an irAE of pembrolizumab. It would typically present with more dramatic symptoms like coughing up blood (hemoptysis).</li><li>\u2022 Option A. Pulmonary hemorrhage:</li><li>\u2022 Option B. Colitis: Colitis, or inflammation of the colon, can be an immune-related adverse event of checkpoint inhibitors. However, its primary symptoms would be diarrhea, abdominal pain, and possibly blood in the stool, not respiratory symptoms.</li><li>\u2022 Option B. Colitis:</li><li>\u2022 Option D. Hepatitis: Hepatitis, or inflammation of the liver, can also be an immune-related adverse event. Its typical presentation would involve jaundice, elevated liver enzymes, and possibly right upper quadrant pain, rather than respiratory symptoms.</li><li>\u2022 Option D. Hepatitis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Immune checkpoint inhibitors can cause immune-related adverse events, including pneumonitis, which requires prompt recognition and management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cc7cca5c",
      "audio": ""
    },
    {
      "text": "A patient receiving CAR T-cell therapy develops fever, hypotension, and tachycardia two days after infusion. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Tumor lysis syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cytokine release syndrome (CRS)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Graft-versus-host disease (GVHD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sepsis",
          "correct": false
        }
      ],
      "correct_answer": "B. Cytokine release syndrome (CRS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Cytokine release syndrome (CRS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tumor lysis syndrome: While it can cause fever and electrolyte abnormalities, it's less likely to cause hypotension and tachycardia shortly after T-cell therapy.</li><li>\u2022 Option A. Tumor lysis syndrome:</li><li>\u2022 Option C. GVHD: This occurs in allogeneic stem cell transplantation, not CAR T-cell therapy.</li><li>\u2022 Option C. GVHD:</li><li>\u2022 Option D. Sepsis: Though sepsis can present similarly, the timing and context point more towards CRS in this scenario.</li><li>\u2022 Option D. Sepsis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 CRS is a serious complication of CAR T-cell therapy characterized by a systemic inflammatory response due to cytokine release.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8e8101b3",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient receiving CAR T-cell therapy for refractory large B-cell lymphoma develops confusion, word-finding difficulty, and a severe headache three days after infusion. Which of the following neurological manifestations is LEAST likely to be associated with this patient's suspected diagnosis of Immune effector cell-associated neurotoxicity syndrome (ICANS)?",
      "options": [
        {
          "label": "A",
          "text": "Headache",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aphasia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Delirium",
          "correct": false
        },
        {
          "label": "D",
          "text": "Optic neuritis",
          "correct": true
        }
      ],
      "correct_answer": "D. Optic neuritis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Optic neuritis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Headache: Headache is a very common symptom of ICANS, often presenting early in the course of the syndrome.</li><li>\u2022 Option A. Headache:</li><li>\u2022 Option B. Aphasia: Aphasia, or difficulty with language, is another frequent manifestation of ICANS, reflecting the impact of cerebral edema on language centers in the brain.</li><li>\u2022 Option B. Aphasia:</li><li>\u2022 Option C. Delirium: Delirium, or acute confusional state, is a hallmark of ICANS and can range from mild confusion to severe agitation.</li><li>\u2022 Option C. Delirium:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 ICANS is a serious complication of CAR T-cell therapy that can present with a variety of neurological symptoms. Recognizing these symptoms early is crucial for prompt management and improved patient outcomes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7212728d",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with breast cancer is undergoing adjuvant chemotherapy. Three days after her most recent cycle, she presents to the emergency department with a fever of 38.7\u00b0C (101.7\u00b0F) and generalized weakness. Her past medical history is significant for hypertension, well-controlled with medication. On examination, she appears fatigued but is otherwise stable. Laboratory tests reveal an absolute neutrophil count (ANC) of 500 cells/\u00b5L, confirming neutropenia. Given her presentation with fever and neutropenia, the emergency department team considers her risk of complications using the Multinational Association for Supportive Care in Cancer (MASCC) risk index to guide her management. Based on the MASCC risk index for febrile neutropenia, which of the following factors would categorize this patient as low risk?",
      "options": [
        {
          "label": "A",
          "text": "Presence of hypotension",
          "correct": false
        },
        {
          "label": "B",
          "text": "History of chronic obstructive pulmonary disease (COPD)",
          "correct": false
        },
        {
          "label": "C",
          "text": "No dehydration requiring intravenous fluids",
          "correct": true
        },
        {
          "label": "D",
          "text": "Fever of unknown origin without localizing signs or symptoms",
          "correct": false
        }
      ],
      "correct_answer": "C. No dehydration requiring intravenous fluids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Presence of hypotension would categorize a patient as high risk, as it indicates hemodynamic instability, which is a serious complication of febrile neutropenia.</li><li>\u2022 Option A.</li><li>\u2022 Option B. A history of chronic obstructive pulmonary disease (COPD) would also place a patient in a higher risk category, as underlying lung disease can complicate the management of febrile neutropenia.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Option D. Fever of unknown origin without localizing signs or symptoms could apply to many cases of febrile neutropenia and, by itself, does not necessarily categorize a patient as low risk according to the MASCC risk index. Other factors, such as the patient's overall clinical stability, presence of comorbidities, and intensity of the chemotherapy regimen, also need to be considered.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The MASCC risk index is used to identify febrile neutropenia patients who are at low risk for complications and might be suitable for outpatient management. Factors that indicate lower risk include stable vital signs, no significant comorbidities like COPD, and no dehydration requiring intravenous fluids.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "64362d6d",
      "audio": ""
    },
    {
      "text": "A 67-year-old man with metastatic lung cancer on chemotherapy develops fever, chills, and tenderness with purulent discharge at his PICC line site. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Febrile neutropenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tumor-related fever",
          "correct": false
        },
        {
          "label": "C",
          "text": "Central line-associated bloodstream infection (CLABSI)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pneumonia",
          "correct": false
        }
      ],
      "correct_answer": "C. Central line-associated bloodstream infection (CLABSI)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CLABSI</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Febrile neutropenia: While this patient likely has neutropenia due to chemotherapy, the local signs of infection at the PICC line point more specifically towards CLABSI.</li><li>\u2022 Option A. Febrile neutropenia:</li><li>\u2022 Option B. Tumor-related fever: This is less likely in the presence of clear signs of infection at the catheter site.</li><li>\u2022 Option B. Tumor-related fever:</li><li>\u2022 Option D. Pneumonia: While possible, the absence of respiratory symptoms and the presence of local signs of infection at the catheter site make CLABSI more likely.</li><li>\u2022 Option D. Pneumonia:</li><li>\u2022 Educational objective: CLABSI is a serious complication of central venous catheters. Prompt recognition and treatment are essential to prevent morbidity and mortality.</li><li>\u2022 Educational objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2985a60d",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with a known history of prostate cancer presents to your clinic complaining of severe back pain that has been progressively worsening over the past few weeks. The pain is particularly intense at night, making it difficult for him to sleep, and it does not improve with rest. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Muscle strain",
          "correct": false
        },
        {
          "label": "B",
          "text": "Osteoarthritis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metastatic spinal cord compression",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lumbar disc herniation",
          "correct": false
        }
      ],
      "correct_answer": "C. Metastatic spinal cord compression",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Metastatic spinal cord compression (MSCC)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Muscle strain: Muscle strain typically presents with localized pain that worsens with movement and improves with rest. It's less likely to be severe at night or associated with a history of cancer.</li><li>\u2022 Option A. Muscle strain:</li><li>\u2022 Option B. Osteoarthritis: Osteoarthritis is a degenerative joint disease that can cause back pain, but it's usually associated with stiffness and pain that worsens with activity and improves with rest. The patient's age and cancer history make MSCC more likely.</li><li>\u2022 Option B. Osteoarthritis:</li><li>\u2022 Option D. Lumbar disc herniation: While a herniated disc can cause severe back pain, it's often associated with radicular pain (shooting pain down the leg) and neurological deficits. The patient's presentation and cancer history are more consistent with MSCC.</li><li>\u2022 Option D. Lumbar disc herniation:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Back pain in a patient with a history of cancer, especially if it's worse at night or unrelieved by rest, warrants prompt evaluation for possible MSCC. Early diagnosis and treatment are critical to prevent neurological complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e652defd",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of lung cancer presents with severe back pain and weakness in his legs. Neurological examination reveals decreased lower extremity strength and hyperreflexia. What is the MOST appropriate initial management step?",
      "options": [
        {
          "label": "A",
          "text": "Plain X-ray of the spine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Urgent intravenous dexamethasone",
          "correct": true
        },
        {
          "label": "C",
          "text": "Whole spine MRI",
          "correct": false
        },
        {
          "label": "D",
          "text": "Surgical decompression",
          "correct": false
        }
      ],
      "correct_answer": "B. Urgent intravenous dexamethasone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Urgent intravenous dexamethasone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Plain X-ray of the spine: While plain X-rays can sometimes show bony destruction suggestive of metastases, they are not sensitive enough to visualize the spinal cord or nerve roots, which are crucial for assessing the extent of compression.</li><li>\u2022 Option A. Plain X-ray of the spine:</li><li>\u2022 Option C. Whole spine MRI: MRI is the gold standard for diagnosing MSCC, but it should not delay the administration of dexamethasone, which is crucial to prevent further neurological deterioration.</li><li>\u2022 Option C. Whole spine MRI:</li><li>\u2022 Option D. Surgical decompression: While surgery may be indicated in some cases of MSCC, it is not the initial management step. High-dose dexamethasone should be given first to reduce spinal cord edema and stabilize the patient before considering surgical intervention.</li><li>\u2022 Option D. Surgical decompression:</li><li>\u2022 Educational objective: In patients with suspected MSCC and neurological deficits, urgent high-dose dexamethasone is the priority to reduce spinal cord edema and prevent further neurological damage.</li><li>\u2022 Educational objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5eb1d7f0",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with acute myeloid leukemia (AML) undergoing chemotherapy presents to the emergency department with a 2-day history of fever, right lower quadrant abdominal pain, and watery diarrhea. His absolute neutrophil count (ANC) is 300/\u00b5L. Abdominal CT scan reveals cecal wall thickening. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Appendicitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diverticulitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Neutropenic enterocolitis (typhlitis)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ischemic colitis",
          "correct": false
        }
      ],
      "correct_answer": "C. Neutropenic enterocolitis (typhlitis)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Neutropenic enterocolitis (typhlitis)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Appendicitis: While appendicitis can present with similar symptoms, it is less likely in this patient with neutropenia and cecal wall thickening.</li><li>\u2022 Option A. Appendicitis:</li><li>\u2022 Option B. Diverticulitis: Diverticulitis typically affects the left colon and is less common in younger individuals.</li><li>\u2022 Option B. Diverticulitis:</li><li>\u2022 Option D. Ischemic colitis: Ischemic colitis is more common in older individuals with cardiovascular risk factors. It usually presents with bloody diarrhea and is less likely in the context of neutropenia.</li><li>\u2022 Option D. Ischemic colitis:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Neutropenic enterocolitis is a life-threatening complication that can occur in patients with severe neutropenia. Early recognition and prompt treatment are essential.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "832267c2",
      "audio": ""
    },
    {
      "text": "A 25-year-old male with Burkitt's lymphoma is undergoing chemotherapy. Three days after starting treatment, he presents with fatigue, muscle cramps, and nausea. Lab results show: Potassium: 6.2 mEq/L Uric acid: 9.0 mg/dL Phosphate: 5.5 mg/dL Calcium: 9.5 mg/dL Which of the following electrolyte abnormalities found in this patient is NOT a criterion for the diagnosis of Laboratory Tumor Lysis Syndrome (LTLS)?",
      "options": [
        {
          "label": "A",
          "text": "Hyperkalemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hyperuricemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperphosphatemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypercalcemia",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypercalcemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hypercalcemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hyperkalemia: This is a defining feature of LTLS, as the breakdown of tumor cells releases intracellular potassium into the bloodstream.</li><li>\u2022 Option A. Hyperkalemia:</li><li>\u2022 Option B. Hyperuricemia: Tumor cell lysis releases nucleic acids, which are metabolized to uric acid, leading to hyperuricemia in LTLS.</li><li>\u2022 Option B. Hyperuricemia:</li><li>\u2022 Option C. Hyperphosphatemia: The breakdown of tumor cells also releases intracellular phosphate, contributing to hyperphosphatemia in LTLS.</li><li>\u2022 Option C. Hyperphosphatemia:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 LTLS is a potentially life-threatening oncologic emergency characterized by specific electrolyte abnormalities: hyperkalemia, hyperuricemia, hyperphosphatemia, and sometimes hypocalcemia. CTLS (\u2265 1) (Clinical criteria for TLS) : AKI, arrhythmias, Sz, symptomatic hypocalcemia Prompt recognition and management of LTLS are critical to prevent complications like acute kidney injury, cardiac arrhythmias, and seizures.</li><li>\u2022 LTLS is a potentially life-threatening oncologic emergency characterized by specific electrolyte abnormalities: hyperkalemia, hyperuricemia, hyperphosphatemia, and sometimes hypocalcemia.</li><li>\u2022 CTLS (\u2265 1) (Clinical criteria for TLS) : AKI, arrhythmias, Sz, symptomatic hypocalcemia</li><li>\u2022 CTLS (\u2265 1)</li><li>\u2022 (Clinical criteria for TLS) :</li><li>\u2022 Prompt recognition and management of LTLS are critical to prevent complications like acute kidney injury, cardiac arrhythmias, and seizures.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "163735b9",
      "audio": ""
    },
    {
      "text": "A 25-year-old male presents to your clinic with a rapidly growing neck mass that has caused him discomfort over the past few weeks. He also reports feeling fatigued and has lost some weight recently. On examination, you palpate a large, firm, non-tender lymph node in his left cervical region. A biopsy of the lymph node reveals Burkitt lymphoma. Further workup shows his lactate dehydrogenase (LDH) level is 3 times the upper limit of normal. Considering his diagnosis and laboratory findings, which Tumor Lysis Syndrome (TLS) risk category does this patient fall into?",
      "options": [
        {
          "label": "A",
          "text": "Low risk",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intermediate risk",
          "correct": false
        },
        {
          "label": "C",
          "text": "High risk",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cannot be determined",
          "correct": false
        }
      ],
      "correct_answer": "C. High risk",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) High risk</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Low risk: Low-risk malignancies generally have a slower growth rate and lower tumor burden, making TLS less likely.</li><li>\u2022 Option A. Low risk:</li><li>\u2022 Option B. Intermediate risk: Intermediate-risk malignancies have a moderate risk of TLS, often based on specific tumor characteristics or laboratory findings. In this case, the patient's elevated LDH level and rapid tumor growth place him in the high-risk category.</li><li>\u2022 Option B. Intermediate risk:</li><li>\u2022 Option D. Cannot be determined: The information provided is sufficient to determine the patient's TLS risk category.</li><li>\u2022 Option D. Cannot be determined:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Burkitt lymphoma is a high-risk malignancy for TLS, especially when associated with elevated LDH levels. Patients with high-risk TLS require aggressive preventive measures, including intensive hydration and uric acid-lowering therapy, to minimize the risk of complications.</li><li>\u2022 Burkitt lymphoma is a high-risk malignancy for TLS, especially when associated with elevated LDH levels.</li><li>\u2022 Patients with high-risk TLS require aggressive preventive measures, including intensive hydration and uric acid-lowering therapy, to minimize the risk of complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4188fc14",
      "audio": ""
    },
    {
      "text": "A 64-year-old man presents to the emergency department with progressive swelling of his face and neck over the past two weeks. He also reports increasing breathlessness, especially when lying flat, and a feeling of fullness in his head. His medical history is significant for a 40-pack-year smoking history, although he quit smoking 10 years ago. On examination, his face appears plethoric, and there is evident distension of the veins in his neck and chest. Additionally, he exhibits mild cyanosis of the upper body and swelling of the arms. A chest X-ray reveals a mass in the right upper mediastinum. Based on the patient's presentation and history, which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute heart failure",
          "correct": false
        },
        {
          "label": "B",
          "text": "Superior vena cava (SVC) syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pulmonary embolism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Constrictive pericarditis",
          "correct": false
        }
      ],
      "correct_answer": "B. Superior vena cava (SVC) syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Superior vena cava (SVC) syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acute heart failure can cause facial and upper extremity swelling due to fluid overload, but it is less likely to present with the pronounced venous distension and plethoric face that are characteristic of SVC syndrome.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Option C. Pulmonary embolism typically presents with acute shortness of breath, chest pain, and possibly hemoptysis, but not with the venous distension and facial swelling seen in SVC syndrome.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. Constrictive pericarditis can cause symptoms of venous congestion due to impaired cardiac filling, but it usually presents with generalized edema, ascites, and elevated jugular venous pressure, rather than the localized swelling of the face and neck and the specific venous distension seen in SVC syndrome.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Superior vena cava (SVC) syndrome is characterized by obstruction of the SVC, leading to impaired venous return from the head, neck, and upper extremities. Symptoms include facial and upper extremity swelling, plethoric facial appearance, distended neck and chest veins, and cyanosis of the upper body. A mediastinal mass, especially in patients with a significant smoking history, raises suspicion for an underlying malignancy such as lung cancer as a cause of SVC syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ce4b274",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with a history of smoking presents with facial swelling, distended neck veins, and shortness of breath. Chest X-ray shows a large right lung mass. Which of the following malignancies is the MOST likely cause of this patient's diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Small cell lung cancer (SCLC)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Non-small cell lung cancer (NSCLC)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Lymphoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metastatic breast cancer",
          "correct": false
        }
      ],
      "correct_answer": "B. Non-small cell lung cancer (NSCLC)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Small cell lung cancer (SCLC): While SCLC can also cause SVC syndrome, it is less common than NSCLC as a cause.</li><li>\u2022 Option A. Small cell lung cancer (SCLC):</li><li>\u2022 Option C. Lymphoma: Lymphoma can sometimes cause SVC syndrome, but it is less frequent than lung cancer.</li><li>\u2022 Option C. Lymphoma:</li><li>\u2022 Option D. Metastatic breast cancer: While metastatic breast cancer can spread to the mediastinum and cause SVC syndrome, it's less common than primary lung cancer as a cause in this clinical scenario.</li><li>\u2022 Option D. Metastatic breast cancer:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 SVC syndrome is a medical emergency caused by obstruction of the superior vena cava, leading to impaired venous return from the head, neck, and upper extremities. Lung cancer, particularly NSCLC, is the most common cause of SVC syndrome.</li><li>\u2022 SVC syndrome is a medical emergency caused by obstruction of the superior vena cava, leading to impaired venous return from the head, neck, and upper extremities.</li><li>\u2022 Lung cancer, particularly NSCLC, is the most common cause of SVC syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "90a6515c",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman presents with weight loss, fatigue, and a left supraclavicular lymph node. Biopsy reveals metastatic adenocarcinoma. Extensive imaging fails to identify a primary tumor site. Immunohistochemistry (IHC) is ordered to help determine the origin of the malignancy. Which IHC staining pattern would MOST STRONGLY suggest a gastrointestinal (GI) primary?",
      "options": [
        {
          "label": "A",
          "text": "CK7 positive, CK20 negative, TTF-1 negative",
          "correct": false
        },
        {
          "label": "B",
          "text": "CK7 negative, CK20 positive, CDX2 positive",
          "correct": true
        },
        {
          "label": "C",
          "text": "CK7 positive, TTF-1 positive, Napsin A positive",
          "correct": false
        },
        {
          "label": "D",
          "text": "ER positive, PR positive, HER2 negative",
          "correct": false
        }
      ],
      "correct_answer": "B. CK7 negative, CK20 positive, CDX2 positive",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) CK7 negative, CK20 positive, CDX2 positive</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. CK7 positive, CK20 negative, TTF-1 negative: This pattern is more suggestive of lung or breast cancer.</li><li>\u2022 Option A. CK7 positive, CK20 negative, TTF-1 negative:</li><li>\u2022 Option C. CK7 positive, TTF-1 positive, Napsin A positive: This pattern is strongly indicative of lung adenocarcinoma.</li><li>\u2022 Option C. CK7 positive, TTF-1 positive, Napsin A positive:</li><li>\u2022 Option D. ER positive, PR positive, HER2 negative: This pattern is typically seen in breast cancer.</li><li>\u2022 Option D. ER positive, PR positive, HER2 negative:</li><li>\u2022 Educational objective: IHC staining can aid in identifying the primary site in cancers of unknown primary (CUP), guiding further management and treatment decisions.</li><li>\u2022 Educational objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2e4556e8",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman Non-smoker presents to your clinic with a persistent cough and recent episodes of coughing up blood (hemoptysis). Chest X-ray reveals a suspicious lung mass. A biopsy is performed, and you suspect lung adenocarcinoma based on the initial histopathology. Which of the following immunohistochemical (IHC) markers would be MOST helpful in confirming this diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "TTF-1",
          "correct": true
        },
        {
          "label": "B",
          "text": "CDX2",
          "correct": false
        },
        {
          "label": "C",
          "text": "S-100",
          "correct": false
        },
        {
          "label": "D",
          "text": "ER",
          "correct": false
        }
      ],
      "correct_answer": "A. TTF-1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. CDX2: CDX2 is a marker of intestinal differentiation and is typically used to identify cancers of gastrointestinal origin.</li><li>\u2022 Option B. CDX2:</li><li>\u2022 Option C. S-100: S-100 is a marker for melanomas and neural crest-derived tumors.</li><li>\u2022 Option C. S-100:</li><li>\u2022 Option D. ER (Estrogen Receptor): ER is a hormone receptor that is primarily used in the context of breast cancer. While some lung adenocarcinomas can be ER-positive, it's not a specific or sensitive marker for this diagnosis.</li><li>\u2022 Option D. ER (Estrogen Receptor):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 While smoking is a major risk factor for lung cancer, adenocarcinoma can occur in non-smokers as well. TTF-1 remains a valuable IHC marker for confirming the diagnosis of lung adenocarcinoma, regardless of smoking history. IHC staining can aid in differentiating between various types of lung cancer and metastases, which is critical for guiding treatment decisions.</li><li>\u2022 While smoking is a major risk factor for lung cancer, adenocarcinoma can occur in non-smokers as well.</li><li>\u2022 TTF-1 remains a valuable IHC marker for confirming the diagnosis of lung adenocarcinoma, regardless of smoking history.</li><li>\u2022 IHC staining can aid in differentiating between various types of lung cancer and metastases, which is critical for guiding treatment decisions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6f28cfd4",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman presents with metastatic adenocarcinoma of unknown primary origin. Imaging and biopsy have failed to identify the primary site. What is the most appropriate initial approach to the treatment of her cancer?",
      "options": [
        {
          "label": "A",
          "text": "Platinum and 5-FU",
          "correct": true
        },
        {
          "label": "B",
          "text": "Pembrolizumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Platinum and etoposide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Palliative care with a focus on symptom management",
          "correct": false
        }
      ],
      "correct_answer": "A. Platinum and 5-FU",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Platinum and 5-FU</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Pembrolizumab, a PD-1 inhibitor, has shown promise in certain types of cancers, particularly those with high levels of microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). While it represents an exciting advancement in cancer therapy, pembrolizumab would typically be considered in the context of CUP after specific testing for MSI-H or dMMR, or PD-L1 expression, rather than as an initial empiric treatment.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Option C. Platinum and etoposide are often used together in the treatment of small cell lung cancer and other neuroendocrine tumors, but without evidence of a neuroendocrine component, this regimen would not be the first choice for an adenocarcinoma of unknown primary.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. While palliative care and symptom management are crucial aspects of cancer treatment, especially in advanced disease, they are not typically the initial approach for a patient who may still benefit from systemic therapy aimed at controlling the disease.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with metastatic adenocarcinoma of unknown primary origin, an empiric chemotherapy regimen that includes a platinum agent (cisplatin or carboplatin) and 5-fluorouracil (5-FU) is often used as the initial treatment approach, aiming to control the disease and alleviate symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "75fed47d",
      "audio": ""
    },
    {
      "text": "A 54-year-old woman presents to the oncology clinic with a 3-month history of unexplained weight loss, night sweats, and a palpable mass in her left axilla. A comprehensive workup, including mammography, abdominal CT, PET scan, and colonoscopy, fails to identify a primary tumor site. Biopsy of the axillary mass reveals adenocarcinoma. Which of the following features is considered unfavorable in the prognosis of cancer of unknown primary?",
      "options": [
        {
          "label": "A",
          "text": "Single, small axillary node involvement",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adenocarcinoma",
          "correct": true
        },
        {
          "label": "C",
          "text": "Elevated serum tumor markers with a single site of metastasis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Absence of liver metastasis",
          "correct": false
        }
      ],
      "correct_answer": "B. Adenocarcinoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Adenocarcinoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Single, small axillary node involvement, especially in women, can sometimes be managed similarly to breast cancer, with a relatively better prognosis than other forms of CUP. This is often considered a subset with a favorable prognosis if it resembles breast cancer histologically and clinically.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Option C. Elevated serum tumor markers with a single site of metastasis could influence prognosis, depending on the specific context and markers involved. However, this alone does not universally signify an unfavorable prognosis without considering other clinical and histopathological features.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. The absence of liver metastasis is generally a favorable prognostic sign in CUP. Liver involvement is often associated with a more aggressive disease course and a poorer prognosis.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the context of cancer of unknown primary (CUP), adenocarcinoma histology is generally considered to have an unfavorable prognosis compared to other subsets of CUP that may have more defined treatment approaches and better outcomes, such as squamous cell carcinoma confined to lymph nodes or women with axillary nodal metastases resembling breast cancer</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c88295f6",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman with a history of squamous cell lung cancer presents with fatigue, constipation, and confusion. Her laboratory tests reveal a serum calcium level of 13 mg/dL. Which of the following is the MOST Common mechanism underlying her hypercalcemia?",
      "options": [
        {
          "label": "A",
          "text": "Increased bone resorption mediated by parathyroid hormone-related protein (PTHrP)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ectopic production of 1,25-dihydroxyvitamin D (1,25 DHCC)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Osteolytic bone metastases",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Increased bone resorption mediated by parathyroid hormone-related protein (PTHrP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Increased bone resorption mediated by parathyroid hormone-related protein (PTHrP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Ectopic production of 1,25-dihydroxyvitamin D (1,25 DHCC): This mechanism is more commonly seen in lymphomas and some other solid tumors, not as frequently in squamous cell lung cancer.</li><li>\u2022 Option B. Ectopic production of 1,25-dihydroxyvitamin D (1,25 DHCC):</li><li>\u2022 Option C. Osteolytic bone metastases: While possible, it is less frequent than PTHrP production as the cause of hypercalcemia in squamous cell lung cancer.</li><li>\u2022 Option C. Osteolytic bone metastases:</li><li>\u2022 Option D. All of the above: Although all three mechanisms can contribute to hypercalcemia in SCC, PTHrP-mediated bone resorption is the most prevalent.</li><li>\u2022 Option D. All of the above:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 PTHrP-mediated bone resorption is the predominant mechanism of hypercalcemia in squamous cell lung cancer and certain other malignancies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e8b92341",
      "audio": ""
    },
    {
      "text": "A 70-year-old man with advanced lung cancer presents with confusion, polyuria, and dehydration. Laboratory tests reveal a serum calcium level of 13.5 mg/dL. The most likely diagnosis is humoral hypercalcemia of malignancy. Which of the following is the most appropriate initial treatment?",
      "options": [
        {
          "label": "A",
          "text": "Oral calcium supplements",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intravenous bisphosphonates",
          "correct": true
        },
        {
          "label": "C",
          "text": "Thiazide diuretics",
          "correct": false
        },
        {
          "label": "D",
          "text": "Calcitonin",
          "correct": false
        }
      ],
      "correct_answer": "B. Intravenous bisphosphonates",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Intravenous bisphosphonates</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Oral calcium supplements : Would be contraindicated as the patient already has hypercalcemia.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Oral calcium supplements</li><li>\u2022 Option C. Thiazide diuretics : Would be inappropriate as they tend to increase serum calcium levels by promoting renal reabsorption of calcium.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Thiazide diuretics</li><li>\u2022 Option D. Calcitonin : Can be used as an additional therapy for hypercalcemia, but it has a much weaker effect compared to bisphosphonates and is often used in conjunction with bisphosphonates for a quicker response.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Calcitonin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The appropriate initial management of hypercalcemia of malignancy involves the use of intravenous bisphosphonates, after initial hydration with intravenous fluids. Bisphosphonates inhibit osteoclastic bone resorption and reduce serum calcium levels</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac0c6d55",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman complains of fatigue, constipation, increased thirst and urination, decreased appetite, and unintentional weight loss. Labs reveal hypercalcemia, normal creatinine, suppressed PTH, and elevated PTHrP. A chest X-ray identifies a right upper lung mass. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Primary hyperparathyroidism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sarcoidosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Multiple myeloma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Humoral hypercalcemia of malignancy",
          "correct": true
        }
      ],
      "correct_answer": "D. Humoral hypercalcemia of malignancy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Humoral hypercalcemia of malignancy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Primary hyperparathyroidism: This would cause hypercalcemia but with elevated PTH levels, not suppressed.</li><li>\u2022 Option A. Primary hyperparathyroidism:</li><li>\u2022 Option B. Sarcoidosis: Sarcoidosis can cause hypercalcemia due to increased vitamin D production, but PTHrP would not be elevated.</li><li>\u2022 Option B. Sarcoidosis:</li><li>\u2022 Option C. Multiple myeloma: While myeloma can cause hypercalcemia through bone destruction, PTHrP is usually not elevated.</li><li>\u2022 Option C. Multiple myeloma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The combination of hypercalcemia, suppressed PTH, and elevated PTHrP in the setting of a malignancy is indicative of humoral hypercalcemia of malignancy.</li><li>\u27a4 Question Id-19836 Unique Key-Q3882817</li><li>\u27a4 Question Id-19836 Unique Key-Q3882817</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f8aa3e6a",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of small cell lung cancer (SCLC) presents with confusion, lethargy, and muscle cramps. Laboratory findings reveal hyponatremia with a serum sodium level of 120 mEq/L, high urine sodium, and high urine osmolality. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Central diabetes insipidus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nephrogenic diabetes insipidus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Primary hyperaldosteronism",
          "correct": false
        }
      ],
      "correct_answer": "C. Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Central diabetes insipidus: This condition is caused by deficient production of ADH, leading to excessive water loss and hypernatremia (high serum sodium), not hyponatremia.</li><li>\u2022 Option A. Central diabetes insipidus:</li><li>\u2022 Option B. Nephrogenic diabetes insipidus: In this condition, the kidneys are unable to respond to ADH, also leading to excessive water loss and hypernatremia.</li><li>\u2022 Option B. Nephrogenic diabetes insipidus:</li><li>\u2022 Option D. Primary hyperaldosteronism: This condition is characterized by excessive aldosterone production, leading to sodium retention, hypertension, and hypokalemia. It does not typically cause hyponatremia.</li><li>\u2022 Option D. Primary hyperaldosteronism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SIADH is characterized by hyponatremia with inappropriately concentrated urine due to excessive ADH secretion. SCLC is a common cause of SIADH.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dd71ba29",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman smoker with a recent diagnosis of small cell lung cancer (SCLC) presents with rapid weight gain, proximal muscle weakness, and easy bruising. She also reports experiencing mood swings and insomnia. On examination, she has central obesity, facial plethora, and purple striae on her abdomen. Her blood pressure is 150/90 mmHg. Further investigations reveal hypokalemia and hyperglycemia. Which of the following is the MOST likely underlying mechanism for her clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Ectopic ACTH production",
          "correct": true
        },
        {
          "label": "B",
          "text": "Primary adrenal adenoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pituitary ACTH-secreting adenoma (Cushing's disease)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Exogenous glucocorticoid use",
          "correct": false
        }
      ],
      "correct_answer": "A. Ectopic ACTH production",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Ectopic ACTH production</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Primary adrenal adenoma: While an adrenal adenoma could cause Cushing's syndrome, it wouldn't explain the recent onset of symptoms in the context of SCLC.</li><li>\u2022 Option B. Primary adrenal adenoma:</li><li>\u2022 Option C. Pituitary ACTH-secreting adenoma (Cushing's disease): Cushing's disease is less likely in this scenario, especially with a known SCLC diagnosis.</li><li>\u2022 Option C. Pituitary ACTH-secreting adenoma (Cushing's disease):</li><li>\u2022 Option D. Exogenous glucocorticoid use: This is less likely given the absence of a history of glucocorticoid use and the presence of SCLC.</li><li>\u2022 Option D. Exogenous glucocorticoid use:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ectopic Cushing's syndrome is a paraneoplastic syndrome caused by the ectopic production of ACTH by non-pituitary tumors.</li><li>\u27a4 Recognizing the clinical features of Cushing's syndrome in patients with cancer is crucial for prompt diagnosis and management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "025d3259",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with recurrent episodes of flushing, accompanied by diarrhea and abdominal cramping. She has also noticed a rash on her face and neck that worsens during these episodes. On physical examination, you note telangiectasias on her cheeks and a palpable liver mass. Which of the following diagnostic tests is MOST likely to be elevated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Serum cortisol",
          "correct": false
        },
        {
          "label": "B",
          "text": "24-hour urinary 5-HIAA",
          "correct": true
        },
        {
          "label": "C",
          "text": "Serum calcitonin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum gastrin",
          "correct": false
        }
      ],
      "correct_answer": "B. 24-hour urinary 5-HIAA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 24-hour urinary 5-HIAA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Serum cortisol: Cortisol is elevated in Cushing's syndrome, which presents with different clinical features (central obesity, muscle weakness, hypertension).</li><li>\u2022 Option A. Serum cortisol:</li><li>\u2022 Option C. Serum calcitonin: Calcitonin is a marker for medullary thyroid carcinoma (MTC), which can also cause flushing but usually presents with a neck mass or thyroid nodules.</li><li>\u2022 Option C. Serum calcitonin:</li><li>\u2022 Option D. Serum gastrin: Gastrin is elevated in gastrinomas (a type of neuroendocrine tumor), which primarily cause peptic ulcers and abdominal pain, not the classic carcinoid syndrome symptoms.</li><li>\u2022 Option D. Serum gastrin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors. 24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</li><li>\u27a4 Carcinoid syndrome is caused by the release of vasoactive substances, mainly serotonin, from carcinoid tumors.</li><li>\u27a4 24-hour urinary 5-HIAA is the diagnostic test of choice for carcinoid syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b47e6b9",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of weight loss and fatigue presents with recurrent episodes of confusion, sweating, and tremors. These episodes typically occur in the morning or after prolonged fasting. His blood glucose level during one of these episodes is 40 mg/dL. Abdominal imaging reveals a large retroperitoneal mass. Which of the following is the MOST likely cause of this patient's hypoglycemia?",
      "options": [
        {
          "label": "A",
          "text": "Insulinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adrenal insufficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ectopic production of IGF-2 by the tumor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pituitary insufficiency",
          "correct": false
        }
      ],
      "correct_answer": "C. Ectopic production of IGF-2 by the tumor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ectopic production of IGF-2 by the tumor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Insulinoma: Insulinomas are pancreatic neuroendocrine tumors that secrete insulin, leading to hypoglycemia. However, the presence of a retroperitoneal mass makes this less likely.</li><li>\u2022 Option A. Insulinoma:</li><li>\u2022 Option B. Adrenal insufficiency: Adrenal insufficiency can cause hypoglycemia, but it's usually associated with other symptoms like hypotension, fatigue, and hyperpigmentation.</li><li>\u2022 Option B. Adrenal insufficiency:</li><li>\u2022 Option D. Pituitary insufficiency: Pituitary insufficiency can cause secondary adrenal insufficiency, which can lead to hypoglycemia. However, it's less likely in this patient with a retroperitoneal mass.</li><li>\u2022 Option D. Pituitary insufficiency:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Non-islet cell hypoglycemia is a rare but important paraneoplastic syndrome associated with certain tumors. Recognizing this syndrome is crucial for proper management and treatment of the underlying malignancy.</li><li>\u27a4 Non-islet cell hypoglycemia is a rare but important paraneoplastic syndrome associated with certain tumors.</li><li>\u27a4 Recognizing this syndrome is crucial for proper management and treatment of the underlying malignancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c736741c",
      "audio": ""
    },
    {
      "text": "A 50-year-old man presents with persistent bone pain and muscle weakness for several months. He has a history of recurrent fractures. Laboratory findings show hypophosphatemia, normal serum calcium, and decreased 1,25-dihydroxyvitamin D levels. Imaging studies reveal multiple bone lesions. Which of the following is the MOST likely underlying cause of his condition?",
      "options": [
        {
          "label": "A",
          "text": "Primary hyperparathyroidism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin D deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mesenchymal tumor producing FGF23",
          "correct": true
        },
        {
          "label": "D",
          "text": "Multiple myeloma",
          "correct": false
        }
      ],
      "correct_answer": "C. Mesenchymal tumor producing FGF23",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Primary hyperparathyroidism: This would cause hypercalcemia, not hypophosphatemia.</li><li>\u2022 Option A. Primary hyperparathyroidism:</li><li>\u2022 Option B. Vitamin D deficiency: This would also cause hypophosphatemia, but 1,25-dihydroxyvitamin D levels would be low or inappropriately normal, not decreased.</li><li>\u2022 Option B. Vitamin D deficiency:</li><li>\u2022 Option D. Multiple myeloma: Myeloma can cause bone pain and fractures, but it typically presents with hypercalcemia and renal insufficiency.</li><li>\u2022 Option D. Multiple myeloma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23. Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment. Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</li><li>\u27a4 Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by tumors that secrete FGF23.</li><li>\u27a4 Recognizing the characteristic clinical and laboratory findings is crucial for prompt diagnosis and treatment.</li><li>\u27a4 Identifying and removing the underlying tumor can lead to resolution of the osteomalacia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "23b267ea",
      "audio": ""
    },
    {
      "text": "A 60-year-old man presents to his primary care physician with complaints of breast tenderness and enlargement over the past 3 months. He has also noticed a significant decrease in his libido and erectile function during this time. On physical examination, you note bilateral gynecomastia without palpable masses and testicular atrophy. Laboratory findings reveal a normal testosterone level, elevated estradiol level, and a slightly elevated hCG level. A chest CT scan demonstrates a mass in the right lung's lower lobe, with no evidence of metastasis. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Male breast cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gynecomastia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Male feminization",
          "correct": true
        },
        {
          "label": "D",
          "text": "Non cancerous breast lump",
          "correct": false
        }
      ],
      "correct_answer": "C. Male feminization",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Male feminization</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Male breast cancer: Usually presents as a unilateral, hard, and sometimes painful mass located beneath the nipple, without necessarily being associated with elevated estradiol levels or symptoms of feminization.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Male breast cancer:</li><li>\u2022 Option B. Gynecomastia: Refers to the benign enlargement of breast tissue in males and can be a component of male feminization syndrome, but by itself, it does not explain the full clinical picture, including the lung mass and hormonal imbalances.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Gynecomastia:</li><li>\u2022 Option D. Non-cancerous breast lumps: Can cause breast enlargement, but they do not typically lead to hormonal changes like elevated estradiol or the systemic symptoms of feminization.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Non-cancerous breast lumps:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Male feminization syndrome, or paraneoplastic hyperestrogenism, can occur when tumors (commonly lung tumors) produce hormones or hormone-like substances leading to elevated estrogen levels, resulting in feminization effects such as gynecomastia, decreased libido, and erectile dysfunction. The diagnosis is supported by the presence of a lung mass, normal testosterone, elevated estradiol, and slightly elevated hCG levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0b2fee47",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with acute myeloid leukemia presents with stomatitis as shown in the image. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Dermatomyositis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paraneoplastic pemphigus",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pyoderma gangrenosum",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sweet syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Paraneoplastic pemphigus",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162506.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Paraneoplastic pemphigus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dermatomyositis: Generally presents with a heliotrope rash (purple discoloration around the eyes) and Gottron's papules, not typically with the severe oral involvement shown.</li><li>\u2022 Option A.</li><li>\u2022 Dermatomyositis:</li><li>\u2022 Option C. Pyoderma gangrenosum: Is a neutrophilic dermatosis that usually presents as rapidly progressing painful skin ulcers, primarily on the legs, not in the oral cavity.</li><li>\u2022 Option C.</li><li>\u2022 Pyoderma gangrenosum:</li><li>\u2022 Option D. Sweet syndrome: or acute febrile neutrophilic dermatosis, presents with painful erythematous plaques on the skin, typically without the severe mucosal involvement depicted.</li><li>\u2022 Option D.</li><li>\u2022 Sweet syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Paraneoplastic pemphigus is associated with underlying malignancies and presents with painful mucosal erosions and various skin lesions. It is important to recognize the oral manifestations which can be severe and impact a patient's ability to eat and maintain oral hygiene.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07f99ed5",
      "audio": ""
    },
    {
      "text": "A 58-year-old male patient presents with fever, arthralgia, and painful erythematous plaques on her upper extremities as shown in the image. Laboratory tests reveal leukocytosis with neutrophilia and anemia. A bone marrow biopsy is performed, suspecting an underlying hematological disorder. Which of the following conditions is most likely associated with this patient's presentation?",
      "options": [
        {
          "label": "A",
          "text": "Chronic lymphocytic leukemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Myelodysplastic syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hodgkin's lymphoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Polycythemia vera",
          "correct": false
        }
      ],
      "correct_answer": "B. Myelodysplastic syndrome",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-163404.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Myelodysplastic syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chronic lymphocytic leukemia (CLL): May be associated with various skin manifestations, but Sweet's syndrome is more classically associated with myeloid disorders.</li><li>\u2022 Option A.</li><li>\u2022 Chronic lymphocytic leukemia (CLL):</li><li>\u2022 Option C. Hodgkin's lymphoma: Is not commonly associated with Sweet's syndrome. Hodgkin's lymphoma typically presents with lymphadenopathy and sometimes with B symptoms (fever, weight loss, night sweats), but not typically with the cutaneous manifestations seen in Sweet's syndrome.</li><li>\u2022 Option C.</li><li>\u2022 Hodgkin's lymphoma:</li><li>\u2022 Option D. Polycythemia vera: Could present with a plethoric face and splenomegaly and is a myeloproliferative disorder, but it is not the hematologic disorder most typically associated with Sweet's syndrome.</li><li>\u2022 Option D.</li><li>\u2022 Polycythemia vera:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sweet's syndrome, characterized by painful erythematous plaques, fever, and arthralgias, is often associated with hematological disorders, particularly myelodysplastic syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a0617c89",
      "audio": ""
    },
    {
      "text": "A 48-year-old male, with a known case of GERD presents with a 6-month history of weight loss, decreased appetite along with darkening and thickening of the skin on his neck and axillae. The areas are asymptomatic but have been progressively worsening. He has no other significant past medical history. On examination, you note hyperpigmented, velvety plaques in the affected areas along with the small nodule near the umblicus. Given the patient's presentation, which of the following is the MOST likely underlying condition?",
      "options": [
        {
          "label": "A",
          "text": "Addison's disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulin resistance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gastric adenocarcinoma",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hypothyroidism",
          "correct": false
        }
      ],
      "correct_answer": "C. Gastric adenocarcinoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Gastric adenocarcinoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Addison's disease: While Addison's disease can cause hyperpigmentation, it is typically more diffuse and doesn't have the velvety texture characteristic of acanthosis nigricans. Additionally, Addison's disease would present with other symptoms like hypotension, fatigue, and electrolyte imbalances.</li><li>\u2022 Option A. Addison's disease:</li><li>\u2022 Option B. Insulin resistance: While insulin resistance can cause acanthosis nigricans, it's usually seen in younger individuals with obesity and metabolic syndrome. The rapid progression, associated symptoms, and the presence of a Sister Mary Joseph nodule in this case point more towards malignancy.</li><li>\u2022 Option B. Insulin resistance:</li><li>\u2022 Option D. Hypothyroidism: Hypothyroidism can cause skin changes like dryness and coarseness, but it doesn't typically cause the velvety hyperpigmentation seen in acanthosis nigricans.</li><li>\u2022 Option D. Hypothyroidism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rapidly progressive acanthosis nigricans in an adult, especially with associated symptoms like weight loss, decreased appetite, and the presence of a Sister Mary Joseph nodule, should prompt immediate investigation for an underlying malignancy.</li><li>\u27a4 Gastric adenocarcinoma is the most common malignancy associated with acanthosis nigricans in adults, and the presence of a Sister Mary Joseph nodule further supports this possibility.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6c6dc089",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with progressive muscle weakness and peculiar rashes present on her knuckles and eyes as shown below. She also reports difficulty swallowing and has noticed a scaly rash over her shoulders and upper back. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Systemic lupus erythematosus (SLE)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dermatomyositis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Scleroderma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Polymyositis",
          "correct": false
        }
      ],
      "correct_answer": "B. Dermatomyositis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-163958.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Dermatomyositis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Systemic lupus erythematosus (SLE): While SLE can cause a malar rash and muscle weakness, it doesn't typically present with the specific skin findings seen in dermatomyositis (heliotrope rash, Gottron's papules, shawl sign).</li><li>\u2022 Option A. Systemic lupus erythematosus (SLE):</li><li>\u2022 Option C. Scleroderma: Scleroderma primarily affects the skin and internal organs, causing thickening and tightening of the skin. It doesn't typically present with the muscle weakness or characteristic rash seen in dermatomyositis.</li><li>\u2022 Option C. Scleroderma:</li><li>\u2022 Option D. Polymyositis: Polymyositis presents with muscle weakness but lacks the characteristic skin manifestations of dermatomyositis.</li><li>\u2022 Option D. Polymyositis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dermatomyositis is an inflammatory myopathy characterized by muscle weakness and distinctive skin manifestations. It is also associated with an increased risk of malignancy, particularly ovarian cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ced7e3d",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman presents to the clinic with a 2-month history of progressive memory loss, confusion, and episodes of hallucinations. Her family also reports a change in her behavior, describing her as increasingly irritable and sometimes displaying inappropriate emotional responses. She was recently diagnosed with lung cancer. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Cortical encephalitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Limbic encephalitis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cerebellar encephalitis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Brainstem encephalitis",
          "correct": false
        }
      ],
      "correct_answer": "B. Limbic encephalitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Limbic encephalitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cortical encephalitis: Would involve more widespread cerebral cortex symptoms, including significant changes in cognition, motor, and sensory functions but might not specifically target memory and emotional regulation as in limbic encephalitis.</li><li>\u2022 Option A.</li><li>\u2022 Cortical encephalitis:</li><li>\u2022 Option C. Cerebellar encephalitis: Would primarily affect coordination, gait, and balance due to inflammation of the cerebellum, and would be less likely to cause the memory and behavioral symptoms described.</li><li>\u2022 Option C.</li><li>\u2022 Cerebellar encephalitis:</li><li>\u2022 Option D. Brainstem encephalitis: Would involve symptoms related to the functions of the brainstem, including vital functions, cranial nerve functions, and coordination, rather than primarily memory and behavior.</li><li>\u2022 Option D.</li><li>\u2022 Brainstem encephalitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Limbic encephalitis presents with progressive memory loss, confusion, behavioral changes, and sometimes hallucinations due to the involvement of the limbic system. It can be associated with lung cancer as a paraneoplastic syndrome, where the immune system's response to the cancer also affects the nervous system.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "efe11e07",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with a recent diagnosis of ovarian cancer is brought to the emergency department due to altered mental status, memory loss, and involuntary movements. Her family reports that she has also been experiencing seizures. Further evaluation reveals anti-NMDA receptor antibodies in her serum. Which of the following is the most appropriate initial treatment for this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Corticosteroids and intravenous immunoglobulin (IVIG) or plasma exchange",
          "correct": true
        },
        {
          "label": "B",
          "text": "Antiepileptic drugs only",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chemotherapy for ovarian cancer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Radiation therapy to the brain",
          "correct": false
        }
      ],
      "correct_answer": "A. Corticosteroids and intravenous immunoglobulin (IVIG) or plasma exchange",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Corticosteroids and intravenous immunoglobulin (IVIG) or plasma exchange</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Antiepileptic drugs only: While antiepileptic drugs are necessary to manage seizures, they do not address the underlying autoimmune process.</li><li>\u2022 Option B. Antiepileptic drugs only:</li><li>\u2022 Option C. Chemotherapy for ovarian cancer: While treating the underlying cancer is important, immediate immunotherapy is crucial to control the neurological symptoms and prevent further brain damage.</li><li>\u2022 Option C. Chemotherapy for ovarian cancer:</li><li>\u2022 Option D. Radiation therapy to the brain: Radiation therapy is not the primary treatment for anti-NMDA receptor encephalitis.</li><li>\u2022 Option D. Radiation therapy to the brain:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-NMDA receptor encephalitis is a potentially reversible autoimmune disorder that requires prompt recognition and treatment with immunotherapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d6239117",
      "audio": ""
    },
    {
      "text": "Which of the following statements regarding antibodies in paraneoplastic neurological syndromes (PNS) is FALSE?",
      "options": [
        {
          "label": "A",
          "text": "Antibodies against intracellular antigens are almost always paraneoplastic.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Antibodies against cell surface antigens can be autoimmune and may not always be associated with cancer.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Antibodies can be detected in both CSF and serum.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The presence of antibodies in CSF excludes an autoimmune cause.",
          "correct": true
        }
      ],
      "correct_answer": "D. The presence of antibodies in CSF excludes an autoimmune cause.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) The presence of antibodies in CSF excludes an autoimmune cause.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Antibodies against intracellular antigens are almost always paraneoplastic: This is generally true. Antibodies targeting intracellular antigens, such as Hu, Yo, or Ri, are highly suggestive of a paraneoplastic neurological syndrome.</li><li>\u2022 Option A. Antibodies against intracellular antigens are almost always paraneoplastic:</li><li>\u2022 Option B. Antibodies against cell surface antigens can be autoimmune and may not always be associated with cancer: This is also accurate. Some antibodies target cell surface antigens, and these can be associated with autoimmune conditions without an underlying malignancy.</li><li>\u2022 Option B. Antibodies against cell surface antigens can be autoimmune and may not always be associated with cancer:</li><li>\u2022 Option C. Antibodies can be detected in both CSF and serum: This is correct. In PNS, the antibodies can often be found in both the cerebrospinal fluid (CSF) and the serum.</li><li>\u2022 Option C. Antibodies can be detected in both CSF and serum:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The presence of antibodies in CSF does not differentiate between paraneoplastic and autoimmune causes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f6a6d50",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with a BG of CA Breast on chemotherapy presents with progressive ataxia and opsoclonus (rapid, multidirectional eye movements). Which antibody is MOST likely to be found in her serum?",
      "options": [
        {
          "label": "A",
          "text": "Anti-Hu",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-Yo",
          "correct": false
        },
        {
          "label": "C",
          "text": "ANNA-2",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anti-Ma2",
          "correct": false
        }
      ],
      "correct_answer": "C. ANNA-2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) ANNA - 2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anti-Hu: Anti-Hu antibodies are associated with paraneoplastic encephalomyelitis and sensory neuronopathy, which typically present with sensory loss, limb weakness, and autonomic dysfunction.</li><li>\u2022 Option A. Anti-Hu:</li><li>\u2022 Option B. Anti-Yo: Anti-Yo antibodies are linked to paraneoplastic cerebellar degeneration, causing ataxia, but not typically opsoclonus. They are more commonly associated with gynecological and breast cancers.</li><li>\u2022 Option B. Anti-Yo:</li><li>\u2022 Option D. Anti-Ma2: Anti-Ma2 antibodies are associated with limbic encephalitis and brainstem encephalitis, which usually present with psychiatric symptoms, seizures, and sometimes brainstem dysfunction.</li><li>\u2022 Option D. Anti-Ma2:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Certain antibodies are highly associated with specific paraneoplastic neurological syndromes. In this case, the presence of ataxia and opsoclonus, particularly in a patient with breast cancer, points strongly toward anti-Ri antibodies. Recognizing these paraneoplastic syndromes is crucial for early diagnosis and appropriate management.</li><li>\u27a4 Certain antibodies are highly associated with specific paraneoplastic neurological syndromes.</li><li>\u27a4 In this case, the presence of ataxia and opsoclonus, particularly in a patient with breast cancer, points strongly toward anti-Ri antibodies.</li><li>\u27a4 Recognizing these paraneoplastic syndromes is crucial for early diagnosis and appropriate management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6749f201",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman with a history of small cell lung cancer (SCLC) presents with unexplained vision loss and abnormal retinal pigmentation. Which of the following antibodies is MOST likely associated with her suspected diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Anti-Hu antibodies",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-Yo antibodies",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-recoverin antibodies",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anti-amphiphysin antibodies",
          "correct": false
        }
      ],
      "correct_answer": "C. Anti-recoverin antibodies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anti-recoverin antibodies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anti-Hu antibodies: These antibodies are associated with paraneoplastic encephalomyelitis and sensory neuronopathy, which typically present with neurological symptoms like ataxia, sensory loss, and autonomic dysfunction, not primarily vision loss.</li><li>\u2022 Option A. Anti-Hu antibodies:</li><li>\u2022 Option B. Anti-Yo antibodies: Anti-Yo antibodies are linked to paraneoplastic cerebellar degeneration, causing ataxia but not typically vision loss.</li><li>\u2022 Option B. Anti-Yo antibodies:</li><li>\u2022 Option D. Anti-amphiphysin antibodies: These antibodies are associated with stiff person syndrome, a rare neurological disorder characterized by muscle rigidity and spasms.</li><li>\u2022 Option D. Anti-amphiphysin antibodies:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cancer-associated retinopathy is a paraneoplastic syndrome that can cause vision loss in patients with underlying malignancies, particularly SCLC. Anti-recoverin antibodies are highly specific for CAR and their presence can help confirm the diagnosis.</li><li>\u27a4 Cancer-associated retinopathy is a paraneoplastic syndrome that can cause vision loss in patients with underlying malignancies, particularly SCLC.</li><li>\u27a4 Anti-recoverin antibodies are highly specific for CAR and their presence can help confirm the diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e05e1427",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with recent diagnosis of Hodgkin's lymphoma presents to neurology clinic with a 3-month history of progressive unsteadiness and difficulty walking. He reports feeling clumsy and has noticed frequent stumbling, particularly when trying to navigate stairs. Additionally, he mentions episodes of slurred speech and difficulty swallowing. Given the presentation, which of the following antibodies is not involved in the condition?",
      "options": [
        {
          "label": "A",
          "text": "Anti-mGluR1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-mGluR2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-Tr",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti LGI1",
          "correct": true
        }
      ],
      "correct_answer": "D. Anti LGI1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anti LGI1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anti-mGluR1 : Antibodies are associated with paraneoplastic cerebellar degeneration, especially in cases related to Hodgkin's lymphoma. These antibodies target the metabotropic glutamate receptor 1, which is involved in neuronal signaling in the cerebellum.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Anti-mGluR1</li><li>\u2022 Option B. Anti-mGluR2 : Antibodies target the metabotropic glutamate receptor 2. While less commonly associated with PCD, they have been implicated in some paraneoplastic neurological syndromes.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Anti-mGluR2</li><li>\u2022 Option C. Anti-Tr: Antibodies are strongly associated with paraneoplastic cerebellar degeneration, particularly in patients with Hodgkin's lymphoma. They are one of the hallmark antibodies for this association.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Anti-Tr:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Paraneoplastic cerebellar degeneration (PCD) associated with Hodgkin's lymphoma is commonly linked with Anti-mGluR1 and Anti-Tr antibodies, which target neuronal components in the cerebellum. In contrast, Anti-LGI1 antibodies are associated with limbic encephalitis and present with a different clinical picture, including seizures and cognitive changes, rather than the cerebellar dysfunction seen in PCD.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3e434cd3",
      "audio": ""
    },
    {
      "text": "A 65-year-old male smoker with a 50-pack-year history presents with fatigue and a ruddy complexion. His hemoglobin is elevated at 18 g/dL and hematocrit is 55%. Which of the following malignancies is the MOST likely underlying cause of his erythrocytosis?",
      "options": [
        {
          "label": "A",
          "text": "Renal cell carcinoma (RCC)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hepatocellular carcinoma (HCC)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cerebellar hemangioblastoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Small cell lung cancer (SCLC)",
          "correct": false
        }
      ],
      "correct_answer": "A. Renal cell carcinoma (RCC)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Hepatocellular carcinoma (HCC): While HCC can also be associated with erythrocytosis, it's less common than RCC. Additionally, there's no mention of risk factors for HCC in this patient's history.</li><li>\u2022 Option B. Hepatocellular carcinoma (HCC):</li><li>\u2022 Option C. Cerebellar hemangioblastoma: Although hemangioblastomas can produce erythropoietin and cause erythrocytosis, they are much rarer than RCC and usually present with neurological symptoms.</li><li>\u2022 Option C. Cerebellar hemangioblastoma:</li><li>\u2022 Option D. Small cell lung cancer (SCLC): SCLC is a possible cause of paraneoplastic erythrocytosis, but it's less common than RCC. The patient's smoking history increases the risk of lung cancer, but the absence of other respiratory symptoms makes it less likely in this scenario.</li><li>\u2022 Option D. Small cell lung cancer (SCLC):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Erythrocytosis can be a paraneoplastic manifestation of RCC, and appropriate evaluation is warranted in patients with unexplained erythrocytosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "91e2acbf",
      "audio": ""
    },
    {
      "text": "A 63-year-old woman presents to the emergency department with acute onset of left-sided weakness and slurred speech that began 2 hours ago. She also mentions experiencing a burning sensation in her palms and soles for the past month, which she attributed to her new gardening hobby. On examination, she has noticeable splenomegaly. Laboratory tests reveal a platelet count of 950,000/\u03bcL, hemoglobin of 12.2 g/dL, and a white blood cell count of 7,800/\u03bcL. A chest X-ray reveals a mass in the right lung hilum. Which protein is most likely responsible for this patient's thrombocytosis?",
      "options": [
        {
          "label": "A",
          "text": "Erythropoietin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Thrombopoietin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vascular endothelial growth factor (VEGF)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Interleukin-6 (IL-6)",
          "correct": true
        }
      ],
      "correct_answer": "D. Interleukin-6 (IL-6)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Interleukin-6 (IL-6)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Erythropoietin: Primarily regulates red blood cell production and is more associated with polycythemia than thrombocytosis.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Erythropoietin:</li><li>\u2022 Option B. Thrombopoietin: Is the primary growth factor for platelet production. While it directly regulates platelet production, in the context of paraneoplastic thrombocytosis, it's the production of cytokines like IL-6 by the tumor that indirectly leads to increased thrombopoietin levels and subsequent thrombocytosis.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Thrombopoietin:</li><li>\u2022 Option C. Vascular endothelial growth factor (VEGF ): Is mainly involved in angiogenesis and not directly in the regulation of platelet production.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Vascular endothelial growth factor (VEGF</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Interleukin-6 (IL-6) can be produced by tumor cells and lead to paraneoplastic thrombocytosis in patients with malignancies such as lung cancer. IL-6 acts indirectly by stimulating the liver to produce more thrombopoietin, which then promotes increased platelet production in the bone marrow. Recognizing the role of IL-6 in paraneoplastic syndromes is important for understanding the systemic effects of certain cancers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "06ba0439",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman with a history of cervical cancer is being considered for targeted radionuclide therapy using an alpha-emitting radiopharmaceutical. The discussion focuses on the ionizing power of alpha particles in targeting residual microscopic disease. Which statement best describes the ionizing power of alpha particles in this therapy?",
      "options": [
        {
          "label": "A",
          "text": "Low ionizing power for deep tissue penetration and targeting distant metastases.",
          "correct": false
        },
        {
          "label": "B",
          "text": "High ionizing power causing dense ionization with limited penetration, ideal for localized disease.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Extremely high ionizing power causing widespread damage beyond targeted cells, high toxicity risk.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Similar ionizing power to beta particles but with longer range, suitable for larger tumors.",
          "correct": false
        }
      ],
      "correct_answer": "B. High ionizing power causing dense ionization with limited penetration, ideal for localized disease.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) High ionizing power causing dense ionization with limited penetration, ideal for localized disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Alpha particles actually have low penetration in tissue, not deep tissue penetration, which limits their use to more localized or superficial treatments rather than targeting distant metastases.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Option C. While alpha particles have a high ionizing power, they do not cause widespread damage beyond targeted cells due to their limited penetration range. The risk of toxicity is more related to their potential to cause significant damage within a short range, which is why they need to be precisely targeted.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. Alpha particles have a much higher ionizing power compared to beta particles but a much shorter range in tissue. Beta particles can penetrate deeper into tissue, making them suitable for larger tumors, whereas alpha particles are more effective for localized treatment due to their short range.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alpha-emitting radiopharmaceuticals are utilized in targeted radionuclide therapy for their high ionizing power, which allows for dense ionization and significant DNA damage within cancer cells. Their limited penetration depth makes them ideal for treating localized microscopic disease while minimizing collateral damage to surrounding healthy tissue.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1f3ef7d6",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with early-stage breast cancer has undergone lumpectomy and is now consulting with her radiation oncologist about adjuvant radiation therapy. The oncologist explains that the treatment will involve using a machine called a linear accelerator. Which of the following BEST describes how a linear accelerator generates X-rays for radiation therapy?",
      "options": [
        {
          "label": "A",
          "text": "It uses radioactive decay of elements like cobalt-60 to emit X-rays.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It accelerates electrons to high speeds, which then collide with a tungsten target to produce X-rays.",
          "correct": true
        },
        {
          "label": "C",
          "text": "It accelerates protons in a circular path, and these protons generate X-rays when they hit a target.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It manipulates the path of high-speed electrons using magnetic fields to produce X-rays.",
          "correct": false
        }
      ],
      "correct_answer": "B. It accelerates electrons to high speeds, which then collide with a tungsten target to produce X-rays.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It accelerates electrons to high speeds, which then collide with a tungsten target to produce X-rays.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It uses radioactive decay of elements like cobalt-60 to emit X-rays: This describes the principle behind older cobalt-60 radiotherapy units, which are less commonly used today.</li><li>\u2022 Option A. It uses radioactive decay of elements like cobalt-60 to emit X-rays:</li><li>\u2022 Option C. It accelerates protons in a circular path, and these protons generate X-rays when they hit a target: This is the principle of proton therapy, a more specialized form of radiation therapy that uses protons instead of X-rays.</li><li>\u2022 Option C. It accelerates protons in a circular path, and these protons generate X-rays when they hit a target:</li><li>\u2022 Option D. It manipulates the path of high-speed electrons using magnetic fields to produce X-rays: This describes the mechanism of a synchrotron, a type of particle accelerator used for research purposes and not typically for clinical radiation therapy.</li><li>\u2022 Option D. It manipulates the path of high-speed electrons using magnetic fields to produce X-rays:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Linear accelerators are the primary source of X-rays in modern radiation therapy for cancer treatment. They generate high-energy X-rays by accelerating electrons and colliding them with a tungsten target.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "60fcc74b",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient with a deep-seated brain tumor is being considered for radiation therapy. The treatment plan involves using a type of radiation that has a distinct advantage in sparing surrounding healthy tissues while delivering a high dose to the tumor. Which type of radiation therapy is being considered for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Conventional photon therapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gamma knife radiosurgery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Proton beam therapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "Intensity-modulated radiation therapy (IMRT)",
          "correct": false
        }
      ],
      "correct_answer": "C. Proton beam therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Proton beam therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Conventional photon therapy: Uses X-rays to treat cancer. While effective, it may not offer the same level of precision in sparing surrounding tissues as proton therapy, especially for deep-seated tumors.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Conventional photon therapy:</li><li>\u2022 Option B. Gamma knife radiosurgery: Is a form of stereotactic radiosurgery that uses focused beams of gamma rays to treat small to medium-sized lesions, primarily in the brain. While it is highly precise, it may not be the best option for larger tumors or those located deep within the brain.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Gamma knife radiosurgery:</li><li>\u2022 Option D. Intensity-modulated radiation therapy (IMRT): Is an advanced form of photon therapy that modulates the intensity of the radiation beams to conform to the shape of the tumor. It offers improved sparing of healthy tissues compared to conventional photon therapy but still uses X-rays, which have a different dose distribution compared to protons.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Intensity-modulated radiation therapy (IMRT):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Proton beam therapy is particularly advantageous for treating deep-seated tumors, such as those in the brain, due to its ability to deliver a high dose of radiation to the tumor with minimal exposure to surrounding healthy tissues. This is achieved through the unique dose distribution of protons, characterized by the Bragg peak.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "12556884",
      "audio": ""
    },
    {
      "text": "A radiologist is reviewing a chest X-ray of a 50-year-old patient. They note a clear distinction between the denser, brighter areas representing the ribs and the darker areas representing the lungs. This contrast allows them to visualize the lung parenchyma and identify any potential abnormalities. Which of the following radiation interactions is PRIMARILY responsible for creating the contrast observed on this chest X-ray?",
      "options": [
        {
          "label": "A",
          "text": "Compton scattering",
          "correct": false
        },
        {
          "label": "B",
          "text": "Photoelectric effect",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pair production",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bremsstrahlung radiation",
          "correct": false
        }
      ],
      "correct_answer": "B. Photoelectric effect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Photoelectric effect</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Compton scattering: Contributes to image noise and reduces contrast.</li><li>\u2022 Option A. Compton scattering:</li><li>\u2022 Option C. Pair production: Occurs at very high photon energies, not typically used in diagnostic imaging.</li><li>\u2022 Option C. Pair production:</li><li>\u2022 Option D. Bremsstrahlung radiation: Is the process of X-ray production, not an interaction within the patient.</li><li>\u2022 Option D. Bremsstrahlung radiation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The photoelectric effect is crucial in generating image contrast in diagnostic radiology due to its dependence on the atomic number of the tissues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4ea6d496",
      "audio": ""
    },
    {
      "text": "The Law of Bergonie and Tribondeau describes the relative radiosensitivity of different cell types. Which of the following statements BEST encapsulates this law?",
      "options": [
        {
          "label": "A",
          "text": "Cells with a high mitotic rate and low differentiation are more radiosensitive.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cells with a low mitotic rate and high differentiation are more radiosensitive.",
          "correct": false
        },
        {
          "label": "C",
          "text": "All cell types are equally sensitive to radiation.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Radiosensitivity is independent of cell type and depends only on the radiation dose.",
          "correct": false
        }
      ],
      "correct_answer": "A. Cells with a high mitotic rate and low differentiation are more radiosensitive.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cells with a high mitotic rate and low differentiation are more radiosensitive.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Cells with a low mitotic rate and high differentiation are more radiosensitive: This is the opposite of the correct answer. Highly differentiated and slowly dividing cells are generally more resistant to radiation.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 Cells with a low mitotic rate and high differentiation are more radiosensitive:</li><li>\u2022 Option C. All cell types are equally sensitive to radiation: This is incorrect. Different cell types exhibit varying degrees of radiosensitivity based on their proliferative and differentiation status.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 All cell types are equally sensitive to radiation:</li><li>\u2022 Option D. Radiosensitivity is independent of cell type and depends only on the radiation dose: While radiation dose is a crucial factor, the inherent radiosensitivity of different cell types also plays a major role in determining the extent of radiation damage.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Radiosensitivity is independent of cell type and depends only on the radiation dose:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Law of Bergonie and Tribondeau is a fundamental principle in radiation biology that explains why some tissues are more susceptible to radiation damage than others. This has important implications for radiation therapy planning and minimizing side effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b45eb63",
      "audio": ""
    },
    {
      "text": "A medical physicist is calculating the absorbed dose of radiation received by a patient during a radiotherapy session. Which of the following units is used to measure the absorbed dose of radiation in tissues?",
      "options": [
        {
          "label": "A",
          "text": "Sievert (Sv)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gray (Gy)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Becquerel (Bq)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Roentgen (R)",
          "correct": false
        }
      ],
      "correct_answer": "B. Gray (Gy)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Gray (Gy)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sievert (Sv) : Is a unit that measures the biological effect of the absorbed radiation, not the absorbed dose itself. It takes into account the type of radiation and its biological effectiveness, and is often used in radiation protection to quantify the risk associated with the exposure to ionizing radiation.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Sievert (Sv)</li><li>\u2022 Option C. Becquerel (Bq) : Is a unit of radioactivity that measures the rate of decay or disintegration of radioactive material. It is defined as one disintegration per second and is not a measure of absorbed dose.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Becquerel (Bq)</li><li>\u2022 Option D. Roentgen (R) : Is an older unit that was used to measure the exposure or the amount of ionization produced in air by X-rays or gamma rays. It does not directly measure the absorbed dose in tissue, which is why it has largely been replaced by the Gray in medical and scientific contexts.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 Roentgen (R)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Gray (Gy) is the unit used to measure the absorbed dose of radiation in tissues, indicating the amount of radiation energy deposited per unit mass of tissue. It is a critical measurement in radiation therapy planning to ensure that the target area receives the prescribed dose while minimizing the dose to surrounding healthy tissues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c5a6e102",
      "audio": ""
    },
    {
      "text": "Which of the following tissues has the LOWEST tissue weighting factor, indicating it is the LEAST sensitive to radiation?",
      "options": [
        {
          "label": "A",
          "text": "Bone marrow",
          "correct": false
        },
        {
          "label": "B",
          "text": "Salivary glands",
          "correct": true
        },
        {
          "label": "C",
          "text": "Thyroid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Gonads",
          "correct": false
        }
      ],
      "correct_answer": "B. Salivary glands",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Salivary glands</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bone marrow: Bone marrow is highly radiosensitive due to its role in blood cell production. It has a tissue weighting factor of 0.12, indicating a relatively high risk of stochastic effects from radiation exposure.</li><li>\u2022 Option A. Bone marrow:</li><li>\u2022 Option C. Thyroid: The thyroid gland has an intermediate tissue weighting factor of 0.04, indicating moderate radiosensitivity. It's more sensitive than salivary glands but less sensitive than bone marrow or gonads.</li><li>\u2022 Option C. Thyroid:</li><li>\u2022 Option D. Gonads: The gonads (ovaries and testes) are also relatively radiosensitive due to their role in reproduction. They have a tissue weighting factor of 0.08.</li><li>\u2022 Option D. Gonads:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tissues with low tissue weighting factors are less sensitive to radiation, meaning they can tolerate higher doses before experiencing significant damage.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "35566b52",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a glioblastoma is undergoing radiation therapy to his brain. The radiation oncologist explains that while radiation therapy can be effective in treating the tumor, it's important to be aware of potential side effects due to the varying sensitivity of different cell types to radiation. Considering the principles of radiosensitivity, which of the following cell types within the radiation field is MOST likely to be the LEAST affected by the radiation therapy?",
      "options": [
        {
          "label": "A",
          "text": "Lymphocytes circulating in the blood",
          "correct": false
        },
        {
          "label": "B",
          "text": "Spermatogonia in the testes",
          "correct": false
        },
        {
          "label": "C",
          "text": "Intestinal epithelial cells lining the gut",
          "correct": false
        },
        {
          "label": "D",
          "text": "Neurons in the brain",
          "correct": true
        }
      ],
      "correct_answer": "D. Neurons in the brain",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Neurons in the brain</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lymphocytes circulating in the blood: Lymphocytes are a type of white blood cell involved in the immune response. They are actively dividing and relatively undifferentiated, making them quite sensitive to radiation.</li><li>\u2022 Option A. Lymphocytes circulating in the blood:</li><li>\u2022 Option B. Spermatogonia in the testes: Spermatogonia are the stem cells in the testes that give rise to sperm. They are constantly dividing, making them highly radiosensitive.</li><li>\u2022 Option B. Spermatogonia in the testes:</li><li>\u2022 Option C. Intestinal epithelial cells lining the gut: These cells have a high turnover rate, constantly dividing to replenish the gut lining. This rapid cell division makes them more susceptible to radiation damage.</li><li>\u2022 Option C. Intestinal epithelial cells lining the gut:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The radiosensitivity of different cell types varies, and understanding these differences is important in predicting and managing the potential side effects of radiation therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0e893f1c",
      "audio": ""
    },
    {
      "text": "A patient with Hodgkin lymphoma is receiving radiation therapy. Which of the following side effects is the physician MOST likely to monitor for due to the high radiosensitivity of the affected tissue?",
      "options": [
        {
          "label": "A",
          "text": "Cataracts",
          "correct": false
        },
        {
          "label": "B",
          "text": "Myelosuppression",
          "correct": true
        },
        {
          "label": "C",
          "text": "Infertility",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cognitive decline",
          "correct": false
        }
      ],
      "correct_answer": "B. Myelosuppression",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Myelosuppression</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cataracts: Cataracts are a long-term complication of radiation therapy, particularly when the lens of the eye is within the radiation field. While possible, they are less likely to be a primary concern during the active treatment phase compared to myelosuppression.</li><li>\u2022 Option A. Cataracts:</li><li>\u2022 Option C. Infertility: Infertility can occur if the gonads (testes or ovaries) are within the radiation field. In Hodgkin lymphoma treatment, the radiation field is often directed at lymph nodes in the chest, neck, or abdomen, making direct gonadal exposure less likely.</li><li>\u2022 Option C. Infertility:</li><li>\u2022 Option D. Cognitive decline: Cognitive decline is a potential late complication of radiation therapy to the brain, but it's not a primary concern in the treatment of Hodgkin lymphoma, where the radiation field usually doesn't encompass the brain</li><li>\u2022 Option D. Cognitive decline:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bone marrow is a highly radiosensitive tissue, and myelosuppression is a common side effect of radiation therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2fd44e89",
      "audio": ""
    },
    {
      "text": "A pregnant radiation worker is concerned about the potential effects of radiation on her fetus. What is the recommended dose limit for the entire pregnancy?",
      "options": [
        {
          "label": "A",
          "text": "0.5 mSv",
          "correct": false
        },
        {
          "label": "B",
          "text": "1 mSv",
          "correct": false
        },
        {
          "label": "C",
          "text": "5 mSv",
          "correct": true
        },
        {
          "label": "D",
          "text": "20 mSv",
          "correct": false
        }
      ],
      "correct_answer": "C. 5 mSv",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 5 mSv</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 0.5 mSv: This is the recommended monthly dose limit for a pregnant radiation worker, not the limit for the entire pregnancy.</li><li>\u2022 Option A. 0.5 mSv:</li><li>\u2022 monthly</li><li>\u2022 Option B. 1 mSv: This is the annual dose limit for the general public, which is lower than the limit for occupational exposure during pregnancy.</li><li>\u2022 Option B. 1 mSv:</li><li>\u2022 Option D. 20 mSv: This is the annual dose limit for radiation workers, which is significantly higher than the limit for pregnancy.</li><li>\u2022 Option D. 20 mSv:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pregnant radiation workers should take precautions to limit their radiation exposure to protect the developing fetus.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "351ac93f",
      "audio": ""
    },
    {
      "text": "Which diagnostic modality typically involves the least radiation exposure?",
      "options": [
        {
          "label": "A",
          "text": "CT head",
          "correct": false
        },
        {
          "label": "B",
          "text": "Extremity X-ray",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chest X-ray",
          "correct": false
        },
        {
          "label": "D",
          "text": "PET-CT whole body",
          "correct": false
        }
      ],
      "correct_answer": "B. Extremity X-ray",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Extremity X-ray</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. A CT (Computed Tomography) head scan involves a higher dose of radiation than an extremity X-ray because it uses multiple X-ray beams and a computer to create detailed cross-sectional images of the head, including the brain. CT scans provide more detailed information but at the cost of higher radiation exposure.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Option C. A chest X-ray is a common diagnostic test that uses a small amount of radiation to produce images of the chest, including the heart, lungs, airways, blood vessels, and bones of the spine and chest. While a chest X-ray involves more radiation than an extremity X-ray, it is still lower in dose compared to a CT scan.</li><li>\u2022 Option</li><li>\u2022 C.</li><li>\u2022 Option D. A PET-CT (Positron Emission Tomography-Computed Tomography) whole-body scan combines a PET scan, which uses a radioactive tracer to show organ and tissue function, with a CT scan, which provides detailed anatomical information. This combination results in a higher radiation dose compared to the other options, making it the modality with the highest radiation exposure among those listed.</li><li>\u2022 Option</li><li>\u2022 D.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Among the diagnostic modalities listed, an extremity X-ray involves the least radiation exposure due to its focus on small areas and use of relatively low doses of radiation. It is important to consider the radiation dose and the diagnostic value of imaging tests when selecting the most appropriate modality for patient evaluation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1abd6277",
      "audio": ""
    },
    {
      "text": "The radiation exposure from a whole-body PET-CT scan is approximately equivalent to how many days/ months/ years of natural background radiation?",
      "options": [
        {
          "label": "A",
          "text": "10 days",
          "correct": false
        },
        {
          "label": "B",
          "text": "12 years",
          "correct": false
        },
        {
          "label": "C",
          "text": "8 years",
          "correct": true
        },
        {
          "label": "D",
          "text": "1 year",
          "correct": false
        }
      ],
      "correct_answer": "C. 8 years",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 8 years</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 10 days: Of natural background radiation exposure is significantly less than the dose received from a whole-body PET-CT scan, which utilizes both the ionizing radiation from CT imaging and the radioactive tracer used in PET scanning.</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 10 days:</li><li>\u2022 Option B. 12 years: Of natural background radiation exposure is higher than the typical exposure from a whole-body PET-CT scan, although estimates can vary based on specific protocols and equipment used.</li><li>\u2022 Option</li><li>\u2022 B.</li><li>\u2022 12 years:</li><li>\u2022 Option D. 1 year: Of natural background radiation exposure is less than the typical dose received from a whole-body PET-CT scan. The comparison to several years of natural background radiation helps to contextualize the relative magnitude of exposure from such medical imaging procedures.</li><li>\u2022 Option</li><li>\u2022 D.</li><li>\u2022 1 year:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The radiation exposure from a whole-body PET-CT scan is roughly equivalent to 8 years of natural background radiation, highlighting the significant amount of radiation involved in such diagnostic procedures. This comparison underscores the importance of judicious use of high-radiation diagnostic tests, ensuring that the potential benefits outweigh the risks associated with radiation exposure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e968ddb3",
      "audio": ""
    },
    {
      "text": "A radiation oncologist is planning a course of radiotherapy for a patient with a large, solid tumor. The oncologist is concerned about the presence of hypoxic regions within the tumor, as these areas are known to be relatively resistant to radiation. To enhance the effectiveness of the treatment, the oncologist decides to fractionate the radiation dose, delivering it in multiple smaller doses over several weeks. Which of the following, oncologist primarily leveraging by using fractionated radiotherapy to target hypoxic tumor cells?",
      "options": [
        {
          "label": "A",
          "text": "Re-assortment",
          "correct": false
        },
        {
          "label": "B",
          "text": "Re-oxygenation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Repair",
          "correct": false
        },
        {
          "label": "D",
          "text": "Repopulation",
          "correct": false
        }
      ],
      "correct_answer": "B. Re-oxygenation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Re-assortment: This refers to the redistribution of tumor cells into more radiosensitive phases of the cell cycle after radiation. While this can contribute to overall tumor cell killing, it's not the primary mechanism for overcoming hypoxia.</li><li>\u2022 Option A. Re-assortment:</li><li>\u2022 Option C. Repair: This process allows normal tissues to recover between radiation fractions, reducing toxicity. However, it's not directly related to addressing hypoxia in tumor cells.</li><li>\u2022 Option C. Repair:</li><li>\u2022 Option D. Repopulation: This refers to the accelerated growth of both normal and tumor cells between fractions. While it can benefit normal tissue repair, it can also lead to tumor regrowth and is not specifically aimed at hypoxic cells.</li><li>\u2022 Option D. Repopulation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Re-oxygenation is a critical factor in the success of fractionated radiotherapy. By allowing time between doses for hypoxic tumor cells to become oxygenated, it increases their radiosensitivity and improves the overall effectiveness of the treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07e0fdae",
      "audio": ""
    },
    {
      "text": "A radiation oncologist is considering the impact of oxygen on the effectiveness of radiation therapy for a tumor. The oxygen enhancement ratio (OER) is a measure of the increased effectiveness of ionizing radiation in the presence of oxygen. What is the typical value of the OER for X-rays?",
      "options": [
        {
          "label": "A",
          "text": "1",
          "correct": false
        },
        {
          "label": "B",
          "text": "1.5",
          "correct": false
        },
        {
          "label": "C",
          "text": "2.5",
          "correct": false
        },
        {
          "label": "D",
          "text": "3",
          "correct": true
        }
      ],
      "correct_answer": "D. 3",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. An OER of 1 would imply no difference in radiation sensitivity between oxygenated and anoxic conditions, which contradicts the known radiosensitizing effect of oxygen.</li><li>\u2022 Option A.</li><li>\u2022 1</li><li>\u2022 Option B. An OER of 1.5 would indicate a moderate increase in radiation sensitivity due to oxygen, but this value is lower than what is typically observed for X-rays.</li><li>\u2022 Option B.</li><li>\u2022 1.5</li><li>\u2022 Option C. An OER of 2.5 indicates a significant increase in radiation sensitivity with oxygen, but it's still lower than the more commonly accepted value of 3 for X-rays.</li><li>\u2022 Option C.</li><li>\u2022 2.5</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The oxygen enhancement ratio (OER) for X-rays is around 3, indicating that the presence of oxygen makes cells three times more susceptible to radiation damage compared to anoxic conditions. Understanding OER is crucial in radiation therapy, as it underscores the importance of tumor oxygenation in enhancing the therapeutic effect of radiation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "61c23fab",
      "audio": ""
    },
    {
      "text": "A 58-year-old man with newly diagnosed head and neck squamous cell carcinoma (HNSCC) is about to start radiation therapy. His oncologist discusses the potential side effects of radiation, including mucositis (inflammation of the mucous membranes) and xerostomia (dry mouth). The oncologist also mentions the possibility of using a radioprotector to mitigate these side effects. However, they express concerns about one specific radioprotector due to its potential to worsen mucositis and xerostomia, despite being the most extensively studied in this context. Which of the following radioprotectors is the oncologist MOST likely referring to?",
      "options": [
        {
          "label": "A",
          "text": "Zinc oxide (ZnO)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pentoxifylline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amifostine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Granulocyte-macrophage colony-stimulating factor (GM-CSF)",
          "correct": false
        }
      ],
      "correct_answer": "C. Amifostine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Amifostine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Zinc oxide (ZnO): Zinc oxide is primarily used topically for its anti-inflammatory and wound-healing properties. It's not a systemic radioprotector and doesn't have the side effects mentioned.</li><li>\u2022 Option A. Zinc oxide (ZnO):</li><li>\u2022 Option B. Pentoxifylline: Pentoxifylline improves blood flow and has some radioprotective effects, but it's not associated with exacerbating mucositis or xerostomia.</li><li>\u2022 Option B. Pentoxifylline:</li><li>\u2022 Option D. Granulocyte-macrophage colony-stimulating factor (GM-CSF): GM-CSF stimulates white blood cell production and can help reduce the risk of infection during radiation therapy. It's not known to cause mucositis or xerostomia.</li><li>\u2022 Option D. Granulocyte-macrophage colony-stimulating factor (GM-CSF):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While amifostine is a well-studied radioprotector, its potential to worsen mucositis and xerostomia in HNSCC patients limits its clinical use. This highlights the importance of carefully considering the potential benefits and risks of any intervention, even those that are well-researched, in the context of specific patient populations and treatment modalities.</li><li>\u27a4 While amifostine is a well-studied radioprotector, its potential to worsen mucositis and xerostomia in HNSCC patients limits its clinical use.</li><li>\u27a4 This highlights the importance of carefully considering the potential benefits and risks of any intervention, even those that are well-researched, in the context of specific patient populations and treatment modalities.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d2c5194",
      "audio": ""
    },
    {
      "text": "50-year-old man with localized prostate cancer is undergoing external beam radiation therapy. The radiation oncologist uses a technique that involves delivering radiation from multiple angles, with varying doses to precisely target the tumor and spare surrounding normal tissues. This technique is called:",
      "options": [
        {
          "label": "A",
          "text": "3D conformal radiation therapy (3D CRT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intensity-modulated radiation therapy (IMRT)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Volumetric modulated arc therapy (VMAT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Image-guided radiation therapy (IGRT)",
          "correct": false
        }
      ],
      "correct_answer": "B. Intensity-modulated radiation therapy (IMRT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Intensity-modulated radiation therapy (IMRT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 3D conformal radiation therapy (3D CRT): While 3D CRT uses 3D imaging to shape radiation beams to the tumor, it does not modulate the intensity of the beam within each field. IMRT, on the other hand, can vary the intensity within each beam, allowing for even more precise dose delivery and sparing of surrounding normal tissues.</li><li>\u2022 Option A. 3D conformal radiation therapy (3D CRT):</li><li>\u2022 Option C. Volumetric modulated arc therapy (VMAT): VMAT is an advanced form of IMRT where the radiation beam is continuously modulated as it rotates around the patient. While it offers even further precision and efficiency compared to traditional IMRT, the question stem emphasizes the use of multiple angles with varying doses, which is a core feature of IMRT.</li><li>\u2022 Option C. Volumetric modulated arc therapy (VMAT):</li><li>\u2022 Option D. Image-guided radiation therapy (IGRT): IGRT involves the use of imaging during treatment to ensure accurate targeting. While it enhances precision, it's not a specific radiation delivery technique like IMRT or 3D CRT. IGRT can be used in conjunction with various delivery methods, including IMRT.</li><li>\u2022 Option D. Image-guided radiation therapy (IGRT):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 IMRT is a sophisticated radiotherapy technique that allows for precise dose delivery and improved sparing of normal tissues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a505658",
      "audio": ""
    },
    {
      "text": "A 52-year-old woman undergoes a lumpectomy for a 2 cm, stage I, estrogen receptor-positive breast tumor. The patient is interested in adjuvant radiation therapy to reduce the risk of local recurrence. Which of the following radiation therapy regimens is most appropriate for this patient following breast-conserving surgery?",
      "options": [
        {
          "label": "A",
          "text": "45 Gy in 25 fractions over 5 weeks",
          "correct": false
        },
        {
          "label": "B",
          "text": "50 Gy in 25 fractions over 5 weeks, plus a boost of 10 Gy to the tumor bed",
          "correct": true
        },
        {
          "label": "C",
          "text": "60 Gy in 30 fractions over 6 weeks",
          "correct": false
        },
        {
          "label": "D",
          "text": "66 Gy in 33 fractions over 6.5 weeks",
          "correct": false
        }
      ],
      "correct_answer": "B. 50 Gy in 25 fractions over 5 weeks, plus a boost of 10 Gy to the tumor bed",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 45 Gy in 25 fractions over 5 weeks: Is a standard dose for whole breast irradiation, but it does not include a boost to the tumor bed, which is typically recommended for additional risk reduction.</li><li>\u2022 Option A. 45 Gy in 25 fractions over 5 weeks:</li><li>\u2022 Option C. 60 Gy in 30 fractions over 6 weeks: Is a higher total dose than typically used for adjuvant breast irradiation following breast-conserving surgery and may be more appropriate for certain other cancer types or treatment settings.</li><li>\u2022 Option C. 60 Gy in 30 fractions over 6 weeks:</li><li>\u2022 Option D. 66 Gy in 33 fractions over 6.5 weeks: Is also a higher total dose than typically used for adjuvant breast irradiation and may increase the risk of side effects without providing additional benefit in the setting of early-stage breast cancer following lumpectomy.</li><li>\u2022 Option D. 66 Gy in 33 fractions over 6.5 weeks:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Following breast-conserving surgery for early-stage breast cancer, the standard adjuvant radiation therapy regimen involves whole breast irradiation with a total dose of approximately 45-50 Gy delivered over 5 weeks, often with an additional boost of 10 Gy to the lumpectomy bed to further reduce the risk of local recurrence.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8ec70b57",
      "audio": ""
    },
    {
      "text": "A neurosurgeon is considering a non-invasive treatment option for a patient with a small, well-defined brain tumor. Which of the following radiation therapy techniques involves delivering a high dose of radiation to a precise target in the brain in a single session, minimizing exposure to surrounding healthy tissue?",
      "options": [
        {
          "label": "A",
          "text": "Intensity-Modulated Radiation Therapy (IMRT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Volumetric Modulated Arc Therapy (VMAT)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stereotactic Radiosurgery (SRS)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Stereotactic Body Radiation Therapy (SBRT)",
          "correct": false
        }
      ],
      "correct_answer": "C. Stereotactic Radiosurgery (SRS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Intensity-Modulated Radiation Therapy (IMRT): (IMRT) is an advanced form of radiation therapy that modulates the intensity of the radiation beams, allowing for the delivery of precise radiation doses to a tumor while minimizing the dose to surrounding normal tissue. IMRT is used for various cancers throughout the body, not limited to the brain.</li><li>\u2022 Option A. Intensity-Modulated Radiation Therapy (IMRT):</li><li>\u2022 Option B. Volumetric Modulated Arc Therapy (VMAT): (VMAT) is an advanced form of IMRT that delivers radiation by rotating the radiation machine around the patient, allowing for rapid and precise treatment of the tumor from multiple angles. Like IMRT, VMAT is used for various cancers, not just in the brain.</li><li>\u2022 Option B. Volumetric Modulated Arc Therapy (VMAT):</li><li>\u2022 Option D.  Stereotactic Body Radiation Therapy (SBRT): (SBRT) is similar to SRS in its precision and delivery of high-dose radiation, but it is used for tumors outside the brain, such as those in the lung, liver, spine, and prostate.</li><li>\u2022 Option D.  Stereotactic Body Radiation Therapy (SBRT):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Stereotactic radiosurgery (SRS) is a precise, non-invasive radiation therapy technique used to deliver a high dose of radiation to a small, well-defined target in the brain in a single session, minimizing exposure to surrounding healthy tissue.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "21c6db15",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with a history of lung cancer presents with new-onset seizures. Imaging reveals a single, 2 cm well-circumscribed lesion in the right frontal lobe, consistent with a brain metastasis. Which of the following treatment modalities is MOST appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Whole-brain radiation therapy (WBRT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Conventional external beam radiation therapy (EBRT)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stereotactic radiosurgery (SRS)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Brachytherapy",
          "correct": false
        }
      ],
      "correct_answer": "C. Stereotactic radiosurgery (SRS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Whole-brain radiation therapy (WBRT): WBRT treats the entire brain and is typically reserved for patients with multiple brain metastases or those who are at high risk of developing new metastases. It can cause cognitive decline and other side effects.</li><li>\u2022 Option A. Whole-brain radiation therapy (WBRT):</li><li>\u2022 Option B. Conventional external beam radiation therapy (EBRT): EBRT is less precise than SRS and typically requires multiple treatment sessions. It is also associated with a higher risk of side effects.</li><li>\u2022 Option B. Conventional external beam radiation therapy (EBRT):</li><li>\u2022 Option D. Brachytherapy: Brachytherapy involves placing radioactive sources directly into or near the tumor. It is not typically used for brain metastases.</li><li>\u2022 Option D. Brachytherapy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SRS is the preferred treatment for solitary brain metastases due to its precision, efficacy, and convenience.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "00f2e22a",
      "audio": ""
    },
    {
      "text": "A 65-year-old male with localized prostate cancer is being considered for a procedure, as shown in the image. Which of the following sources is not commonly used in the above procedure?",
      "options": [
        {
          "label": "A",
          "text": "Palladium-103",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iodine-125",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cesium-131",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cesium-137",
          "correct": true
        }
      ],
      "correct_answer": "D. Cesium-137",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-121235.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Palladium-103, Iodine-125, and Cesium-131: These are all commonly used radioactive isotopes in prostate brachytherapy. They emit low-energy radiation that is effective in treating the tumor while minimizing damage to surrounding tissues.</li><li>\u2022 Palladium-103, Iodine-125, and Cesium-131:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Prostate brachytherapy is a precise and effective treatment for localized prostate cancer. The choice of radioactive isotope depends on various factors, including tumor characteristics and desired dose rate.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3443899a",
      "audio": ""
    },
    {
      "text": "A radiation oncologist is planning to use the following instrument shown in the image for the treatment of cancer. Which of the following cancers is most likely to be treated with the instrument?",
      "options": [
        {
          "label": "A",
          "text": "Prostate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cervical",
          "correct": true
        },
        {
          "label": "C",
          "text": "Skin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Brain",
          "correct": false
        }
      ],
      "correct_answer": "B. Cervical",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-121514.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Prostate: Prostate cancer is also treated with brachytherapy, but the applicators used for prostate cancer typically involve seed implants rather than the ring applicators shown in the image.</li><li>\u2022 Option A. Prostate:</li><li>\u2022 Option C. Skin: Skin cancer treatments typically do not use this type of brachytherapy applicator. Instead, external beam radiation or superficial brachytherapy might be used depending on the type and stage of the skin cancer.</li><li>\u2022 Option C. Skin:</li><li>\u2022 Option D. Brain: Brain cancers are not commonly treated with brachytherapy. Treatment for brain tumors more often involves external beam radiation therapy, including stereotactic radiosurgery or Gamma Knife surgery.</li><li>\u2022 Option D. Brain:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The instrument shown in the image is a brachytherapy applicator likely used for the treatment of cervical cancer, which allows for localized radiation treatment directly to the affected area with minimal impact on surrounding healthy tissue.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a2a57dc2",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a common indication for prophylactic whole-brain irradiation (WBI)?",
      "options": [
        {
          "label": "A",
          "text": "Small cell lung cancer (SCLC)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute lymphoblastic leukemia (ALL)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Medulloblastoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Non-small cell lung cancer (NSCLC)",
          "correct": true
        }
      ],
      "correct_answer": "D. Non-small cell lung cancer (NSCLC)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A and option B. Small cell lung cancer (SCLC) and acute lymphoblastic leukemia (ALL): Are common indications for prophylactic WBI.</li><li>\u2022 Option A and option B.</li><li>\u2022 Option C. Medulloblastoma: Is treated with CSI, not prophylactic WBI.</li><li>\u2022 Option C. Medulloblastoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prophylactic WBI is used selectively in cancers with high risk of brain metastasis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04cc8b0c",
      "audio": ""
    },
    {
      "text": "A 4-year-old child presents with a medulloblastoma. Which of the following radiation therapy techniques is MOST appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "TSEB",
          "correct": false
        },
        {
          "label": "B",
          "text": "CSI",
          "correct": true
        },
        {
          "label": "C",
          "text": "WBI",
          "correct": false
        },
        {
          "label": "D",
          "text": "TBI",
          "correct": false
        }
      ],
      "correct_answer": "B. CSI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. TSEB: TSEB is used for cutaneous lymphomas.</li><li>\u2022 Option A. TSEB:</li><li>\u2022 Option C. WBI: Prophylactic WBI is used to prevent brain metastasis in certain cancers.</li><li>\u2022 Option C. WBI:</li><li>\u2022 Option D. TBI: TBI is used as conditioning before allogeneic stem cell transplantation.</li><li>\u2022 Option D. TBI:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CSI is crucial in treating medulloblastoma to address potential leptomeningeal spread.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83dbcea5",
      "audio": ""
    },
    {
      "text": "Which of the following is a common indication for using total skin electron beam therapy (TSEBT) as part of the treatment regimen?",
      "options": [
        {
          "label": "A",
          "text": "Localized basal cell carcinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute sunburn",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mycosis fungoides",
          "correct": true
        },
        {
          "label": "D",
          "text": "Psoriasis",
          "correct": false
        }
      ],
      "correct_answer": "C. Mycosis fungoides",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Localized basal cell carcinoma: Localized basal cell carcinoma is typically treated with more focused forms of radiation therapy or other modalities such as surgical excision, cryotherapy, or topical treatments, rather than TSEBT which treats the entire skin surface.</li><li>\u2022 Option A. Localized basal cell carcinoma:</li><li>\u2022 Option B. Acute sunburn: Acute sunburn is a condition caused by excessive exposure to ultraviolet (UV) radiation from the sun, leading to skin inflammation and damage. It does not require radiation therapy as a treatment.</li><li>\u2022 Option B. Acute sunburn:</li><li>\u2022 Option D. Psoriasis: Psoriasis is a chronic autoimmune skin condition characterized by red, itchy, and scaly patches. Treatment options include topical treatments, phototherapy, systemic medications, and biologics, but not typically TSEBT.</li><li>\u2022 Option D. Psoriasis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Total skin electron beam therapy (TSEBT) is primarily indicated for the treatment of mycosis fungoides, a type of cutaneous T-cell lymphoma, as it allows for uniform radiation delivery across the entire skin surface, effectively targeting malignant cells without significant penetration into deeper tissues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "293e89d8",
      "audio": ""
    },
    {
      "text": "A patient presents to the emergency department 6 hours after a radiation accident with nausea, vomiting, and headache. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute radiation syndrome (ARS)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Chronic radiation syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Radiation-induced cancer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Radiation-induced cataracts",
          "correct": false
        }
      ],
      "correct_answer": "A. Acute radiation syndrome (ARS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Chronic radiation syndrome: This develops over months or years of low-dose radiation exposure, not within hours.</li><li>\u2022 Option B. Chronic radiation syndrome:</li><li>\u2022 Option C. Radiation-induced cancer: Cancer is a long-term effect of radiation exposure and wouldn't present with symptoms this quickly.</li><li>\u2022 Option C. Radiation-induced cancer:</li><li>\u2022 Option D. Radiation-induced cataracts: Cataracts develop slowly over time due to radiation exposure and wouldn't be an immediate concern in this scenario.</li><li>\u2022 Option D. Radiation-induced cataracts:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Early symptoms of ARS are non-specific and can easily be mistaken for other conditions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "823d55bc",
      "audio": ""
    },
    {
      "text": "Which of the following is the most important factor in determining the severity of acute radiation syndrome (ARS)?",
      "options": [
        {
          "label": "A",
          "text": "Age of the individual",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type of radiation exposure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dose of radiation received",
          "correct": true
        },
        {
          "label": "D",
          "text": "Time since exposure",
          "correct": false
        }
      ],
      "correct_answer": "C. Dose of radiation received",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Age of the individual: While age can influence an individual's overall health and resilience, it is not the primary determinant of ARS severity. Younger individuals may recover faster, but the dose received is the key factor in determining the initial damage.</li><li>\u2022 Option A. Age of the individual:</li><li>\u2022 Option B. Type of radiation exposure: The type of radiation (alpha, beta, gamma, X-ray, neutron) does influence the biological effectiveness of the radiation, but the dose is still the primary determinant of overall severity. Different radiation types have different weighting factors in terms of damage, but the absorbed dose takes this into account.</li><li>\u2022 Option B. Type of radiation exposure:</li><li>\u2022 Option D. Time since exposure: Time since exposure is important for determining the onset and progression of symptoms, but the dose ultimately determines the extent of the damage and potential for recovery. Early intervention can be crucial, but it cannot reverse the damage caused by a high dose of radiation.</li><li>\u2022 Option D. Time since exposure:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Radiation dose is the primary determinant of ARS severity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a99b908a",
      "audio": ""
    },
    {
      "text": "What is the typical dosage range for radiotherapy in the treatment of cancer, and which of the following is a deterministic effect of local irradiation?",
      "options": [
        {
          "label": "A",
          "text": "20-40 Gy; Acute skin erythema",
          "correct": true
        },
        {
          "label": "B",
          "text": "50-70 Gy; Stochastic tumor induction",
          "correct": false
        },
        {
          "label": "C",
          "text": "10-30 Gy; Hormesis",
          "correct": false
        },
        {
          "label": "D",
          "text": "60-80 Gy; Radiation pneumonitis",
          "correct": false
        }
      ],
      "correct_answer": "A. 20-40 Gy; Acute skin erythema",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. 50-70 Gy; Stochastic tumor induction: Stochastic tumor induction, or the development of a second cancer due to radiation exposure, is a stochastic effect, meaning it has a chance of occurring that increases with dose, but its severity does not depend on the dose. It typically occurs many years after radiation exposure.</li><li>\u2022 Option B. 50-70 Gy; Stochastic tumor induction:</li><li>\u2022 Option C. 10-30 Gy; Hormesis: Hormesis is a concept that low doses of radiation may have beneficial effects. It is not typically associated with the therapeutic dose ranges used in cancer treatment.</li><li>\u2022 Option C. 10-30 Gy; Hormesis:</li><li>\u2022 Option D. 60-80 Gy; Radiation pneumonitis: Radiation pneumonitis is a deterministic effect that can occur following irradiation of the chest, potentially within the 20-40 Gy range but more commonly associated with higher doses, particularly when large volumes of lung tissue are irradiated. It presents as inflammation of the lung tissue and usually occurs within weeks to a few months after therapy.</li><li>\u2022 Option D. 60-80 Gy; Radiation pneumonitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The typical dosage range for curative radiotherapy in cancer treatment varies but often falls within approximately 20-70 Gy, administered over several weeks. Acute skin erythema is a deterministic effect associated with radiotherapy and can occur within lower ranges of this dosage spectrum. Deterministic effects have a threshold and their severity increases with the dose above this threshold, unlike stochastic effects, which are probability-based and do not have a threshold.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "26ea7b48",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman in her 6th week of pregnancy is involved in a motor vehicle accident. She is hemodynamically stable but requires a CT scan of the abdomen and pelvis to rule out internal injuries. The estimated fetal dose is 80 mGy. The fetus is at GREATEST risk for which of the following?",
      "options": [
        {
          "label": "A",
          "text": "Miscarriage",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fetal malformation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Low IQ/Mental Retardation",
          "correct": false
        },
        {
          "label": "D",
          "text": "No risk",
          "correct": false
        }
      ],
      "correct_answer": "B. Fetal malformation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Miscarriage: While high doses of radiation can increase the risk of miscarriage, especially in the very early stages of pregnancy, the risk is lower at 6 weeks compared to the risk of malformations.</li><li>\u2022 Option A. Miscarriage:</li><li>\u2022 Option C. Low IQ/Mental Retardation: This is a potential risk with radiation exposure between 9-15 weeks of gestation, but less likely at 6 weeks.</li><li>\u2022 Option C. Low IQ/Mental Retardation:</li><li>\u2022 Option D. No risk: There is no \"no risk\" level of radiation exposure during pregnancy. Although the risk from a single CT scan is low, it is not zero, and the potential for malformation is the greatest concern at this gestational age.</li><li>\u2022 Option D. No risk:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The risk of specific radiation-induced effects on the developing fetus varies depending on the gestational age at the time of exposure. The 3rd-8th weeks are the most critical period for the development of fetal malformations</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "93640d15",
      "audio": ""
    },
    {
      "text": "A 50-year-old man with a history of Hodgkin's lymphoma treated with mediastinal radiation 10 years ago presents with progressive dyspnea and orthopnea. He also reports fatigue and chest discomfort. On examination, you note elevated jugular venous pressure and muffled heart sounds. Which of the following is the most likely cause of his symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Radiation pneumonitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pericardial effusion",
          "correct": false
        },
        {
          "label": "C",
          "text": "Constrictive pericarditis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pulmonary embolism",
          "correct": false
        }
      ],
      "correct_answer": "C. Constrictive pericarditis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Constrictive pericarditis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Radiation pneumonitis: While possible, radiation pneumonitis typically occurs within the first few months after radiation therapy and is less likely to present years later.</li><li>\u2022 Option A. Radiation pneumonitis:</li><li>\u2022 Option B. Pericardial effusion: Pericardial effusion can also be caused by radiation, but it usually presents with more acute symptoms and would not explain the muffled heart sounds.</li><li>\u2022 Option B. Pericardial effusion:</li><li>\u2022 Option D. Pulmonary embolism: Pulmonary embolism is unlikely given the patient's history of radiation therapy and the clinical findings.</li><li>\u2022 Option D. Pulmonary embolism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Constrictive pericarditis is a late complication of radiation therapy to the chest that can present with dyspnea, orthopnea, and signs of right-sided heart failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e2363042",
      "audio": ""
    },
    {
      "text": "A 32-year-old man presents to the neurology clinic with complaints of progressive memory difficulties, difficulty concentrating, and episodes of confusion over the past six months. He has a history of medulloblastoma, for which he underwent surgical resection followed by cranial irradiation therapy 10 years ago. His neurological examination is notable for mild cognitive impairment without focal deficits. Which of the following is the most likely late effect of cranial irradiation that this patient is experiencing?",
      "options": [
        {
          "label": "A",
          "text": "Acute radiation necrosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Leukoencephalopathy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Meningioma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Radiotherapy myelopathy",
          "correct": false
        }
      ],
      "correct_answer": "B. Leukoencephalopathy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acute radiation necrosis: Acute radiation necrosis is a potential acute or subacute complication of radiation therapy, usually occurring within the first few months to years after treatment. It involves the necrosis (death) of brain tissue due to radiation damage, but it is not consistent with the patient's long-term post-irradiation timeframe.</li><li>\u2022 Option A. Acute radiation necrosis:</li><li>\u2022 Option C. Meningioma: Meningioma is a type of benign brain tumor that can be a secondary effect of cranial irradiation, typically occurring many years after exposure. While it could cause cognitive symptoms depending on its location, the patient's presentation of diffuse cognitive symptoms without focal deficits or mention of a new mass lesion makes leukoencephalopathy more likely.</li><li>\u2022 Option C. Meningioma:</li><li>\u2022 Option D. Radiotherapy myelopathy: Radiotherapy myelopathy is a rare late complication affecting the spinal cord after radiation therapy. It typically presents with symptoms related to spinal cord dysfunction such as weakness, sensory loss, or bowel/bladder dysfunction, not primarily cognitive impairment.</li><li>\u2022 Option D. Radiotherapy myelopathy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Leukoencephalopathy is a late effect of cranial irradiation that can manifest as progressive cognitive impairments, including memory difficulties, concentration issues, and confusion. It results from radiation-induced damage to the white matter of the brain and typically develops several years after treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "810ef694",
      "audio": ""
    },
    {
      "text": "A 65-year-old female with a history of breast cancer treated with radiation therapy (RT) 6 months ago presents with a painful, erythematous rash on her chest within the radiation field. She recently started chemotherapy with doxorubicin and cyclophosphamide (AC). Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Contact dermatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Radiation recall syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cellulitis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allergic reaction",
          "correct": false
        }
      ],
      "correct_answer": "B. Radiation recall syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Contact dermatitis: While contact dermatitis can cause a rash, it typically occurs in areas exposed to irritants or allergens, not necessarily within a previous radiation field. The patient's history of recent chemotherapy makes radiation recall syndrome more likely.</li><li>\u2022 Option A. Contact dermatitis:</li><li>\u2022 Option C. Cellulitis: Cellulitis is a bacterial skin infection characterized by warmth, redness, and swelling. However, it is less likely in this patient due to the rash occurring within the radiation field and the temporal association with chemotherapy initiation.</li><li>\u2022 Option C. Cellulitis:</li><li>\u2022 Option D. Allergic reaction: Although an allergic reaction to chemotherapy is possible, it is less likely to be localized to the radiation field and typically presents with other systemic symptoms like fever or hives. Radiation recall syndrome is a more specific inflammatory reaction related to previous radiation exposure.</li><li>\u2022 Option D. Allergic reaction:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Radiation recall syndrome is a rare but important consideration in patients receiving chemotherapy after radiation therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "087c4b66",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents for a routine follow-up appointment 5 years after completing radiation therapy for Hodgkin lymphoma. She is currently asymptomatic and disease-free. Which of the following statements BEST reflects her risk for developing a second solid cancer related to her previous radiation therapy?",
      "options": [
        {
          "label": "A",
          "text": "The risk is highest during the first year after radiation and declines rapidly thereafter.",
          "correct": false
        },
        {
          "label": "B",
          "text": "The risk peaks around 5 years after radiation and then gradually declines.",
          "correct": false
        },
        {
          "label": "C",
          "text": "The risk remains constant over time, independent of the time elapsed since radiation.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The risk increases gradually over time, with the highest risk occurring >7 years after radiation.",
          "correct": true
        }
      ],
      "correct_answer": "D. The risk increases gradually over time, with the highest risk occurring >7 years after radiation.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) The risk increases gradually over time, with the highest risk occurring >7 years after radiation.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The risk is highest during the first year after radiation and declines rapidly thereafter: This is incorrect. The risk of developing a second solid cancer increases with time after radiation exposure.</li><li>\u2022 Option A. The risk is highest during the first year after radiation and declines rapidly thereafter:</li><li>\u2022 Option B. The risk peaks around 5 years after radiation and then gradually declines: While some radiation-induced cancers may appear around 5 years, the risk for many solid tumors continues to rise beyond this point.</li><li>\u2022 Option B. The risk peaks around 5 years after radiation and then gradually declines:</li><li>\u2022 Option C. The risk remains constant over time, independent of the time elapsed since radiation: This is incorrect. The risk of developing a second solid cancer is not constant and generally increases with time since radiation exposure.</li><li>\u2022 Option C. The risk remains constant over time, independent of the time elapsed since radiation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The risk of developing a second solid cancer after radiation therapy is a long-term concern for patients. The risk increases over time, with the peak incidence often occurring 7-10 years or more after exposure. Continued surveillance and monitoring are essential for the early detection and management of potential secondary malignancies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a42b723",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true regarding the latency period for a second hematological cancer after radiotherapy?",
      "options": [
        {
          "label": "A",
          "text": "The latency period is typically less than 1 year.",
          "correct": false
        },
        {
          "label": "B",
          "text": "The latency period is usually more than 2 years.",
          "correct": true
        },
        {
          "label": "C",
          "text": "The latency period is always more than 20 years.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The latency period is variable and depends on the type of primary cancer.",
          "correct": false
        }
      ],
      "correct_answer": "B. The latency period is usually more than 2 years.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The latency period is typically less than 1 year: This is generally considered too short for the latency period associated with the development of second hematological cancers after radiotherapy. These cancers usually take a few years to develop due to the time required for radiation-induced DNA damage to manifest in the hematopoietic system.</li><li>\u2022 Option A. The latency period is typically less than 1 year:</li><li>\u2022 Option C. The latency period is always more than 20 years: This is not accurate for hematological cancers, which tend to have a shorter latency period compared to solid tumors. Hematological malignancies like AML or MDS typically manifest within a decade after radiotherapy.</li><li>\u2022 Option C. The latency period is always more than 20 years:</li><li>\u2022 Option D. The latency period is variable and depends on the type of primary cancer: While the latency period can indeed vary based on several factors, including the type of primary cancer, the statement is too broad. Specifically, for second hematological cancers following radiotherapy, the latency period is more consistently within the range of 2 to 10 years.</li><li>\u2022 Option D. The latency period is variable and depends on the type of primary cancer:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The latency period for second hematological cancers following radiotherapy, such as acute myeloid leukemia or myelodysplastic syndromes, typically ranges from 2 to 10 years. This shorter latency period compared to solid tumors reflects the time required for radiation-induced damage to affect hematopoietic stem cells and lead to hematological malignancy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6708223c",
      "audio": ""
    },
    {
      "text": "A 65-year-old female with a history of Right breast cancer treated with radiation therapy (RT) 6 months ago presents with a painful rash on the right side as shown in the image. She recently started chemotherapy with doxorubicin and cyclophosphamide (AC). Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Contact dermatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Radiation recall syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cellulitis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allergic reaction",
          "correct": false
        }
      ],
      "correct_answer": "B. Radiation recall syndrome",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-124126.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Contact dermatitis: While contact dermatitis can cause a rash, it typically occurs in areas exposed to irritants or allergens, not necessarily within a previous radiation field. The patient's history of recent chemotherapy makes radiation recall syndrome more likely.</li><li>\u2022 Option A. Contact dermatitis:</li><li>\u2022 Option C. Cellulitis: Cellulitis is a bacterial skin infection characterized by warmth, redness, and swelling. However, it is less likely in this patient due to the rash occurring within the radiation field and the temporal association with chemotherapy initiation.</li><li>\u2022 Option C. Cellulitis:</li><li>\u2022 Option D. Allergic reaction: Although an allergic reaction to chemotherapy is possible, it is less likely to be localized to the radiation field and typically presents with other systemic symptoms like fever or hives. Radiation recall syndrome is a more specific inflammatory reaction related to previous radiation exposure.</li><li>\u2022 Option D. Allergic reaction:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Radiation recall syndrome is a rare but important consideration in patients receiving chemotherapy after radiation therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e5cefcc4",
      "audio": ""
    },
    {
      "text": "A 65-year-old postmenopausal woman with a family history of breast cancer is concerned about her risk of developing the disease. Her past medical history is significant for fibroadenoma and alcohol use. Which of the following factors most significantly increases her risk for breast cancer?",
      "options": [
        {
          "label": "A",
          "text": "Family history of breast cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Past history of fibroadenoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Advanced age",
          "correct": true
        },
        {
          "label": "D",
          "text": "Moderate alcohol consumption",
          "correct": false
        }
      ],
      "correct_answer": "C. Advanced age",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Advanced age</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Family history of breast cancer: Although a family history of breast cancer is an important risk factor, especially if the cancer occurred in a first-degree relative or involved high-risk genes like BRCA1 or BRCA2, the overall risk increases with age regardless of family history.</li><li>\u2022 Option A. Family history of breast cancer:</li><li>\u2022 Option B. Past history of fibroadenoma : Fibroadenomas are benign breast tumors and are not considered a significant risk factor for developing breast cancer. They are common in younger women and do not significantly increase the risk of breast cancer.</li><li>\u2022 Option B. Past history of fibroadenoma</li><li>\u2022 Option D. Moderate alcohol consumption : While alcohol consumption is associated with an increased risk of breast cancer, the risk level is generally lower compared to the risk associated with advancing age. The risk increases with the amount of alcohol consumed, but age remains a more significant factor.</li><li>\u2022 Option D. Moderate alcohol consumption</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Advanced age is a significant risk factor for breast cancer, with most cases diagnosed in women aged 50 years and older. The risk increases with age due to factors such as cumulative exposure to estrogen and the increased likelihood of genetic mutations over time.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "607baddc",
      "audio": ""
    },
    {
      "text": "A 52-year-old woman presents with a 6-month history of a persistent, itchy rash on her right nipple. The area is also slightly red and crusted. On examination, you note a small amount of clear discharge from the nipple. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute mastitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ductal ectasia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paget disease of the breast",
          "correct": true
        },
        {
          "label": "D",
          "text": "Contact dermatitis",
          "correct": false
        }
      ],
      "correct_answer": "C. Paget disease of the breast",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Paget disease of the breast</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acute mastitis: Mastitis is a breast infection that typically presents with pain, swelling, redness, and fever. It is less likely to cause chronic eczema-like changes.</li><li>\u2022 Option A. Acute mastitis:</li><li>\u2022 Option B. Ductal ectasia: Ductal ectasia is a benign condition characterized by dilated ducts and thick, sticky nipple discharge, usually green or black in color. It is not typically associated with eczema.</li><li>\u2022 Option B. Ductal ectasia:</li><li>\u2022 Option D. Contact dermatitis: Contact dermatitis is an allergic skin reaction that can cause a rash. However, it is unlikely to be limited to the nipple and present with nipple discharge.</li><li>\u2022 Option D. Contact dermatitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Paget disease of the breast is an important differential diagnosis for patients presenting with chronic nipple eczema and discharge. A biopsy is necessary to confirm the diagnosis and determine the extent of the underlying malignancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7968bdb7",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with skin changes over her left breast as shown in the image. This finding is most suggestive of the involvement of which of the following?",
      "options": [
        {
          "label": "A",
          "text": "Cooper's ligament",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dermal lymphatics",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chest wall",
          "correct": false
        },
        {
          "label": "D",
          "text": "Skin",
          "correct": false
        }
      ],
      "correct_answer": "B. Dermal lymphatics",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115533.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Dermal lymphatics</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cooper's ligaments: These are fibrous bands that support breast tissue, and their involvement would lead to retraction and dimpling but not the widespread skin changes seen in peau d'orange.</li><li>\u2022 Option A. Cooper's ligaments:</li><li>\u2022 Option C. Chest wall: Chest wall involvement would present with pain, fixation of the breast, and possibly ulceration, but not the specific peau d'orange pattern.</li><li>\u2022 Option C. Chest wall:</li><li>\u2022 Option D. Skin: While the skin is involved, the primary cause of peau d'orange is the blockage of lymphatic drainage within the dermis, not a primary skin condition.</li><li>\u2022 Option D. Skin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Peau d'orange is a highly suggestive sign of inflammatory breast cancer due to tumor invasion of the dermal lymphatics. It requires prompt evaluation and diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5679113f",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman undergoes her annual screening mammogram. The radiologist identifies an abnormality which is shown below. There are no associated masses or architectural distortions. Which BI-RADS category is MOST appropriate for this finding?",
      "options": [
        {
          "label": "A",
          "text": "BI-RADS 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "BI-RADS 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "BI-RADS 3",
          "correct": false
        },
        {
          "label": "D",
          "text": "BI-RADS 4",
          "correct": true
        }
      ],
      "correct_answer": "D. BI-RADS 4",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115548.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) BI-RADS 4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. BI-RADS 1: Negative, normal mammogram</li><li>\u2022 Option A. BI-RADS 1:</li><li>\u2022 Option B. BI-RADS 2: Benign finding, no further workup needed</li><li>\u2022 Option B. BI-RADS 2:</li><li>\u2022 Option C. BI-RADS 3: Probably benign, but short-term follow-up is recommended</li><li>\u2022 Option C. BI-RADS 3:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pleomorphic microcalcifications on a mammogram are a suspicious finding and should be investigated further with biopsy to rule out malignancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "15fe9818",
      "audio": ""
    },
    {
      "text": "A 29-year-old woman presents to her primary care physician with a palpable lump in her left breast that she discovered three weeks ago during a self-examination. She reports that the lump is painless and mobile. A mammography is performed, which is shown in the image. Given the clinical presentation and mammography findings, what is the appropriate treatment for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Enucleation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Wide local excision with 1 cm margin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Local radiotherapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mastectomy",
          "correct": false
        }
      ],
      "correct_answer": "A. Enucleation",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115604.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Enucleation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Wide local excision with 1 cm margin: Is typically reserved for malignant lesions where clear margins are necessary to ensure complete removal of cancerous cells.</li><li>\u2022 Option B. Wide local excision with 1 cm margin:</li><li>\u2022 Option C. Local radiotherapy : Is a treatment modality used in the management of breast cancer, not benign lesions like fibroadenomas.</li><li>\u2022 Option C. Local radiotherapy</li><li>\u2022 Option D. Mastectomy: Or complete removal of the breast, is a more radical treatment generally reserved for invasive breast cancer or high-risk patients and is not indicated for benign lesions such as fibroadenomas.</li><li>\u2022 Option D. Mastectomy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fibroadenomas are benign breast tumors characterized by mammography findings of round densities with smooth borders and popcorn calcification. They can be managed conservatively with observation or enucleated if symptomatic or upon patient request.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3c2b4b30",
      "audio": ""
    },
    {
      "text": "A 48-years-old woman presents with a rapidly enlarging mass in her right breast that has doubled in size over the past 2 months. The mass is now mildly tender to the touch. Ultrasound-guided core needle biopsy done and shown below. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Invasive ductal carcinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fibrocystic changes",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fibroadenoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phyllodes tumor",
          "correct": true
        }
      ],
      "correct_answer": "D. Phyllodes tumor",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-115621.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Phyllodes tumor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Invasive ductal carcinoma: While invasive ductal carcinoma is the most common type of breast cancer, it typically does not grow as rapidly as described in this vignette.</li><li>\u2022 Option A. Invasive ductal carcinoma:</li><li>\u2022 Option B. Fibrocystic changes: Fibrocystic changes are benign and typically do not present with a rapidly enlarging mass.</li><li>\u2022 Option B. Fibrocystic changes:</li><li>\u2022 Option C. Fibroadenoma: Fibroadenomas are benign tumors that typically grow slowly and are well-circumscribed. They are not associated with the leaf-like pattern seen in the biopsy.</li><li>\u2022 Option C. Fibroadenoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Phyllodes tumors are uncommon but should be considered in the differential diagnosis of rapidly growing breast masses, particularly when histopathology shows a leaf-like pattern and hypercellular stromal tissue.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "710de31a",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman presents with a newly diagnosed invasive ductal carcinoma of the breast. Immunohistochemistry (IHC) reveals that the tumor is strongly positive for both estrogen (ER) and progesterone (PR) receptors, negative for human epidermal growth factor receptor 2 (HER2), and has a low Ki-67 index (<14%). Which of the following treatment options is MOST appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Chemotherapy alone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Endocrine therapy alone",
          "correct": true
        },
        {
          "label": "C",
          "text": "Anti-HER2 therapy alone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Combined endocrine and chemotherapy",
          "correct": false
        }
      ],
      "correct_answer": "B. Endocrine therapy alone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Endocrine therapy alone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chemotherapy alone: While chemotherapy can be beneficial in some breast cancers, Luminal A tumors are generally slow-growing and have a better prognosis. Endocrine therapy alone is usually sufficient to manage the disease and improve outcomes.</li><li>\u2022 Option A. Chemotherapy alone:</li><li>\u2022 Option C. Anti-HER2 therapy alone: This patient's tumor is HER2-negative, meaning it does not overexpress the HER2 protein. Therefore, anti-HER2 therapy would not be effective in this case.</li><li>\u2022 Option C. Anti-HER2 therapy alone:</li><li>\u2022 Option D. Combined endocrine and chemotherapy: While some patients with Luminal A tumors may benefit from the addition of chemotherapy, it is typically reserved for those with higher risk features (e.g., larger tumor size, lymph node involvement). In this patient's case, the low Ki-67 index suggests a low risk of proliferation, making endocrine therapy alone the most appropriate initial treatment choice.</li><li>\u2022 Option D. Combined endocrine and chemotherapy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Luminal A breast cancer is hormone receptor-positive and typically responds well to endocrine therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83d8045a",
      "audio": ""
    },
    {
      "text": "58-year-old postmenopausal woman is diagnosed with locally advanced breast cancer (LABC) with involvement of the chest wall and skin. Biopsy reveals a hormone receptor (HR)-positive, HER2-negative tumor. Which of the following is the MOST appropriate neoadjuvant chemotherapy (NACT) regimen for this patient?",
      "options": [
        {
          "label": "A",
          "text": "DCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)",
          "correct": false
        },
        {
          "label": "B",
          "text": "AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)",
          "correct": true
        },
        {
          "label": "C",
          "text": "TC-AC (Docetaxel, Cyclophosphamide, Doxorubicin) + Anti-PD1 (Immune Checkpoint Inhibitor)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Letrozole (aromatase inhibitor)",
          "correct": false
        }
      ],
      "correct_answer": "B. AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option  A. DCHP: This regimen includes Trastuzumab and Pertuzumab, which are anti-HER2 therapies not indicated for HER2-negative tumors.</li><li>\u2022 Option  A. DCHP:</li><li>\u2022 Option C. TC-AC + Anti-PD1: This regimen includes an immune checkpoint inhibitor, which is typically reserved for triple-negative breast cancer (TNBC) and is not indicated in this case.</li><li>\u2022 Option C. TC-AC + Anti-PD1:</li><li>\u2022 Option D. Letrozole : This is an endocrine therapy and is not suitable for NACT in LABC. It may be used as adjuvant therapy after surgery.</li><li>\u2022 Option D. Letrozole</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The choice of neoadjuvant chemotherapy in LABC depends on the tumor's hormone receptor and HER2 status. For HR-positive, HER2-negative LABC in postmenopausal women, AC-T is the preferred regimen.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8c59d0a0",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman presents to oncologist after being diagnosed with left breast invasive ductal carcinoma. On examination, two axillary nodes are palpable on the right side. Given the findings, what is the stage of the cancer?",
      "options": [
        {
          "label": "A",
          "text": "Stage IIIa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Stage IV",
          "correct": true
        },
        {
          "label": "C",
          "text": "Stage IIIc",
          "correct": false
        },
        {
          "label": "D",
          "text": "Stage II",
          "correct": false
        }
      ],
      "correct_answer": "B. Stage IV",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Stage IV</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The stages are as follows:</li><li>\u2022 The stages are as follows:</li><li>\u2022 Stage II: The cancer is in the breast and may have spread to up to three axillary lymph nodes but not to distant sites. Stage IIIa: The cancer has extended into multiple axillary lymph nodes or the nodes are clumped together, but there is no spread to distant organs. Stage IIIc: The cancer is found in 10 or more axillary lymph nodes, nodes near the collarbone, or internal mammary nodes, but not to distant organs. Stage IV: The cancer has metastasized beyond the regional lymph nodes to distant organs, which could include contralateral lymph nodes or other body areas.</li><li>\u2022 Stage II: The cancer is in the breast and may have spread to up to three axillary lymph nodes but not to distant sites.</li><li>\u2022 Stage IIIa: The cancer has extended into multiple axillary lymph nodes or the nodes are clumped together, but there is no spread to distant organs.</li><li>\u2022 Stage IIIc: The cancer is found in 10 or more axillary lymph nodes, nodes near the collarbone, or internal mammary nodes, but not to distant organs.</li><li>\u2022 Stage IV: The cancer has metastasized beyond the regional lymph nodes to distant organs, which could include contralateral lymph nodes or other body areas.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In breast cancer staging, stage IV indicates distant metastasis. This can include metastatic spread to lymph nodes not typically involved in local or regional breast cancer dissemination, such as contralateral cervical lymph nodes. This stage is consistent with the most advanced form of the disease, where the cancer has spread to other parts of the body beyond the breast and regional lymph nodes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "17e82f16",
      "audio": ""
    },
    {
      "text": "A 48-year-old woman with a newly diagnosed T2N0 invasive ductal carcinoma of the right breast undergoes neoadjuvant chemotherapy (NACT). After NACT, she is restaged as ycT1cN1. Which of the following is the MOST appropriate surgical approach for managing the axilla in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Sentinel lymph node biopsy (SLNB)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Axillary lymph node dissection (ALND)",
          "correct": false
        },
        {
          "label": "C",
          "text": "No axillary surgery",
          "correct": false
        },
        {
          "label": "D",
          "text": "Observation with serial ultrasounds",
          "correct": false
        }
      ],
      "correct_answer": "A. Sentinel lymph node biopsy (SLNB)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. ALND: ALND is more extensive and associated with greater morbidity than SLNB. It would only be considered if the SLNB is positive.</li><li>\u2022 Option B. ALND:</li><li>\u2022 Option C. No axillary surgery: Even though the patient is clinically node-negative after NACT, there is still a risk of residual disease in the axilla. SLNB is necessary to assess this risk.</li><li>\u2022 Option C. No axillary surgery:</li><li>\u2022 Option D. Observation with serial ultrasounds: While ultrasound can be helpful in monitoring the axilla, it is not a substitute for definitive staging with SLNB.</li><li>\u2022 Option D. Observation with serial ultrasounds:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The management of the axilla in breast cancer has evolved, and SLNB is now the preferred approach for staging the axilla in many cases. The decision between SLNB and ALND depends on clinical and pathological factors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "840d96e9",
      "audio": ""
    },
    {
      "text": "A 48-year-old woman with HR-positive, HER2-negative breast cancer has a PIK3CA mutation detected on tumor genomic testing. Which of the following medications would be most appropriate to add to her treatment regimen?",
      "options": [
        {
          "label": "A",
          "text": "Abemaciclib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alpelisib",
          "correct": true
        },
        {
          "label": "C",
          "text": "Olaparib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pembrolizumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Alpelisib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Alpelisib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Abemaciclib: Abemaciclib is a CDK4/6 inhibitor, which is approved for HR-positive, HER2-negative breast cancer. However, it is not specifically targeted for PIK3CA mutations.</li><li>\u2022 Option A. Abemaciclib:</li><li>\u2022 Option C. Olaparib: Olaparib is a PARP inhibitor primarily used in breast cancer patients with BRCA1/2 mutations. It is not indicated for PIK3CA mutations.</li><li>\u2022 Option C. Olaparib:</li><li>\u2022 Option D. Pembrolizumab: Pembrolizumab is an immune checkpoint inhibitor used in some types of triple-negative breast cancer (TNBC). It does not target PIK3CA mutations and is not indicated for HR-positive breast cancer.</li><li>\u2022 Option D. Pembrolizumab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Targeted therapies like Alpelisib can be effective for specific breast cancer mutations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c419e6f0",
      "audio": ""
    },
    {
      "text": "A 38-year-old woman with metastatic triple-negative breast cancer (TNBC) has a germline BRCA1 mutation. Which of the following treatments is MOST likely to be effective in this scenario?",
      "options": [
        {
          "label": "A",
          "text": "Endocrine therapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Trastuzumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Olaparib",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pertuzumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Olaparib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Olaparib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Endocrine therapy: Triple-negative breast cancer (TNBC) lacks hormone receptors (estrogen and progesterone) and HER2 receptors, making it unresponsive to endocrine therapies that target these pathways.</li><li>\u2022 Option A. Endocrine therapy:</li><li>\u2022 Option B. Trastuzumab: This is an anti-HER2 therapy specifically designed for HER2-positive breast cancer. TNBC, by definition, is HER2-negative, making Trastuzumab ineffective.</li><li>\u2022 Option B. Trastuzumab:</li><li>\u2022 Option D. Pertuzumab: Similar to Trastuzumab, Pertuzumab is also an anti-HER2 therapy and is not indicated for TNBC.</li><li>\u2022 Option D. Pertuzumab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 PARP inhibitors are a targeted therapy for BRCA-mutated breast cancers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "70fec19c",
      "audio": ""
    }
  ]
}